Conditions: Immune Thrombocytopenia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 61
Healthy volunteers: no

Brief summary:
Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed to respond or relapsed after prior therapy, with a platelet count \<30,000/µL. Patient will be randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and placebo; administered orally twice a day.

Detailed description:
This study will evaluate the efficacy, safety, tolerability,pharmacokinetics (PK), and pharmacodynamics (PD) of select (200 mg BID and 400 mg BID) doses of SKI-O-703 in persistent and chronic ITP patients who have failed to respond or relapsed after prior therapy, with a platelet count \<30,000/µL. on 2 occasions at least 7 days apart with the confirmatory count on the first day of treatment.

subjects will participate in 3 treatment groups (24 subjects in each of the active treatment groups and 12 subjects in the placebo group). The total study duration will be 20 weeks per subject, which consists of up to 4 weeks of screening period, 12 weeks of treatment period, and 4 weeks of follow-up period.

Arms:
arm 1: 2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks arm 2: 4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks arm 3: 4 capsules of placebo during 12 weeks

Interventions: intervention 1: SKI-O-703 intervention 2: Placebo oral tablet
Intervention descriptions: intervention 1: The SKI-O-703 capsules will contain 100 mg of drug substance. intervention 2: Placebo capsules are filled with microcrystalline cellulose.

Protocol document:
Prot_002.pdf: 
CLINICAL STUDY PROTOCOL 
IND 139107 
EUDRA-CT 2018-003329-26 
 
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 
Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, 
SYK Inhibitor, in Patients with Persistent and Chronic Immune 
Thrombocytopenia (ITP) 
 
PROTOCOL NO. OSCO-P2101 
 
Page 1


Sponsor: 
Oscotec Inc. 
Korea Bio-Park, Building A, 9th Floor 
700 Daewangpangyo-ro, Bundang-gu 
Seongnam-si, Gyeonggi-do 13488 
The Republic of Korea 
Sponsor Contact: 
 
Medical Monitor: 
Version of Protocol:  
4.0 (Protocol Amendment 3) 
Date of Protocol:  
22 April 2020 
Previous Date(s) and 
Version(s): 
09 August 2019, Version 3.1 (Country-Specific Protocol 
Amendment 2.1 [Republic of Korea]) 
30 April 2019, Version 3.0 (Protocol Amendment 2) 
03 April 2019, Version 2.0 (Protocol Amendment 1) 
09 January 2019, Final (original) 
 
CONFIDENTIAL 
All financial and nonfinancial support for this study will be provided by Oscotec Inc. The 
concepts and information contained in this document or generated during the study are 
considered proprietary and may not be disclosed in whole or in part without the expressed, 
written consent of Oscotec Inc. 
The study will be conducted according to the International Council for Harmonisation 
harmonised tripartite guideline E6(R2): Good Clinical Practice. 
 
Page 2


Oscotec Inc. 
Protocol: OSCO-P2 IO I Version 4.0 (Amendment 3) 
Protocol Approval - Sponsor Signatory 
SKI-O-703 
22 April 
Study Title 
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of 
Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and 
Chronic Immune Thrombocytopenia (ITP) 
Protocol Number OSCO-P2101 
Protocol Date 
22 April 
Protocol accepted and approved by: 
Page 3


Oscotec Inc. 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
Protocol Approval - Principal/Coordinating Investigator 
SKI-O-703 
22 April 
Study Title 
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of 
Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and 
Chronic Immune Thrombocytopenia (ITP) 
Protocol 
Number 
Protocol Date 
OSCO-P2101 
22 April 
Protocol accepted and approved by: 
Page 4


Oscotec Inc. 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
Protocol Approval - Lead Statistician 
SKI-O-703 
22 April 2020 
Study Title 
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of 
Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and 
Chronic Immune Thrombocytopenia (ITP) 
Protocol Number OSCO-P2101 
Protocol Date 
22 April 2020 
Protocol accepted and approved by: 
Page 5


Oscotec Inc. 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
Declaration of Investigator 
SKI-O-703 
22 April 
I have read and understood all sections of the protocol entitled "A Phase 2, Multicenter, 
Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the 
Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and 
Chronic Immune Thrombocytopenia (ITP)" and the accompanying investigator's brochure. 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Protocol Amendment 3, Version 4.0, dated 22 April , the International 
Council for Harmonisation harmonised tripartite guideline E6(R2): Good Clinical Practice 
and all applicable government regulations. I will not make changes to the protocol before 
consulting with Oscotec Inc. or implement protocol changes without independent ethics 
committee approval except to eliminate an immediate risk to subjects. I agree to administer 
study drug only to subjects under my personal supervision or the supervision of a 
subinvestigator. 
I will not supply the investigational drug to any person not authorized to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
Page 6


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
Page 7 
Table of Contents 
Table of Contents .......................................................................................................................7 
List of Tables ............................................................................................................................ 11 
List of Figures .......................................................................................................................... 11 
Protocol Synopsis.....................................................................................................................12 
List of Abbreviations................................................................................................................23 
1 
Introduction ......................................................................................................................25 
1.1 
Clinical Studies .......................................................................................................26 
1.2 
Nonclinical Studies .................................................................................................27 
1.3 
Dose Rationale ........................................................................................................29 
1.4 
Placebo Rationale....................................................................................................31 
1.5 
Benefits and Risks Assessments .............................................................................31 
2 
Study Objectives...............................................................................................................32 
2.1 
Primary Objective ...................................................................................................32 
2.2 
Secondary Objectives..............................................................................................32 
2.3 
Exploratory Objectives ...........................................................................................32 
3 
Investigational Plan ..........................................................................................................33 
3.1 
Study Design ...........................................................................................................33 
3.1.1 
Dose Interruption and Reduction .............................................................36 
3.1.2 
Rationale of Study Design .......................................................................38 
4 
Subject Selection and Withdrawal Criteria ......................................................................40 
4.1 
Selection of Study Population .................................................................................40 
4.1.1 
Inclusion Criteria .....................................................................................40 
4.1.2 
Exclusion Criteria ....................................................................................42 
4.2 
Withdrawal of Subjects From Study Drug and/or the Study ..................................44 
4.2.1 
Reasons for Withdrawal/Discontinuation ................................................44 
4.2.2 
Handling of Withdrawals .........................................................................45 
4.2.3 
Replacements ...........................................................................................46 
5 
Study drugs .......................................................................................................................47 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 8 
5.1 
Method of Assigning Subjects to Treatment Groups ..............................................47 
5.2 
Treatments Administered ........................................................................................47 
5.3 
Identity of Investigational Product..........................................................................48 
5.4 
Management of Clinical Supplies ...........................................................................48 
5.4.1 
Study Drug Packaging and Storage .........................................................48 
5.4.2 
Test Article Accountability ......................................................................49 
5.5 
Overdose Management ...........................................................................................49 
5.6 
Blinding ..................................................................................................................50 
5.6.1 
Breaking the Blind ...................................................................................50 
5.7 
Treatment Compliance ............................................................................................51 
5.8 
Prior and Concomitant Therapy ..............................................................................51 
5.8.1 
Rescue Medications .................................................................................51 
5.8.2 
Management of Nausea and Vomiting .....................................................52 
5.8.3 
Prohibited Concomitant Medications ......................................................52 
6 
Study Assessments and Procedures ..................................................................................54 
6.1 
Study Visits .............................................................................................................54 
6.2 
Demographic and Medical History .........................................................................58 
6.3 
Efficacy Assessments ..............................................................................................58 
6.4 
Safety Assessments .................................................................................................58 
6.4.1 
Physical Examination ..............................................................................58 
6.4.2 
Vital Sign Measurements, Height, and Weight ........................................59 
6.4.3 
Electrocardiograms ..................................................................................59 
6.4.4 
Clinical Laboratory Tests .........................................................................60 
6.4.5 
Adverse Events ........................................................................................61 
6.4.5.1 
Definitions of Adverse Events .................................................................61 
6.4.5.2 
Serious Adverse Events ...........................................................................62 
6.4.5.3 
Eliciting and Documenting Adverse Events ............................................62 
6.4.5.4 
Reporting Adverse Events .......................................................................63 
6.4.5.5 
Reporting Serious Adverse Events ..........................................................63 
6.4.5.6 
Suspected Unexpected Serious Adverse Reactions and Nonserious 
Adverse Events of Special Interest ..........................................................64 
6.4.5.7 
Assessment of Severity ............................................................................65 
6.4.5.8 
Assessment of Causality ..........................................................................65 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 9 
6.4.5.9 
Follow-Up of Subjects Reporting Adverse Events ..................................65 
6.5 
Pharmacokinetic and Pharmacodynamic Assessments ...........................................66 
6.5.1 
Pharmacokinetic Blood Samples .............................................................66 
6.5.2 
Pharmacokinetic Variables .......................................................................67 
6.5.3 
Pharmacodynamic Blood Samples ..........................................................67 
6.5.4 
Pharmacodynamic Variables ....................................................................68 
6.6 
Safety Monitoring Committee ................................................................................68 
6.7 
Pregnancy ................................................................................................................68 
6.8 
Laboratory Analyses ...............................................................................................69 
6.9 
Sample Collections .................................................................................................69 
6.10 Pharmacogenomic Screening ..................................................................................69 
7 
Statistical and Analytical Plan ..........................................................................................70 
7.1 
Primary Endpoint - Platelet Response ....................................................................70 
7.2 
Secondary Endpoints ..............................................................................................70 
7.2.1 
Subjects Achieving Two or More Pre-specified Platelet Counts .............70 
7.2.2 
Change from Baseline in Platelet Counts ................................................70 
7.2.3 
Time to First Platelet Response ...............................................................70 
7.2.4 
Others .......................................................................................................71 
7.3 
Exploratory Endpoints ............................................................................................71 
7.3.1 
Peak Platelet Count ..................................................................................71 
7.3.2 
Bleeding Score .........................................................................................71 
7.3.3 
Quality of Life as Measured by the SF-36 Score ....................................72 
7.4 
Sample Size Calculations ........................................................................................72 
7.5 
Analysis Sets ...........................................................................................................73 
7.6 
Description of Subgroups to be Analyzed ..............................................................74 
7.7 
Statistical Analysis Methodology ...........................................................................74 
7.7.1 
Subject Disposition ..................................................................................74 
7.7.2 
Analyses of Demographic and Baseline Characteristics .........................75 
7.7.3 
Analysis of Platelet Response ..................................................................75 
7.7.4 
Analysis of Secondary Endpoints ............................................................75 
7.7.5 
Analyses of Exploratory Endpoints .........................................................76 
7.7.6 
Pharmacokinetic/Pharmacodynamic Analyses ........................................77 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 10 
7.7.6.1 
Pharmacokinetic Analyses .......................................................................77 
7.7.6.2 
Pharmacodynamic Analyses ....................................................................77 
7.7.6.3 
Exploratory PK/PD Analyses ..................................................................77 
7.7.7 
Safety Analyses ........................................................................................78 
7.7.8 
Interim Analyses ......................................................................................78 
8 
Data Quality Assurance ....................................................................................................79 
8.1 
Data Management ...................................................................................................79 
9 
Ethics ................................................................................................................................80 
9.1 
Independent Ethics Committee or Institutional Review Board ..............................80 
9.2 
Ethical Conduct of the Study ..................................................................................80 
9.3 
Subject Information and Consent ...........................................................................80 
10 Investigator’s Obligations ................................................................................................82 
10.1 Confidentiality ........................................................................................................82 
10.2 Financial Disclosure and Obligations .....................................................................82 
10.3 Investigator Documentation ....................................................................................83 
10.4 Study Conduct .........................................................................................................83 
10.5 Adherence to Protocol ............................................................................................83 
10.6 Adverse Events and Study Report Requirements ...................................................84 
10.7 Investigator’s Final Report .....................................................................................84 
10.8 Records Retention ...................................................................................................84 
10.9 Publications .............................................................................................................84 
11 Study Management ...........................................................................................................85 
11.1 Monitoring ..............................................................................................................85 
11.1.1 
External Data Monitoring Committee .....................................................85 
11.1.2 
Monitoring of the Study ...........................................................................85 
11.1.3 
Inspection of Records ..............................................................................85 
11.2 Management of Protocol Amendments and Deviations..........................................86 
11.2.1 
Modification of the Protocol ....................................................................86 
11.2.2 
Protocol Deviations .................................................................................86 
11.3 Study Termination ...................................................................................................87 
11.4 Final Report ............................................................................................................87 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 11 
12 Reference List...................................................................................................................88 
13 Appendices .......................................................................................................................90 
13.1 Appendix: Partial List of Excluded Drugs Known to be Cytochrome P (CYP)1A2 
and UGT1A1 Inhibitors or Inducers ...............................................................90 
13.2 Protocol Amendment ..............................................................................................90 
13.2.1 
Protocol Amendment 1 - Protocol Version 2.0, Dated 03 April 2019 .....90 
13.2.1.1 Overview of Changes ..............................................................................90 
13.2.1.2 Changes to the Protocol Text ...................................................................91 
13.2.2 
Protocol Amendment 2 - Protocol Version 3.0, Dated 30 April 2019 ...109 
13.2.2.1 Overview of Changes ............................................................................109 
13.2.2.2 Changes to the Protocol Text .................................................................109 
13.2.3 
Country-specific Protocol Amendment 2.1 (Republic of Korea), Version 
3.0, Dated 09 August 2019 ....................................................................122 
13.2.3.1 Overview of Changes ............................................................................122 
13.2.3.2 Changes to the Protocol Text .................................................................122 
13.2.4 
Protocol Amendment 3 - Protocol Version 4.0, Dated 22 April 2020 ...125 
13.2.4.1 Overview of Changes ............................................................................125 
13.2.4.2 Changes to the Protocol Text .................................................................126 
 
List of Tables 
Table 1 
Guidelines for Dose Interruption or Reductiona ............................................. 37 
Table 2 
Schedule of Events .......................................................................................... 55 
Table 3 
The ITP Bleeding Score Assessment .............................................................. 71 
 
List of Figures 
Figure 1 
Study Design Schematic (for the First 5 Subjects in the Safety Run-in Period 
only) ................................................................................................................ 34 
Figure 2 
Study Design Schematic (For Subjects Other Than Enrolled in the Safety 
Run-in Period) ................................................................................................. 35 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 12 
Protocol Synopsis 
Protocol Number: 
OSCO-P2101 
Title: 
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-
Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety 
of Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and 
Chronic Immune Thrombocytopenia (ITP) 
Sponsor: 
Oscotec Inc. 
Korea Bio-Park, Building A, 9th Floor 
700 Daewangpangyo-ro, Bundang-gu 
Seongnam-si, Gyeonggi-do 13488 
The Republic of Korea 
Study Phase: 
Phase 2 
Study Sites: 
This study will be conducted at multiple sites in Korea, US, and EU. 
Indication: 
Immune Thrombocytopenia (ITP) 
Rationale: 
Primary ITP is an acquired immune mediated disorder characterized 
by isolated thrombocytopenia, defined as a peripheral blood platelet 
count less than 100,000/µL. The ITP is classified by duration into 
newly diagnosed (0-3 months), persistent (3-12 months’ duration) and 
chronic (≥12 months’ duration). 
Spleen tyrosine kinase (SYK) is a non-receptor kinase and an 
inflammatory signal mediator. SYK activation has been known to be 
involved in various autoimmune disorders. Since SYK is a key 
mediator of FcγR-triggered intracellular signal in various 
inflammatory immune cells including macrophages, it was proposed 
as a promising therapeutic target to treat ITP. 
A novel small-molecule SYK inhibitor, SKI-O-703, mesylate salt 
form of SKI-O-592, was designed and synthesized by Oscotec Inc. 
SKI-O-703 displayed high selectivity and potency against SYK in 
both biochemical and cell-based assays. Selective SYK inhibition by 
SKI-O-592 prevents FcγR mediated phagocytosis in vitro and 
downregulates CD63 expression on peripheral blood basophils in 
healthy adults. 
SKI-O-703 was efficacious in preventing thrombocytopenia induction 
in an anti-CD41 antibody induced murine ITP model. Intraperitoneal 
injection of anti-CD41 (integrin αIIb) antibody successfully induced 
immediate decrease of platelets within 24 hours. The reduced platelet 
numbers were normalized in 72 hours after αCD41 antibody 
injection. Both once daily and twice daily (BID) treatment of SKI-O-
703 successfully ameliorated the thrombocytopenia in a dose 
dependent manner compared to vehicle treatment. The high dose 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 13 
group of SKI-O-703 (42 mg/kg, equivalent to 30 mg/kg of 
SKI-O-592) showed better protective effect against thrombocytopenia 
induction than R788 (40 mg/kg, equivalent to 30 mg/kg of R406, the 
active compound of prodrug R788). Moreover, the low dose group of 
SKI-O-703 (14 mg/kg, equivalent to 10 mg of SKI-O-592) showed 
comparable efficacy to the high dose group of R788 (40 mg/kg). 
This study will evaluate the efficacy, safety, tolerability, 
pharmacokinetics (PK), and pharmacodynamics (PD) of select 
(200 mg BID and 400 mg BID) doses of SKI-O-703 in persistent and 
chronic ITP patients who have failed to respond or relapsed after 
prior therapy, with a platelet count <30,000/µL. 
Since the 400 mg BID dose level has not been investigated in healthy 
volunteer studies, a safety run-in group will be implemented (ie, first 
5 subjects) and an interim safety and PK data review will be 
performed by the DMC before remaining subjects are enrolled. 
Objectives: 
Primary Objective 
• To evaluate the safety and efficacy on the primary endpoint 
(platelet response) of select (200 mg BID and 400 mg BID) 
doses of SKI-O-703 compared to placebo in patients with 
persistent and chronic ITP, with a platelet count <30,000/µL 
on 2 occasions at least 7 days apart with the confirmatory 
count being taken during Screening. 
Secondary Objectives 
• To evaluate the efficacy on the secondary endpoints of select 
(200 mg BID and 400 mg BID) doses of SKI-O-703 
compared to placebo in patients with persistent and chronic 
ITP 
• To investigate the PK profile of SKI-O-592 (the free base of 
SKI-O-703) and its metabolites (M2 and M4) in patients with 
persistent and chronic ITP 
• To evaluate the effects of SKI-O-703 on PD biomarkers in 
patients with persistent and chronic ITP. 
Exploratory Objectives 
• To evaluate the PK/PD relationship between plasma 
concentrations of SKI-O-592, M2, and M4 and the percent 
change in activated CD63+ basophils in peripheral blood in 
patients with persistent and chronic ITP 
• To evaluate the changes of the exploratory endpoints of select 
(200 mg BID and 400 mg BID) doses of SKI-O-703 
compared to placebo. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 14 
Study Population: 
Inclusion Criteria 
Each subject must meet all the following criteria to be enrolled in this 
study: 
a. 
Able to provide written informed consent and agreeable to the 
schedule of assessments 
b. 
Male or female subjects, aged 18 years or older (or ≥19 years 
of age for Korean subjects per local regulations) 
c. 
Diagnosis of primary ITP (persistent or chronic) made 
according to the American Society of Hematology 2011 
evidence-based guideline 
d. 
Failed to respond or relapsed after at least 1 prior therapy (eg, 
corticosteroids, IVIG, anti-D, rituximab, TPO-receptor 
agonists, splenectomy, and immunosuppressants such as 
vincristine, mycophenolate mofetil, and azathioprine), with a 
platelet count of <30,000/µL on 2 occasions at least 7 days 
apart with the confirmatory count being taken during 
Screening (the most recent result from the central laboratory 
will be considered as the confirmatory platelet count, when an 
unscheduled visit(s) is performed during the screening 
period). Response to such prior therapy is defined as platelet 
count of ≥30,000/µL and >2 times increase from baseline in 
the absence of bleeding. Failure to respond and relapse to 
such prior therapy are defined as failure to achieve and/or 
failure to maintain response on a tolerable regimen of prior 
therapy. 
e. Adequate hematologic, hepatic, and renal function (absolute 
neutrophil count ≥ 1.5 x 109/L, hemoglobin 
[Hgb] ≥ 10.0 g/dL, aspartate aminotransferase [AST] and 
alanine aminotransferase [ALT] ≤ 2.0 x ULN, bilirubin 
≤1.5 x ULN, albumin ≥ 3 g/dL, estimated glomerular filtration 
rate [eGFR] ≥40 mL/min/1.73m2, and creatinine ≤ 1.5 x ULN) 
f. 
ECOG performance status of 0, 1, or 2 
g. 
Both male and female subjects must agree to take the 
following steps to reduce the potential for transmission of 
genetic material containing the investigational product: 
a. Both male and female subjects, the subject and their 
partners of childbearing potential must agree to use 2 of 
the following medically acceptable methods of 
contraception from the time of randomization, during the 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 15 
study, and for 6 months following discontinuation of study 
drug, of which: 
o One must be a highly reliable method of 
contraception, such as: 
 An intrauterine device or intrauterine 
system implanted for at least 30 days prior 
to Day 1  
 Surgical sterilization of one of the partners 
for at least 6 months prior to the date of 
informed consent (assuming this will be the 
only partner for the whole duration of the 
clinical trial) 
 Consistent and correct use of hormonal 
contraceptives (hormonal implants, 
injectables, contraception pills, transdermal 
patches, or contraceptive rings) for at least 
30 days prior to Day 1 
o One supplementary barrier method, such as: 
 Male or female condom always with 
spermicide (a spermicidal 
foam/gel/film/cream)  
 Diaphragm or cervical/vault caps always 
with spermicide (a spermicidal 
foam/gel/film/cream) 
 Double-barrier methods (which means a 
barrier method used by both partners at the 
same time), even when used with 
spermicide, are not considered to be highly 
reliable contraception methods, and as 
such, may not be the only forms of 
contraception used  


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 16 
One of the other listed highly reliable methods 
must be used in conjunction with a barrier 
method. 
b. Female subjects must agree not to breastfeed starting from 
the time of Screening, throughout the study, and until after 
6 months following the last dose of study drug. 
c. Male subjects must agree not to donate sperm starting 
from the time of randomization, throughout the study, and 
until after 6 months following the last dose of study drug  
d. For subjects and partners considered not of childbearing 
potential, the following conditions apply: 
a. Menopausal females must have experienced their 
last period more than 12 months prior to the date 
of informed consent to be classified as not of 
childbearing potential. 
b. Male and female subjects are in a situation of 
abstinence from heterosexual intercourse from 
Screening until after 6 months following the last 
dose of study drug when this is in line with the 
preferred lifestyle of the subject (eg, homosexual 
women and men or a member of a religious order 
such as nuns and priests). 
Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from 
the study: 
1. 
History of any clinically significant disease or disorder that in 
the opinion of the investigator or the sponsor may put the 
subject at risk due to study participation, impact the subject’s 
ability to participate in the study, or influence the study results 
2. 
History of current, active malignancy requiring or likely to 
require chemotherapeutic or surgical treatment during the 
study, with the exception of non-melanoma skin cancer, 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 17 
carcinoma in situ of the cervix, and localized prostate cancer 
managed by active surveillance 
3. 
Transfusion with blood or blood products or plasmapheresis 
within 2 weeks before the first administration of study drug 
(Day 1) 
4. 
PT INR > 1.5 
5. 
History of known inherited coagulopathy (including 
prothrombotic conditions such as Factor V Leiden, APC 
resistance, AT-III deficiency, and lupus anticoagulant), or 
recent arterial or deep venous thrombosis within the preceding 
6 months 
6. 
Change in corticosteroid or immunosuppressant (azathioprine, 
mycophenolate mofetil, cyclosporine) dose within 2 weeks 
prior to Day 1 (more than 10% variation from Day 1 daily 
doses) 
7. 
Treatment with thrombopoietin (TPO) receptor agonists 
within 2 weeks before Day 1 
8. 
Treatment with rituximab or splenectomy within the 8 weeks 
prior to Day 1 
9. 
Treatment with intravenous immunoglobulins (IVIGs) within 
4 weeks prior to Day 1 
10. Infections requiring intravenous antibiotics or hospitalization 
within 3 months prior to Day 1 
11. Subjects had positive test results at Screening for human 
immunodeficiency virus, hepatitis B surface antigen (HBsAg), 
or hepatitis C virus antibody. Subjects with past or resolved 
hepatitis B infection (defined as having a negative HBsAg test 
and a positive IgG antibody to hepatitis B core antigen 
[anti-HBc]) are eligible but hepatitis B virus (HBV) DNA 
must be obtained in these subjects prior to Cycle 1, Day 1, 
and must demonstrate no active infection. Subjects positive 
for hepatitis C virus (HCV) antibody are eligible only if 
polymerase chain reaction (PCR) is negative for HCV RNA.  
12. Received live vaccine within 28 days prior to Day 1 or plan to 
receive one during the study 
13. History or presence of any gastrointestinal, hepatic, or renal 
disease or any other condition known to interfere with the 
absorption, distribution, metabolism, or excretion of drugs 
14. Subject has not recovered from a recent medical/surgical 
procedure or trauma by Day 1 as determined by the 
investigator 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 18 
15. Uncontrolled hypertension (as defined by systolic blood 
pressure ≥160 mmHg or diastolic blood pressure 
≥100 mmHg) 
16. Subject had 12-lead electrocardiogram (ECG) findings of 
corrected QT interval by Fridericia formula (QTcF) > 480 
msec, cardiac arrhythmias, or clinically significant cardiac or 
ECG abnormalities 
17. Subject received any investigational medication within 
30 days or 5 half-lives prior to Day 1, whichever is longer 
18. Concomitant use of any anticoagulants and platelet 
aggregation inhibiting drugs including aspirin (within 14 days 
of planned dosing through end of follow-up) 
19. Female subject who is currently pregnant or breastfeeding 
20. Prior treatment with a SYK inhibitor 
21. Planned surgery in the time frame of the dosing period. 
Study Design: 
This is a randomized, double-blind, multicenter, placebo-controlled, 
parallel dose study to evaluate the efficacy, safety, tolerability, PK, 
and PD of select (200 mg BID and 400 mg BID) doses of SKI-O-703 
in persistent and chronic ITP patients who have failed to respond or 
relapsed after prior therapy, with a platelet count <30,000/µL on 
2 occasions at least 7 days apart with the confirmatory count being 
taken during Screening (the most recent result from the central 
laboratory will be considered as the confirmatory platelet count, when 
an unscheduled visit(s) is performed during the screening period). 
A minimum of 60 subjects are planned to participate in 3 treatment 
groups (24 subjects in each of the active treatment groups and 
12 subjects in the placebo group). Subjects will be randomly assigned 
to 3 groups using a 2:2:1 ratio to receive 1 of the 2 select doses of 
SKI-O-703 or placebo. First 5 subjects randomly assigned in the 
study will have safety run-in period for the first 1 week with interim 
safety and PK assessments on Day 8 (±2 days). Subjects in safety 
run-in period will continue to be dosed whilst the interim analysis is 
being conducted. However, further enrollment in each treatment 
group will only resume after safety and PK data of the first week for 
the first 5 subjects are reviewed and considered satisfactory by the 
Data Monitoring Committee (DMC). A subset of at least 20 subjects, 
who are not included in the safety run-in period, will be randomized 
to undergo PK/PD assessments at a selected number of sites. 
Randomization will be stratified to balance subjects with prior 
TPO-receptor agonist use (yes/no) and degree of baseline 
thrombocytopenia (ie, baseline platelet count < or ≥15,000/µL). 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 19 
The study will include a screening period of up to 4 weeks. After 
completing all screening assessments, subjects who meet all the 
inclusion and none of the exclusion criteria will proceed to the 
treatment period. 
On Day 1, subject’s eligibility will be confirmed and baseline safety 
evaluations will be performed (ECG, physical examination, vital sign 
measurements, and safety laboratory assessment). Then subjects will 
be randomized to receive either one of the doses of SKI-O-703 or 
placebo. The subjects will be administered their morning dose of 
study medication. The evening dose will be administered 12 hours 
after the morning dose. Subjects will be administered study 
medication with enough water to swallow the capsules. The study 
medication will be taken no later than 30 minutes after food. 
After dosing, all subjects will be subjected to safety assessments and 
in addition, subjects in the safety run-in period will be subjected to 
PK assessments and a subset of at least 20 subjects will be subjected 
to PK and PD assessments. The subject will be instructed to 
self-administer the subsequent doses of the study medication in the 
morning and evening (12 hours after the morning dose) for the 
remaining study duration. 
Estimated Study 
Duration: 
The total study duration will be 20 weeks per subject, which consists 
of up to 4 weeks of screening period, 12 weeks of treatment period 
(split into 1-week safety run-in period and 11-week treatment period 
for the first 5 subjects), and 4 weeks of follow-up period. 
Efficacy 
Assessments: 
Primary Endpoint: 
• Patient platelet response is defined as platelet count 
≥ 30,000/µL and doubling the baseline (average of 2 previous 
counts), at any visit during the treatment period and without 
use of rescue medication. 
Secondary Endpoints: 
• Subjects able to achieve 2 or more consecutive platelet counts 
of ≥ 30,000/µL separated by at least 5 days and without use of 
rescue medication 
• Subjects able to achieve 2 or more consecutive platelet counts 
of ≥ 30,000/µL with an increase of platelet count of 
≥20,000/µL from baseline separated by at least 5 days and 
without use of rescue medication  
• Subjects able to achieve 2 or more consecutive platelet counts 
of ≥ 50,000/µL separated by at least 5 days and without use of 
rescue medication 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 20 
• Subjects able to achieve 2 or more consecutive platelet counts 
of ≥ 100,000/µL during the treatment period, separated by at 
least 5 days and without use of rescue medication 
• Subjects able to achieve platelet counts of ≥ 50,000/µL at 3 of 
the last 4 visits 
• Change from baseline in the average of the last 2 platelet 
counts during the treatment period 
• Time to first platelet response (>30,000/µL and 2 x baseline) 
• Number of subjects receiving rescue medication at least once 
during treatment period 
• Subjects with at least one Grade 2 or higher non-skin bleeding 
event during treatment period. 
Exploratory Endpoints: 
• Peak platelet counts during the treatment period without use 
of rescue medication 
• Bleeding score at select time points 
• Quality of life as measured by the SF-36 score. 
Pharmacokinetic 
Assessments: 
Plasma PK parameters will be calculated for SKI-O-592 and its 
metabolites (M2 and M4) in all subjects in the PK/PD subset on 
Day 1 and Week 12 using a noncompartmental approach and will 
include the following: Cmax, Tmax, AUC0-tau, t1/2, Kel, CL/F 
(SKI-O-592 only), Vz/F (SKI-O-592 only), Rmet, and RAUC, as 
applicable. Pharmacokinetic assessments will also be performed on 
Day 8 (±2 days) for subjects in the safety run-in period only. 
Pharmacodynamic 
Assessments: 
Serial blood samples for assessment of the percentage of activated 
CD63+ basophils in peripheral blood will be collected in all subjects 
in the PK/PD subset on Day 1 and Week 12. PD parameters will 
include the following: Emax, TEmax, AUEC0-tau, as applicable. 
Exploratory Endpoint 
An assessment of PK/PD relationship between plasma concentrations 
of SKI-O-592, M2 and M4 and change from baseline in the 
percentage of activated CD63+ basophils in peripheral blood on 
Day 1 and Week 12 
Safety Assessments: Safety variables will include physical examination findings, vital sign 
measurements (systolic and diastolic blood pressure, pulse rate, 
respiratory rate, and temperature), ECG tracings, clinical laboratory 
test results (hematology, coagulation, serum chemistry, and 
urinalysis), bleeding score, quality of life as measured by the SF-36 
score, weight, body mass index, and reporting of adverse events. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 21 
Safety monitoring will begin when subject signs the informed consent 
form and continue through the end-of-study visit (Week 16). 
Study Drug, 
Dosage, and Route 
of Administration: 
SKI-O-703 and placebo will be administered orally. Two dose levels 
of SKI-O-703 will be evaluated in separate groups: 200 mg BID and 
400 mg BID. Third group will be of matching placebo. 
Sample Size: 
A minimum of 60 subjects will be enrolled in the study. Subjects will 
receive either 200 mg BID or 400 mg BID of SKI-O-703 or placebo 
in a 2:2:1 ratio. 
Based on Podolanczuk et al (2009) at least 50% of subjects in the 
active treatment group will be responders (R). A sample size of 
24 subjects per active treatment group and 12 subjects in the placebo 
group will provide approximately 82.7% power to detect a difference 
between response rates of 50% and 1% in the active treatment and 
placebo groups, respectively, at the 2-sided 5% significance level. 
The test statistic used in the sample size calculation was the 2-sided 
Fisher's Exact test using the normal approximation method. 
Subjects that do not receive the study drug or do not provide at least 1 
post baseline measurement will be excluded from the analysis above 
and replaced. 
The sample size calculation was performed using PASS 15 Power 
Analysis and Sample Size Software (2017). NCSS, LLC. Kaysville, 
Utah, USA, ncss.com/software/pass. 
Statistical Methods: Statistical analysis will be performed using SAS software Version 9.4 
or later. The results for each efficacy endpoint will be summarized by 
visit and treatment for all subjects within the intent-to-treat (ITT) 
analysis set using descriptive statistical methods. Continuous 
variables (quantitative endpoints) will be summarized using the 
mean, the standard deviation, median, range (minimum value and 
maximum value), and interquartile. Categorical variables (qualitative 
endpoints) will be summarized using frequency counts (number) and 
percentages. Data will be listed in data listings. 
The primary efficacy endpoint will be summarized as overall platelet 
response rate (ORR) by treatment group and analyzed using Fisher’s 
exact test to compare the difference in ORR between each active 
treatment group and placebo. A logistic regression model will also be 
performed on platelet response and include treatment, baseline 
platelet count and prior TPO-receptor agonist, provided there are 
enough subjects in each subgroup. The odds ratio for the treatment 
effect compared to placebo (together with 95% confidence interval 
and p-value) will be provided. The analysis will be based on the ITT 
analysis set. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 22 
All statistical tests will be 2-sided and performed using a 5% 
significance levels, leading to 95% (2-sided) confidence intervals. 
There will be no adjustments for multiplicity. 
Version and Date of 
Protocol: 
4.0 (Protocol Amendment 3); 22 April 2020 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 23 
List of Abbreviations 
Abbreviation 
Definition 
AE 
adverse event 
AESI 
adverse event of special interest 
ALT 
alanine aminotransferase 
Anti-HBc 
hepatitis B core antigen 
AST 
aspartate aminotransferase 
AUC 
area under the concentration-time curve  
BID 
Twice daily 
CD-ROM 
compact disk read-only memory 
CFR 
Code of Federal Regulations 
CI(s) 
confidence interval(s) 
Cmax 
maximum observed concentration 
CV 
coefficient of variation 
ECG 
12-lead electrocardiogram 
eCRF 
electronic case report form 
FcγR 
Fcγ receptor 
FDA 
US Food and Drug Administration 
GCP 
Good Clinical Practice 
HBsAg 
hepatitis B surface antigen 
HCV 
hepatitis C virus 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IRB 
Institutional Review Board 
ITP 
immune thrombocytopenia 
ITT 
Intent-to-treat 
IVIG 
intravenous immunoglobulin 
IVRS 
interactive voice response system 
MedDRA 
Medical Dictionary for Regulatory Activities 
NOAEL 
no observed adverse effect level 
ORR 
overall platelet response rate 
PCR 
polymerase chain reaction 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 24 
Abbreviation 
Definition 
PD 
pharmacodynamic 
PK 
pharmacokinetic 
QD 
once daily 
QTcF 
corrected QT interval by Fridericia formula 
SAE 
serious adverse event 
SD 
standard deviation 
TEAE 
treatment-emergent adverse event 
TPO 
thrombopoietin 
ULN 
upper limit of normal 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 25 
1 
Introduction 
Primary immune thrombocytopenia (ITP) is an acquired immune mediated disorder 
characterized by isolated thrombocytopenia, defined as a peripheral blood platelet count less 
than 100,000/µL. ITP is classified by duration into newly diagnosed (0-3 months), persistent 
(3-12 months’ duration) and chronic (≥12 months’ duration) (Mitchell et al 2013). The 
estimated incidence is 100 cases per 1 million persons per year, and about half of these cases 
occur in children. Patients with ITP have accelerated clearance of circulating 
immunoglobulin G-coated platelets via Fcγ receptor (FcγR)–bearing macrophages in the 
spleen and liver, leading to different levels of thrombocytopenia and variable degrees of 
mucocutaneous bleeding (Kessler et al 2017, Podolanczuk et al 2009). 
Spleen tyrosine kinase (SYK) is a non-receptor kinase and an inflammatory signal mediator. 
A SYK activation has been known to be involved in various autoimmune disorders. Spleen 
tyrosine kinase is broadly involved in regulating leukocyte immune function, principally by 
facilitating cellular activation in response to receptor engagement of antigen or immune 
complex. Receptors that use SYK for signal transduction include the B-cell antigen receptor, 
Fc receptors, integrins, and members of the lectin and selectin families (Turner et al 2000, 
Mócsai et al 2002, Rogers et al 2005, and Zarbock et al 2008). 
A novel small-molecule SYK inhibitor, SKI-
O-703, mesylate salt form of SKI-O-592, was designed and synthesized by Oscotec Inc. SKI-
O-703 displayed high selectivity and potency against SYK in both biochemical and cell-
based assays. Selective SYK inhibition by SKI-O-592 prevents FcγR mediated phagocytosis 
in vitro and downregulates CD63 expression on peripheral blood basophils in healthy adults. 
Many patients exhibit responses to established therapies, including corticosteroids, 
intravenous immunoglobulin (IVIG), anti-D, splenectomy, and rituximab. Nonetheless, there 
are a significant minority of patients who retain persistently low platelet counts despite 
treatment. They consequently remain at risk of intracranial hemorrhage as well as other 
bleeding complications (Podolanczuk et al 2009). 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 26 
Since SYK is a key mediator of FcγR-triggered intracellular signal in various inflammatory 
immune cells including macrophages, it was proposed as a promising therapeutic target to 
treat ITP. 
1.1 
Clinical Studies 
The safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SKI-O-703 have been 
evaluated in 2 clinical studies, a single ascending dose clinical study (OSCO-P1201) and a 
multiple ascending dose clinical study (OSCO-P1202) in healthy subjects. 
In Study OSCO-P1201, single oral doses of SKI-O-703 ranging from 50 to 800 mg were 
generally safe and well tolerated by the healthy male and female subjects. There were no 
deaths, serious adverse events (SAEs), or treatment-emergent adverse events (TEAEs) that 
led to discontinuation of the study. Ten of 48 subjects (20.8%) reported a total of 18 TEAEs; 
of these, 3 TEAEs were reported by 3 subjects (25.0%) after receiving placebo and 
15 TEAEs were reported by 7 subjects (19.4%) in the SKI-O-703 treatment groups. There 
were no dose-dependent trends noted in the TEAEs reported. The most commonly reported 
TEAE was headache, which was reported by 3 subjects (8.3%) who received SKI-O-703 and 
1 subject (8.3%) who received placebo. All TEAEs across the 50 mg to 600 mg dose range 
were considered mild in intensity; 6 treatment-related moderate-intensity TEAEs, reported in 
2 subjects, occurred at the highest dose of 800 mg SKI-O-703. All TEAEs were resolved by 
the end of the study. All individual hematology and coagulation, serum chemistry, and 
urinalysis values outside of the reference ranges were considered not clinically significant by 
the investigator. No TEAEs related to laboratory parameters were reported. 
In Study OSCO-P1202, multiple oral doses of SKI-O-703 200 mg once daily (QD), 400 mg 
QD, and 200 mg twice daily (BID) were safe and well tolerated by the healthy male and 
female subjects. There were no deaths or SAEs; however, 1 subject reported TEAE of back 
pain that led to discontinuation of 200 mg SKI-O-703 BID. Overall, 7 subjects (29.2%) 
reported a total of 17 TEAEs; of these, 2 subjects (33.3%) reported 6 TEAEs after receiving 
placebo and 5 subjects (27.8%) reported 11 TEAEs after receiving SKI-O-703. The most 
commonly reported TEAEs were nausea and headache, each were reported by 2 subjects 
(33.3%) in the 200 mg SKI-O-703 BID treatment group and by 1 subject (16.7%) in the 
placebo group. All TEAEs were considered mild or moderate in intensity, and both moderate 
TEAEs occurred in the placebo group. Except for 1 subject who reported ongoing TEAEs of 
pyuria and chlamydial infection, all TEAEs were resolved by the end of the study. No 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
apparent treatment- or dose-related trends were observed in clinical laboratory values, 
physical examination findings, or 12-lead electrocardiogram (ECG) results. There was a 
slight trend in the mean increase of systolic blood pressure from baseline in the 200 mg BID 
group at Days 16 and 21, and diastolic blood pressure values at Days 16 and 21 also 
demonstrated a slight trend of a mean increase for all doses of SKI-O-703. There were no 
significant changes in systolic and diastolic blood pressure for all doses of SKI-O-703 versus 
placebo at Days 16 and 21. 
1.2 Nonclinical Studies 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 28 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 29 
1.3 Dose Rationale 
SKI-O-703 was safe and well-tolerated in healthy volunteers when administered as single 
ascending doses over the dose range of 50 to 800 mg (Study OSCO-P1201), and multiple 
ascending doses at 200 mg QD, 400 mg QD and 200 mg BID for 7 days 
(Study OSCO-P1202). Based on the safety data from the various doses administered in these 
studies, there are no specific considerations that would concern the use of SKI-O-703 at 
doses proposed in this Phase 2 study. 
Following multiple ascending doses of SKI-O-703 at 200 mg QD, 400 mg QD, and 
200 mg BID (Study OSCO-P1202), a reduction in the PD endpoint “percentage of basophils 
expressing CD63+” was observed in healthy volunteers; on average, CD63+ expressing 
basophils were suppressed by 95%, 99% and 86% at steady state (Day 7) following 
administration at 200 mg QD, 400 mg QD, and 200 mg BID, respectively. Thereafter, the 
suppression of basophils expressing CD63+ was maintained at –72% or below for up to 2 
and 8 hours following once-daily dosing at 200 mg and 400 mg, respectively, and up to 
12 hours (ie, over a full 24-hr period) following twice-daily dosing at 200 mg. As the PD 
effect was sustained for longer after twice-daily dosing compared to once-daily dosing, 
twice-daily dosing at 200 mg and 400 mg has been selected. 
As 400 mg BID has not been studied previously in humans, exposure (Cmax and AUC0-tau) to 
SKI-O-592, M2, and M4 following 400 mg BID dosing has been estimated based on data 
observed previously at different dose levels. To ensure that predictions are cautious and 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 30 
robust, steady-state Cmax and AUC0-tau following 400 mg BID have been predicted in 2 ways 
using data from Study OSCO-P1202: 
1. AUC0-12 (400 mg, Day 1) × Accumulation Ratio (200 mg BID) 
2. PK Parameter (200 mg BID, Day 7) × 2 
Systemic exposure (Cmax and AUC0-tau) to SKI-O-592, M2, and M4 at 400 mg BID is 
predicted to be higher using the second approach [PK Parameter (200 mg BID, Day 7) × 2]. 
For SKI-O-592, Cmax and AUC0-tau are predicted to be 6160 ng/mL and 14600 h ng/mL, 
respectively, and for M2 Cmax and AUC0-tau are predicted to be 994 ng/mL and 
10000 h ng/mL, respectively, which is well within exposure levels calculated at the NOAEL 
in rats, and comparable to levels previously observed at 800 mg in Study OSCO-P1201. 
However, due to the very low M4 metabolite ratios observed in rats compared to healthy 
volunteers, predicted exposure to M4 (644 ng/mL and 1970 h ng/mL for Cmax and AUC0-tau, 
respectively) is higher than the NOAEL exposure. Therefore, the dosing regimens proposed 
for this study (200 mg BID and 400 mg BID) have been carefully selected to ensure that 
exposure to M4 does not exceed levels observed previously in healthy volunteers 
(Study OSCO-P1201, 800 mg). 
*Note: Because increases in systemic exposure to M4 were less than proportional to the dose 
of SKI-O-703 in Studies OSCO-P1201 and OSCO-P1202, and a reduction in M4 levels was 
observed over time in Study OSCO-P1202, both means of estimating Cmax and AUC0-tau for 
M4 at 400 mg BID are considered to be cautious approaches, potentially overestimating 
exposure at 400 mg BID. An interim safety and PK data review will be performed by the 
DMC for the first 5 subjects dosed (including 2 subjects dosed with 400 mg BID) before the 
remaining subjects are treated. 
Following single oral administration of 400 mg SKI-O-703 (Study OSCO-P1203), overall 
systemic exposure to SKI-O-592, M2 and M4 (AUC0-t and AUC0-inf) was comparable 
between the fed and fasted state, with 90% CI for the ratio (Fed / Fasted) contained entirely 
within the BE limits (0.80, 1.25) for SKI-O-592 and M4. By contrast, when administered in 
the fed state there was an approximate 56%, 43% and 46% reduction in maximum exposure 
(Cmax) for SKI-O-592, M2 and M4, respectively, with an associated 2.5 to 4 hours delay in 
median Tmax across all analytes. Since the overall extent of absorption is unaffected by the 
intake of food, but peak exposure is reduced, dosing is recommended with food in this 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 31 
Phase 2 study to reduce the potential for AEs which may be associated with spikes (i.e. high 
Cmax) in SKI-O-592, M2 and M4. 
1.4 Placebo Rationale 
The proposed study is a double-blind, placebo-controlled, randomized trial of two doses of 
oral SKI-O-703 for patients with persistent and chronic ITP. Subjects will be allowed to 
receive stable doses of background medications including corticosteroids and 
immunosuppressive drugs, in line with the current standard of care. Any subject who cannot 
adhere to the protocol or who discontinues treatment will have an end-of-treatment visit and 
will be followed for the intended duration of the study. 
1.5 Benefits and Risks Assessments 
In the clinical development program, the safety, tolerability, and PK of SKI-O-703 have been 
evaluated in 2 clinical studies, a single ascending dose clinical study (OSCO-P1201) and a 
multiple ascending dose clinical study (OSCO-P1202) in healthy subjects. No deaths and 
SAEs were reported in these studies; however, 1 subject reported TEAE of back pain that led 
to discontinuation of SKI-O-703. All adverse events (AEs) were mild to moderate in 
intensity. 
As described in Section 1.2, SKI-O-703 was efficacious in preventing thrombocytopenia 
induction in an anti-CD41 antibody induced murine ITP model. 
There are no important identified risks with SKI-O-703. The identified potential risks 
associated with SKI-O-703 included immune system effects, gastrointestinal effects, liver 
enzyme changes, cardiovascular effects, and headache. 
Gastrointestinal effects and headache have been observed clinically, while immune system 
effects, liver enzyme changes, and cardiovascular effects are considered important potential 
risks based on non-clinical data and the SKI-O-703 mechanism of action. Considering the 
measures to minimize the risks to patients participating in the SKI-O-703 clinical 
development program, and the nonclinical and clinical evidence highlighted above, the 
benefits of the conduct of the proposed clinical study outweigh the associated risks. 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 32 
2 
Study Objectives 
2.1 
Primary Objective 
To evaluate the safety and efficacy on the primary endpoint (platelet response) of select 
(200 mg BID and 400 mg BID) doses of SKI-O-703 compared to placebo in patients with 
persistent and chronic ITP, with a platelet count <30,000/µL on 2 occasions at least 7 days 
apart with the confirmatory count being taken during Screening. 
2.2 
Secondary Objectives 
The secondary objectives of this study are as below: 
• To evaluate the efficacy on the secondary endpoints of select (200 mg BID and 400 mg 
BID) doses of SKI-O-703 compared to placebo in patients with persistent and chronic 
ITP 
• To investigate the PK profile of SKI-O-592 (the free base of SKI-O-703) and its 
metabolites (M2 and M4) in patients with persistent and chronic ITP 
• To evaluate the effects of SKI-O-703 on PD biomarkers in patients with persistent and 
chronic ITP. 
2.3 
Exploratory Objectives 
The exploratory objectives of this study are as below: 
• To evaluate the PK/PD relationship between plasma concentrations of SKI-O-592, M2, 
and M4 and the percent change in activated CD63+ basophils in peripheral blood in 
patients with persistent and chronic ITP 
• To evaluate the changes of the exploratory endpoints of select (200 mg BID and 400 mg 
BID) doses of SKI-O-703 compared to placebo. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 33 
3 
Investigational Plan 
3.1 
Study Design 
This is a randomized, double-blind, multicenter, placebo-controlled, parallel dose study to 
evaluate the efficacy, safety, tolerability, PK, and PD of select (200 mg BID and 
400 mg BID) doses of SKI-O-703 in persistent and chronic ITP patients who have failed to 
respond or relapsed after prior therapy, with a platelet count <30,000/µL on 2 occasions at 
least 7 days apart with the confirmatory count being taken during Screening (the most recent 
result from the central laboratory will be considered as the confirmatory platelet count, when 
an unscheduled visit(s) is performed during the screening period). 
A minimum of 60 subjects are planned to enroll in 3 treatment groups (24 subjects in each of 
the active treatment groups and 12 subjects in the placebo group). Subjects will be randomly 
assigned to the 3 groups using a 2:2:1 ratio to receive one of the 2 select doses of SKI-O-703 
or placebo. First 5 subjects randomly assigned in the study will have the safety run-in period 
for the first 1 week with interim safety and PK assessments on Day 8 (±2 days). Subjects in 
the safety run-in period will continue to be dosed whilst the interim analysis is being 
conducted. However, further enrollment in each treatment group will only resume after safety 
and PK data of the first week for the first 5 subjects are reviewed and considered satisfactory 
by the Data Monitoring Committee (DMC). A subset of at least 20 subjects, who are not 
included in the safety run-in period, will be randomized to undergo PK/PD assessments at a 
selected number of sites. Randomization will be stratified to balance subjects with respect to 
prior TPO-receptor agonist use (yes/no) and degree of baseline thrombocytopenia (ie, 
baseline platelet count < or ≥15,000/µL). A schematic diagram of the overall study design is 
presented in Figure 1 and Figure 2. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 34 
Figure 1 
Study Design Schematic (for the First 5 Subjects in the Safety 
Run-in Period only) 
 
Abbreviation: BID, twice daily 
Note: First 5 subjects randomly assigned in the study will have safety run-in period for the first 1 week with 
interim safety and PK assessments on Day 8 (±2 days). Subjects in the safety run-in period will continue to 
be dosed whilst the interim analysis is being conducted. However, further enrollment in each treatment 
group will only resume after safety and PK data of the first week for the first 5 subjects are reviewed and 
considered satisfactory by the Data Monitoring Committee. 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 35 
Figure 2 
Study Design Schematic (For Subjects Other Than Enrolled in the 
Safety Run-in Period) 
 
Abbreviation: BID, twice daily 
 
Screening Period 
The study will include up to 4 weeks of screening period. All potential subjects will sign and 
date the informed consent form (ICF) prior to any study assessments or procedures. These 
subjects will be assessed as per the eligibility criteria at Screening. After completing all 
screening assessments, subjects who meet all the inclusion and none of the exclusion criteria 
will proceed to the treatment period. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 36 
12-week Treatment Period 
• 1-week Safety Run-in Period (for the first 5 subjects only): First 5 subjects randomly 
assigned in the study will have the safety run-in period for the first 1 week with interim 
safety and PK assessments on Day 8 (±2 days). Subjects in the safety run-in period will 
continue to be dosed whilst the interim analysis is being conducted. However, further 
enrollment in each treatment group will only resume after safety and PK data of the first 
week for the first 5 subjects are reviewed and considered satisfactory by the DMC. 
For all subjects, on Day 1, subject’s eligibility will be confirmed and baseline safety 
evaluations will be performed (ECG, physical examination, vital sign measurements, and 
safety laboratory assessment). Eligible subjects will be randomly assigned to receive either 
one of the doses of SKI-O-703 or placebo. On Day 1, the investigative site staff will 
administer the morning dose. The evening dose of study medication will be administered 
12 hours after the morning dose. Subjects will be administered the study medication with 
enough water to swallow the capsule. The study medication will be taken no later than 
30 minutes after food. 
After dosing, all subjects will be subjected to safety assessments and a subset of at least 
20 subjects, who are not included in the safety run-in period, will be subjected to PK and PD 
assessments according to the Schedule of Events (Table 2). Subjects enrolled in the safety 
run-in period will be admitted for 24 hours on Days 1, 8, and 84 or 85 of the study. Subjects 
selected for the PK/PD portion of the study will be admitted for 24 hours on Days 1 and 84 
or 85 of the study.  
The maximum duration of study participation for a subject will be 20 weeks, which consists 
of up to 4 weeks of screening period, 12 weeks of treatment period, and 4 weeks of follow-up 
period. 
3.1.1 Dose Interruption and Reduction 
It is recognized that some AEs may require dose adjustment or study drug discontinuation. 
Intra-subject dose reduction or escalation is permitted and based upon treatment-related 
adverse events observed (Table 1). 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 37 
After experiencing an AE, subjects whose laboratory results return to baseline values and 
remain stable for 4 consecutive weeks have the option to increase the dose of SKI-O-703 1 
dose level up to the randomized dose level. 
Table 1 
Guidelines for Dose Interruption or Reductiona 
AE 
Occurrence 
Action 
ALT elevations 
(range 3 to 
5 × ULN)  
Alkaline 
Phosphatase 
> 3 × ULN and 
> 2 × baseline 
First 
• 
If asymptomatic (no nausea, anorexia, vomiting), repeat test within 
72 hoursb and, if stable or lower, may continue dosing of study 
drug. 
• 
If on repeat test value has increased further but remains < 5 × ULN 
and asymptomatic, withhold study drug and retest weekly until 
values becomes stable. When stabilized to < 5 × ULN, continue 
dosing with the study drug. 
• 
If symptomatic or > 5 × ULN, withhold study drug. Follow the 
subject weekly until symptoms abate and values return to baseline 
per confirmation from central laboratory; at which time study drug 
may be restarted at a 50% reduced dose by taking only one daily 
dose.  
Note: Discontinue study drug permanently if the ALT elevation is 
accompanied by an elevation in direct bilirubin to > 2 mg/dL 
(34.2 mmol/L). 
 
Second 
Discontinue study drug permanently. 
ANC <1,000/mm3 
or febrile 
neutropenia 
First 
Withhold dose until ANC ≥ 1000/mm3, or has returned to baseline, 
then reduce the dose by skipping one of the daily dose and increase to 
previous dose if ANC remains stable for 2 weeks on reduced dose. 
Second 
Discontinue study drug permanently if the intolerance reoccurs or 
persists. 
Sustained increased 
systolic 
(> 160 mmHg) or 
sustained increased 
diastolic 
(> 100 mmHg) 
blood pressure in a 
previously 
normotensive 
subject 
First 
Study drug may be withheld for 5 to 7 days and then restarted at a 
reduced dose by skipping one of the daily dose. 
Irrespective of study drug dose adjustment, subjects who develop 
a sustained increased systolic (>140 mmHg) or a sustained 
increased diastolic (>90 mmHg) blood pressure should be started 
on antihypertensive medications (e.g. lisinopril 5mg daily) or have 
their antihypertensive regimen adjusted if already on any 
antihypertensive agent. 
Second 
Discontinue study drug permanently if the hypertension reoccurs or 
persists. 
Intolerable nausea 
or vomiting (see 
Section 5.8.2 for 
further details) 
First 
Study drug may be withheld for 5-7 days and then restarted at a 
reduced dose by skipping evening dose. 
Second 
Discontinue study drug permanently if the intolerance reoccurs or 
persist. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 38 
AE 
Occurrence 
Action 
QTcF >500 ms for 
female subject OR 
>480 ms for male 
subject, at any time 
point 
- 
The ECG should be repeated as triplicate (all three within 2 minutes) 
and a cardiology consult may be obtained as medically necessary. 
• 
If the repeat ECG confirms QTcF >500 ms (females) or >480 ms 
(males), dosing must be interrupted for up to 14 days 
• 
If the QTcF resolves to ≤480 ms (males and females)/they may 
resume dosing at the reduced dose by skipping one of the doses 
(ie, morning or evening) 
• 
If the QTcF remains >480 ms (males and females) after 14 days of 
dose interruption, the study drug must be permanently 
discontinued. 
QTcF change of 
>30 ms from 
baseline 
- 
If the QTcF has increased >30 ms when compared to the baseline with 
no other known etiology, and the principal investigator considers it 
clinically significant then a confirmatory ECG (single) will be 
performed and dose should be reduced by skipping one of the doses 
(ie, morning or evening) for the remainder of the study. 
Abbreviations: ACE, angiotensin-converting-enzyme; AE, adverse event; ALT, alanine aminotransferase; ANC, 
absolute neutrophil count; AST, aspartate aminotransferase; ECG, electrocardiogram; LFTs, liver function 
tests; MOA, mechanism of action; QTcF, corrected QT interval by Fridericia formula; ULN, upper limit of 
normal 
a 
These are examples based on previously observed AEs for agents with similar MOA (ie, fostamatinib). All 
other potential/spontaneous Grade 3/4 AEs that can warrant dose reduction or interruption are not excluded 
and will be assessed on an ongoing basis during the study. Those would be evaluated upon judgment by the 
principal investigator and the safety operations team. 
b 
A central laboratory must be used for repeat ALT, AST, ALP, or ANC. 
 
3.1.2 
Rationale of Study Design 
This double-blind, placebo-controlled study is designed to evaluate the efficacy, safety, 
tolerability, PK, and PD of SKI-O-703 in persistent and chronic ITP patients. The results of 
this study will guide on further clinical evaluation of SKI-O-703 patients with ITP. The 
double-blind placebo-controlled design has been selected to minimize bias in the evaluation 
of the safety, efficacy, PK, and PD. 
Since the 400 mg BID dose level has not been investigated in healthy volunteer studies, a 
safety run-in group will be implemented. To protect the study blind, 5 subjects will be 
included in the safety run-in period to reflect the overall 2:2:1 randomization, resulting in 
2 subjects each being dosed at 400 mg and 200 mg BID and 1 subject being dosed with 
placebo. An interim safety and PK data review will be performed by the DMC once the 
subjects in the safety run-in period complete their Day 8 (±2 days) assessments. Further 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 39 
enrollment in each treatment group will only resume after safety and PK data of the first 
week for the first 5 subjects are reviewed and considered satisfactory by the DMC. 
Serial blood samples (5 mL) for PK assessment of SKI-O-592 and its metabolites (M2 and 
M4) from all subjects in the PK/PD subset will be obtained from this study, which in turn 
would help refine the sparse sampling approaches needed for later Phase 3 studies leading to 
a better population PK analysis in Phase 3. 
The power of a statistical test is typically a function of the magnitude of the treatment effect, 
the designated Type I error rate (α, risk of false-positive result) and the sample size (n). When 
designing a trial, it is important to decide upon the desired study power (typically 80% for a 
Phase 2 study) and calculate the necessary sample size to achieve this goal. Since it is often 
not feasible to conduct large trials during early stage of development, it is necessary to 
identify the strategies to optimize the statistical power of smaller studies. 
In this study, platelet response, defined as platelet count ≥ 30,000/µL and doubling the 
baseline (average of 2 previous counts), at any visit during the treatment period and without 
use of rescue medication, is selected as the primary endpoint. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 40 
4 
Subject Selection and Withdrawal Criteria 
4.1 
Selection of Study Population 
A minimum of 60 subjects will be enrolled at multiple sites in Korea, US, and EU. Subjects 
will be assigned to study drug only if they meet all of the inclusion criteria and none of the 
exclusion criteria. Deviations from the inclusion and exclusion criteria are not allowed 
because they can potentially jeopardize the scientific integrity of the study, regulatory 
acceptability, or patient safety. Therefore, adherence to the criteria as specified in the 
protocol is essential. 
4.1.1 
Inclusion Criteria 
Each subject must meet all of the following criteria to be enrolled in this study: 
1. Able to provide written informed consent and agreeable to the schedule of assessments 
2. Male or female subjects, aged 18 years or older (or ≥19 years of age for Korean subjects 
per local regulations) 
3. Diagnosis of primary ITP (persistent or chronic) made according to the American Society 
of Hematology 2011 evidence-based guideline 
4. Failed to respond or relapsed after at least 1 prior therapy (eg, corticosteroids, IVIG, 
anti-D, rituximab, TPO-receptor agonists, splenectomy, and immunosuppressants such as 
vincristine, mycophenolate mofetil, and azathioprine), with a platelet count of 
<30,000/µL on 2 occasions at least 7 days apart with the confirmatory count being taken 
during Screening (the most recent result from the central laboratory will be considered as 
the confirmatory platelet count, when an unscheduled visit(s) is performed during the 
screening period). Response to such prior therapy is defined as platelet count of 
≥30,000/µL and >2 times increase from baseline in the absence of bleeding. Failure to 
respond and relapse to such prior therapy are defined as failure to achieve and/or failure 
to maintain response on a tolerable regimen of prior therapy. 
5. Adequate hematologic, hepatic, and renal function (absolute neutrophil 
count ≥ 1.5 x 109/L, hemoglobin [Hgb] ≥ 10.0 g/dL, aspartate aminotransferase [AST] 
and alanine aminotransferase [ALT] ≤ 2.0 x ULN, bilirubin ≤1.5 x ULN, albumin 
≥ 3 g/dL, estimated glomerular filtration rate [eGFR] ≥40 mL/min/1.73m2, and 
creatinine ≤ 1.5 x ULN) 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 41 
6. ECOG performance status of 0, 1, or 2 
7. Both male and female subjects must agree to take the following steps to reduce the 
potential for transmission of genetic material containing the investigational product: 
a. Both male and female subjects, the subject and their partners of childbearing 
potential must agree to use 2 of the following medically acceptable methods of 
contraception from the time of randomization, during the study, and for 6 months 
following discontinuation of study drug, of which: 
o One must be a highly reliable method of contraception, such as: 
 An intrauterine device or intrauterine system implanted for at least 
30 days prior to Day 1  
 Surgical sterilization of one of the partners for at least 6 months 
prior to the date of informed consent (assuming this will be the 
only partner for the whole duration of the clinical trial) 
 Consistent and correct use of hormonal contraceptives (hormonal 
implants, injectables, contraception pills, transdermal patches, or 
contraceptive rings) for at least 30 days prior to Day 1 
o One supplementary barrier method, such as: 
 Male or female condom always with spermicide (a spermicidal 
foam/gel/film/cream)  
 Diaphragm or cervical/vault caps always with spermicide (a 
spermicidal foam/gel/film/cream) 
 Double-barrier methods (which means a barrier method used by 
both partners at the same time), even when used with spermicide, 
are not considered to be highly reliable contraception methods, and 
as such, may not be the only forms of contraception used  
One of the other listed highly reliable methods must be used in 
conjunction with a barrier method. 
b. Female subjects must agree not to breastfeed starting from the time of Screening, 
throughout the study, and until after 6 months following the last dose of study 
drug. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 42 
c. Male subjects must agree not to donate sperm starting from the time of 
randomization, throughout the study, and until after 6 months following the last 
dose of study drug  
d. For subjects and partners considered not of childbearing potential, the following 
conditions apply: 
a. Menopausal females must have experienced their last period more than 
12 months prior to the date of informed consent to be classified as not of 
childbearing potential. 
b. Male and female subjects are in a situation of abstinence from 
heterosexual intercourse from Screening until after 6 months following the 
last dose of study drug when this is in line with the preferred lifestyle of 
the subject (eg, homosexual women and men or a member of a religious 
order such as nuns and priests). 
4.1.2 
Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from the study: 
1. 
History of any clinically significant disease or disorder that in the opinion of the 
investigator or the sponsor may put the subject at risk due to study participation, impact 
the subject’s ability to participate in the study, or influence the study results 
2. 
History of current, active malignancy requiring or likely to require chemotherapeutic or 
surgical treatment during the study, with the exception of non-melanoma skin cancer, 
carcinoma in situ of the cervix, and localized prostate cancer managed by active 
surveillance 
3. 
Transfusion with blood or blood products or plasmapheresis within 2 weeks before the 
first administration of study drug (Day 1) 
4. 
PT INR > 1.5 
5. 
History of known inherited coagulopathy (including prothrombotic conditions such as 
Factor V Leiden, APC resistance, AT-III deficiency, and lupus anticoagulant), or recent 
arterial or deep venous thrombosis within the preceding 6 months 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 43 
6. Change in corticosteroid or immunosuppressant (azathioprine, mycophenolate mofetil, 
cyclosporine) dose within 2 weeks prior to Day 1 (more than 10% variation from Day 1 
daily doses) 
7. 
Treatment with thrombopoietin (TPO) receptor agonists within 2 weeks before Day 1 
8. 
Treatment with rituximab or splenectomy within the 8 weeks prior to Day 1 
9. 
Treatment with IVIGs within 4 weeks prior to Day 1 
10. 
Infections requiring intravenous antibiotics or hospitalization within 3 months prior to 
Day 1 
11. 
Subject had positive test results at Screening for human immunodeficiency virus, 
hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody. Subjects with past 
or resolved hepatitis B infection (defined as having a negative HBsAg test and a 
positive IgG antibody to hepatitis B core antigen [anti-HBc]) are eligible but 
hepatitis B virus (HBV) DNA must be obtained in these subject prior to Cycle 1, 
Day 1, and must demonstrate no active infection. Subjects positive for hepatitis C virus 
(HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for 
HCV RNA. 
12. 
Live vaccine within 28 days prior to Day 1 or plan to receive one during the study 
13. 
History or presence of any gastrointestinal, hepatic, or renal disease or any other 
condition known to interfere with the absorption, distribution, metabolism, or excretion 
of drugs 
14. 
Subject has not recovered from a recent medical/surgical procedure or trauma by Day 1 
as determined by the investigator 
15. 
Uncontrolled hypertension (as defined by systolic blood pressure ≥160 mmHg or 
diastolic blood pressure ≥100 mmHg) 
16. 
Subject had ECG findings of corrected QT interval by Fridericia formula 
(QTcF) > 480 msec, cardiac arrhythmias, or clinically significant cardiac or ECG 
abnormalities 
17. 
Subject have received any investigational medication within 30 days or 5 half-lives 
prior to Day 1, whichever was longer 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 44 
18. 
Concomitant use of any anticoagulants and platelet aggregation inhibiting drugs 
including aspirin (within 14 days of planned dosing through end of follow-up) 
19. 
Female subject who is currently pregnant or breastfeeding 
20. 
Prior treatment with a SYK inhibitor 
21. 
Planned surgery in the time frame of the dosing period. 
4.2 
Withdrawal of Subjects From Study Drug and/or the Study 
The duration of the study is defined for each subject as the date signed informed consent is 
provided through date of the last follow-up visit on Week 16. 
4.2.1 
Reasons for Withdrawal/Discontinuation 
Subjects may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by the investigator or at the study site. Every effort should be made 
to keep subjects in the study. The reasons for subjects not completing the study will be 
recorded. A subject may be withdrawn from the study for any of the following reasons: 
1. Noncompliance with the protocol 
2. A serious or intolerable adverse event(s) (AE[s]) that in the investigator’s opinion 
requires withdrawal from the study 
3. Central nervous system bleeding or life-threatening gastro-intestinal bleeding. Please also 
refer to the additional information in the ‘Note’ at the bottom of this section. 
4. Laboratory safety results that reveal clinically significant hematological or biochemical 
changes from the baseline values 
5. Symptoms of an intercurrent illness not consistent with the protocol requirements or that 
justify withdrawal 
6. Lost to follow-up. Subjects that are considered lost to follow-up, reasonable attempts 
must be made to obtain information on the final status of the subject. At a minimum, 
2 phone calls must be made and 1 certified letter must be sent for documentation 
7. Other reasons (eg, pregnancy, development of contraindications of use of study drug, 
breakthrough bleeding) 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 45 
8. The subject withdraws consent or the investigator or sponsor decides to discontinue the 
subject’s participation in the study 
9. Death of the subject. 
Note: Bleeding events in the ITP studies are common during the first few weeks of the study 
before the drug has a chance to take effect; hence, all the bleeding events in this study should 
be recorded as an AE or SAE (based on seriousness criteria). These events should not result 
in removal of the subjects from the study, at least during the first 4 weeks of treatment. As the 
standard of care among the participating countries may differ, platelet transfusions are 
allowed as a rescue therapy for such events; however, these therapies may be reserved for 
serious or life-threatening bleeding events. 
The investigator will also withdraw a subject if Oscotec Inc. terminates the study. Upon 
occurrence of a serious or intolerable AE, the investigator will confer with the sponsor. If a 
subject is discontinued because of an AE, the event will be followed until it is resolved. Any 
subject may withdraw his or her consent at any time. Although Oscotec Inc. has every 
intention of completing the study, Oscotec Inc. reserves the right to discontinue the study at 
any time for clinical or administrative reasons, please refer to Section 11.3 for further details. 
4.2.2 
Handling of Withdrawals 
Subjects are free to withdraw from the study or study drug at any time upon request. Subject 
participation in the study may be stopped at any time at the discretion of the investigator or at 
the request of the sponsor. 
Subjects who discontinue study drug or active participation in the study will no longer 
receive study drug. When a subject withdraws from the study drug or active participation in 
the study, the reason(s) for withdrawal shall be recorded by the investigator on the relevant 
page of the electronic case report form (eCRF). Whenever possible, all subjects who 
discontinue study drug permanently or withdraw from the study prematurely will undergo all 
end-of-study assessments. Subjects who fail to return for final assessments will be contacted 
by the site in an attempt to have them comply with the protocol. Following a minimum of 
2 documented unsuccessful telephone calls, a registered letter will be sent to the subject in a 
final attempt to ensure protocol compliance. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 46 
It is vital to obtain follow-up data on any subject withdrawn because of an AE or SAE. In 
every case, efforts must be made to undertake protocol-specified safety follow-up 
procedures. 
4.2.3 
Replacements 
Subjects who are randomly assigned and not dosed will be replaced. Subjects who 
discontinue the study for any reason after dosing will not be replaced. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 47 
5 
Study drugs 
Two dose levels of SKI-O-703 will be evaluated: 200 mg BID and 400 mg BID. The 
SKI-O-703 capsules will contain 100 mg of drug substance. Placebo capsules are filled with 
microcrystalline cellulose. 
5.1 
Method of Assigning Subjects to Treatment Groups 
Subjects will be randomly assigned in a 2:2:1 ratio to receive SKI-O-703 200 mg BID, 
SKI-O-703 400 mg BID, or matching placebo. A subset of at least 20 subjects will be 
randomized to undergo PK/PD assessments at a selected number of sites. An interactive 
voice response system (IVRS) will be used to administer the randomization schedule. The 
randomization schedule will be generated using SAS software Version 9.4 or later (SAS 
Institute Inc., Cary, North Carolina) for IVRS, which will link sequential subject 
randomization numbers to treatment codes. The randomization will be stratified to balance 
subjects with prior TPO-receptor agonist use (yes/no) and degree of baseline 
thrombocytopenia (ie, baseline platelet count < or ≥15,000/µL). It will also use an 
appropriate block size, which will not be revealed. 
5.2 
Treatments Administered 
Subject specific doses will be prepared and checked by blinded pharmacy staff and 
administered by appropriately trained blinded clinic staff as delegated by the principal 
investigator at the study site. The study drugs will be identical in number and appearance for 
each group. The following dosing scheme will be performed: 
• 200 mg BID group: 2 capsules of 100 mg SKI-O-703 + 2 capsule of placebo 
• 400 mg BID group: 4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo 
• Placebo group: 4 capsules of placebo 
SKI-O-703 200 mg BID, 400 mg BID, and placebo will be administered orally. On Day 1, 
the investigative site staff will administer the morning dose of study medication. The evening 
dose will be administered 12 hours after the morning dose. Subjects will be administered the 
study medication with enough water to swallow the capsules. The investigative site staff will 
check the subject’s mouth to ensure the study drug and entire volume of water was 
swallowed. The study medication will be taken no later than 30 minutes after food. Subjects 
enrolled in the safety run in period will be admitted for 24 hours on Days 1, 8, and 84 or 85 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 48 
of the study. Subjects selected for the PK/PD portion of the study will be admitted for 24 
hours on Days 1 and 84 or 85 of the study. The subject will be instructed to self-administer 
the subsequent doses of the study medication in the morning and evening (12 hours after the 
morning dose) for the remaining study duration. 
Dosing of the study medication that occur on study visit days, subjects will take the morning 
dose of study drug in the office under the guidance of study site personnel after all specified 
study tests and procedures have been completed. However, if the visit cannot be scheduled in 
the morning, the subject will be instructed to take the morning dose at the regular schedule 
on that visit day. 
Each subject’s dosing schedule should be closely monitored by the site at each study visit. 
This will ensure that all subjects enrolled into the study maintain their original dosing 
schedule beginning with the first dose of study drug. 
If the subjects forget to take their study drug dose at their regularly scheduled dosing time, 
they should take the forgotten dose as soon as they remember the dose was missed, within 
4 hours of scheduled timepoint or at least 8 hours before the next scheduled dose. If the 
subjects experience any drug interruption(s), they should notify their study site physician. 
Such protocol violations may result in data that are not deemed evaluable (by the 
investigator) for a protocol analysis and/or may require subject(s) to be discontinued. 
5.3 
Identity of Investigational Product 
SKI-O-703 capsule is a Swedish orange capsule. Oscotec Inc. will provide adequate supplies 
of blinded SKI-O-703 and placebo capsules to the study site. 
SKI-O-703 capsules will contain the active ingredient SKI-O-703 (100 mg). 
Placebo capsules will be identical in appearance to the SKI-O-703 capsule and contain only 
microcrystalline cellulose and magnesium stearate. 
5.4 
Management of Clinical Supplies 
5.4.1 
Study Drug Packaging and Storage 
SKI-O-703 (100 mg) capsules and matching placebo capsules will be manufactured using a 
ProFill® capsule filler, packaged 70 counts each into high density polyethylene bottles, and 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 49 
shipped to the study site. Study drug will be packaged and labelled according to applicable 
local and regulatory requirements. 
Study drug must be stored in accordance with the manufacturer’s instructions. The storage 
conditions and expiry date will be indicated on the label. At the study site, study drug must 
be stored in a securely locked area and kept at a controlled room temperature with excursions 
between 15°C and 30°C. 
5.4.2 
Test Article Accountability 
The sponsor or affiliate will ship a sufficient supply of study drug to the study site. The 
investigator will maintain accurate records of receipt of all test articles, including dates of 
receipt. In addition, accurate records will be kept regarding when and how much test article 
is dispensed and used by each subject in the study. Subjects will be instructed to return all 
drug containers (even if empty) to the study site personnel at each clinic visit. Reasons for 
departure from the expected dispensing regimen must also be recorded. At the completion of 
the study, to satisfy regulatory requirements regarding drug accountability, all study drug will 
be reconciled and retained or destroyed according to applicable regulations. 
Subject dosing will be recorded on eCRF. Study drug will be dispensed bi-weekly (34 doses, 
17 days’ worth of drug at a time) to the subjects. Subjects will be instructed to return all drug 
containers (even if empty) to the study site personnel at each clinic visit. Site personnel will 
document compliance in the study source documents. 
5.5 
Overdose Management 
An overdose is any dose of study drug given to a subject or taken by a subject that exceeds 
the dose described in the protocol. A medication error is a preparation, dispensing, or 
administration error. Any overdose or medication error, with or without associated AEs, must 
be promptly reported to the investigator, medical monitor, and sponsor. Overdoses and 
medication errors without signs or symptoms do not need to be recorded as AEs; in case of 
any AEs associated with the overdose or medication error, these should be reported on 
relevant AE/SAE sections in the eCRF. 
Overdoses and medication errors will be documented as protocol deviations and 
communicated to the clinical study manager and/or safety manager. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 50 
No specific therapy for an overdose of SKI-O-703 exists. In the event of an overdose or 
medication error, therapy appropriate for the subject’s symptoms and clinical status should be 
provided. 
5.6 
Blinding 
This is a double-blind study. Neither the subjects nor the investigator/site personnel will be 
aware of the treatment assignment for the subjects in each cohort. Additionally, the study 
drugs will be identical in number and appearance for each cohort. Blinding will be 
maintained throughout the study by use of active or placebo dosage forms of similar 
appearance. 
The DMC will receive first 1-week safety and PK unblinded data by treatment group or 
unblinded (if necessary) confidential reports of the first 5 subjects enrolled in the safety 
run-in period from an independent statistician for review, which have to be handled strictly 
confidentially. None of these reports can be delivered to unauthorized persons. 
5.6.1 
Breaking the Blind 
A subject’s treatment assignment will not be broken until the end of the study unless medical 
treatment of the subject depends on knowing the study treatment the subject received, eg, 
bleeding events requiring rescue medication do not require breaking the blind unless 
knowing the treatment allocation may result in different management. 
In the event that the blind needs to be broken because of a medical emergency, the 
investigator may unblind an individual subject’s treatment allocation. As soon as possible, the 
investigator should first contact the medical monitor to discuss the medical emergency and 
the reason for revealing the actual treatment received by that subject. The treatment 
assignment will be unblinded through IVRS. Reasons for treatment unblinding must be 
clearly explained and justified in the eCRF. The date on which the code was broken together 
with the identity of the person responsible must also be documented. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 51 
5.7 
Treatment Compliance 
Day 1 doses of the study drug will be administered and recorded by study site personnel, and 
any deviations from the dosing schedule will be entered into the subject’s eCRF. From Day 2 
onwards, subjects will be instructed to self-administer their morning dose of study 
medication. The subject will be instructed to self-administer their evening dose 12 hours after 
the morning dose. Treatment compliance will be determined from subject dosing data in 
eCRF. 
5.8 
Prior and Concomitant Therapy 
Use of all concomitant medications that the subject is receiving at the time of Screening or 
receives during the study must be recorded in the subject’s eCRF. The minimum requirement 
is the reason for drug use, drug name, and the dates of administration (including start and end 
dates), dosage information including dose, route, and frequency are to be recorded in the 
eCRF. This will include all prescription drugs, herbal products, vitamins, minerals, vaccines, 
and over-the-counter medications (including folic acid). Any changes in concomitant 
medications also will be recorded in the subject’s eCRF. 
Any concomitant medication, except the prohibited medications listed in Section 5.8.3, 
deemed necessary for the welfare of the subject during the study may be given at the 
discretion of the investigator. However, it is the responsibility of the investigator to ensure 
that details regarding the medication are recorded in full in the eCRF. 
Subjects will be allowed to receive stable doses of background medications in line with the 
current standard of care. The background medications allowed include corticosteroids 
(<20 mg prednisone equivalent per day) and immunosuppressive drugs such as azathioprine 
(≤50 mg twice daily), mycophenolate mofetil (≤500 mg twice daily), and cyclosporine 
(≤100 mg twice daily). The dose of such background medications should be fixed for at least 
2 weeks before Day 1 and remain unchanged until 12 weeks of treatment have been 
completed or unless rescue therapy is required. 
5.8.1 
Rescue Medications 
In case of bleeding events requiring rescue medication, the following rescue medications are 
permitted: IVIG 1 g/kg/day for 2 days (ie, 2 g/kg), romiplostim 2 to 5 µg/kg, dexamethasone 
40 mg/day for 4 days, other high dose parenteral steroids (ie, solumedrol 1 g IV), platelet 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 52 
transfusions (these may be reserved for serious or life-threatening bleeding events), or 
standard of care as per participating countries. 
Subjects should be withdrawn in case of CNS bleeding or life-threatening GI bleeding (see 
Section 4.2.1). 
5.8.2 
Management of Nausea and Vomiting 
Based on Investigator’s discretion, nausea and vomiting can be managed based the National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grades 
as described below.  
• Grade 1: No routine anti-emetics are necessary. Consider oral domperidone 20 mg 
three times a day as needed or oral metoclopramide 20 mg three times a day as 
needed 
• Grade 2: Oral domperidone 20 mg three times a day as needed or oral 
metoclopramide 20 mg three times a day as needed 
• Grade 3: Oral domperidone 20 mg three times a day as needed or oral 
metoclopramide 20 mg three times a day as needed and consider levomepromazine 
6 mg at night as needed 
• Grade 4: Oral aprepitant 80 mg QD or oral domperidone 20 mg three times a day or 
oral metoclopramide 20 mg three times a day 
5.8.3 Prohibited Concomitant Medications 
The medical monitor must be notified in advance (or as soon as possible thereafter) of any 
instances in which prohibited medications are administered. Prohibited medications during 
the study include: 
• Any biological agents for the treatment of ITP 
• Any rescue medications other than those described in Section 5.8.1 
• Any immunosuppressant drugs other than those described in Section 5.8 
• Change in corticosteroid and immunosuppressants dose as detailed in the exclusion 
criteria 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 53 
• Use of IVIGs within 4 weeks prior to Day 1 
• Treatment with rituximab or splenectomy within the 8 weeks prior to Day 1 
• Any parenteral antibiotics as specified in the exclusion criteria 
• Any live vaccine taken within 28 days prior to Day 1 or plan to receive one during 
the study 
• Concomitant use of any anticoagulants and platelet aggregation inhibiting drugs 
including aspirin (within 14 days of planned dosing through end of follow-up) 
• Known CYP1A2 and UGT1A1 inhibitors and inducers (See Appendix 13.1 for a 
list of suggested named CYP1A2 and UGT1A1 inhibitors and inducers). These 
medications must be discontinued within 5 half-lives or 4 weeks prior to Day 1, 
whichever is longer. 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 54 
6 
Study Assessments and Procedures 
Before performing any study procedures, all potential subjects will sign an ICF. Subjects will 
have the opportunity to have any questions answered before signing the ICF. The investigator 
must address all questions raised by the subject. The investigator will also sign the ICF. 
6.1 
Study Visits 
The total study duration will be 20 weeks per subject, which consists of up to 4 weeks of 
screening period. The treatment period will be 12 weeks (split into 1-week safety run-in 
period and 11-week treatment period for the first 5 subjects). The post-treatment follow-up 
period will be of 4 weeks. Each assessment will be carried out at timepoints indicated in the 
Schedule of Events table and clarified in the footnotes presented below the table. The 
schedule of events is summarized in Table 2.


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 55 
Table 2 
Schedule of Events 
  
  
On-treatment Visits 
Follow-up Clinic Visits 
Early 
Withdrawal/ 
Unscheduled 
visit 
  
Screening 
(D-28 to 
D-1) 
W1 (D1), 
W5 and 
9 (±3 days) 
W1D4 
(±1 day) 
W2D8 
(±2 days) 
W3, 7, 
11 (±3 days) 
W12 (D84 or 
D85) (EOT) 
(±3 days) 
End of Study 
W16 (±1 week) 
Clinic visits 
X 
Xa 
Xa* 
Xa 
Xa 
Xa 
X 
Informed consent 
X 
 
 
 
 
 
 
 
Inclusion/Exclusion criteria 
X 
Xh 
 
 
 
 
 
 
AEs 
<--------------------------------------------------------------------------------------------------------------> 
X 
Concomitant medications 
X 
X 
 
X* 
X 
X 
X 
X 
Height 
X 
 
 
 
 
 
 
 
Weight 
X 
X 
 
X* 
 
X 
X 
X 
Physical examination/medical 
historyb 
X 
X 
 
X* 
X 
X 
X 
X 
ECGc 
X 
X 
 
X 
 
X 
X 
X 
Vital signs 
X 
X 
 
X* 
X 
X 
X 
X 
Urinalysis 
X 
X 
 
X* 
X 
X 
X 
X 
Hep B & C, HIV, HBV DNA, 
HCV RNA 
X 
 
 
 
 
 
 
 
Pregnancy test/ FSHd 
X 
X 
 
 
 
X 
X 
X 
Contraception status 
X 
X 
 
X* 
 
X 
X 
X 
ABO and Rh blood type 
X 
 
 
 
 
 
 
 
Serum chemistry 
X 
X 
 
X* 
X 
X 
X 
X 
Hematology, differential 
X 
X 
Xa,e 
Xa,e 
X 
X 
X 
X 
PT/INR PTT 
X 
 
 
 
 
X 
 
 
Study drug dispensing 
 
X 
 
 
X 
 
 
Xf 
Study drug administration 
 
X 
X 
X* 
X 
X 
 
Xf 
Blood samples for PK and PD 
assessmentsg 
 
Xh 
 
X* 
 
X 
 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 56 
  
  
On-treatment Visits 
Follow-up Clinic Visits 
Early 
Withdrawal/ 
Unscheduled 
visit 
  
Screening 
(D-28 to 
D-1) 
W1 (D1), 
W5 and 
9 (±3 days) 
W1D4 
(±1 day) 
W2D8 
(±2 days) 
W3, 7, 
11 (±3 days) 
W12 (D84 or 
D85) (EOT) 
(±3 days) 
End of Study 
W16 (±1 week) 
Bleeding Scorei 
 
X 
 
X* 
 
X 
X 
X 
Quality of life using SF-36 score 
 
X 
 
 
 
X 
X 
X 
Pharmacogenomic screening 
 
Xj 
 
 
Abbreviations: AEs, adverse events; D, Day; ECG, 12-lead electrocardiogram; EOT, end-of-treatment; FSH, follicle stimulating hormone; HBV, hepatitis B virus; HCV, 
hepatitis C virus; hep, hepatitis; HIV, human immunodeficiency virus; PD, pharmacodynamics; PK, pharmacokinetics; PT/INR, prothrombin time/international normalized 
ratio, PTT, partial thromboplastin time; W, Week 
* 
Subjects in the safety run-in period will have clinic visit on Week 2/Day 8 (±2 days) for the mentioned assessments including hematology (differential) tests. For other 
subjects, this visit will be laboratory only visit to perform hematology (differential) tests only. 
a 
Clinic / laboratory visit windows are about ± 3 days for all dosing period and laboratory visits and about ± 1 week for clinic follow-up visits. The W12/D84 or D85 (EOT) 
visit should be performed while on therapy. 
b 
Complete physical examination at Screening and abbreviated physical examination at other visits. 
c 
For all subjects: predose ECG on the first day of dosing and on Day 1 of each subsequent week as specified in the table above. For subjects in the safety run-in subsets and 
PK/PD subset who are in safety run-in subset only: ECG on the first day of dosing at predose, 1, 2, 4, 8, and 12 hours (±10 min) after the study drug administration. 
d 
For women of childbearing potential only: Serum pregnancy tests are performed at Screening. To confirm pregnancy, urine pregnancy test will be performed locally on Day 1 
prior to randomization and prior to study drug administration on clinic visit days at mentioned timepoints. If urine pregnancy test is negative, dosing will be started; if urine 
pregnancy test is positive then with-hold dosing and perform a serum pregnancy test. FSH testing is needed at Screening for post-menopausal female subjects only. 
e 
Laboratory only visits will be performed on Day 4 ±1 day (Week 1) for all subjects and on Week 2/Day 8 (±2 days) for subjects other than those enrolled in the safety run-in 
period.  
f 
Study drug dispensing and administration can occur at unscheduled visit.  
g 
Samples to be collected as follows: 
For the subjects in the safety run-in period only (for PK only; no PD assessments):  
• 
Day 1: morning predose, 0.25 (+5 min), 0.5 (±5min), 1, 2, 4, 8, and 12 hours (±10 min) (evening predose).  
• 
Day 8 (±2 days): morning predose, 0.25 (+5 min), 0.5 (±5min), 1, 2, 4, 8, and 12 hours (±10 min) (evening predose). 
• 
Week 12: morning predose, 0.25 (+5 min), 0.5 (±5min), 1, 2, 4, 8, and 12 hours (±10 min). 
For the subjects in the PK/PD subset only (for PK/PD): 
• 
Day 1: morning predose, 0.25 (+5 min), 0.5 (±5min), 1, 2, 4, 8, and 12 hours (±10 min) (evening predose).  
• 
Week 12: morning predose, 0.25 (+5 min), 0.5 (±5min), 1, 2, 4, 8, and 12 hours (±10 min). 
For other subjects not included in the safety run-in period or PK/PD subset (for PK only): 
• 
Week 12: morning predose. 
h 
Only on Day 1 (Week 1). 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 57 
i 
Bleeding score assessment as described by Page et al 2007 should be performed on Day 1 of each week specified in the above table and at follow-up visit. 
j 
A blood sample for genotyping will be drawn once at any clinic visit from Day 1 (Week 1) to the end-of-treatment visit, only from subjects who have consented to participate 
in the genetic analysis component of the study. 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 58 
6.2 Demographic and Medical History 
Demographic data and a complete medical history (including prior and concomitant medical 
conditions and procedures; drug, alcohol, and tobacco use; current use of herbal remedies, 
vitamin supplements, grapefruit juice, and caffeine- and xanthine-containing products) will 
be collected at Screening. 
6.3 
Efficacy Assessments 
Efficacy will be assessed based on the laboratory and clinical assessments/bleeding score. 
See Section 7. 
6.4 
Safety Assessments 
Safety variables will include physical examination findings, vital sign measurements 
(systolic and diastolic blood pressure, pulse rate, respiratory rate, and temperature), ECG 
tracings, clinical laboratory test results (hematology, coagulation, serum chemistry, and 
urinalysis), bleeding score, quality of life as measured by the SF-36 score, weight, body mass 
index, and reporting of AEs. 
Bleeding will be assessed according to the bleeding score as described by Page et al 2007. 
These assessments will be carried out at the time points indicated in the schedule of events. 
Safety assessments will be conducted as shown in the schedule of events (Table 2). 
6.4.1 Physical Examination 
A complete physical examination will be performed at the screening visit and an abbreviated 
physical examination at other time points indicated in the schedule of events (Table 2). An 
abbreviated physical examination will include checks of general appearance, head and neck, 
abdomen, lymph nodes, skin, cardiovascular system, respiratory system, and musculoskeletal 
system. 
A complete physical examination will include assessments of skin, head, ears, eyes, nose, 
throat, neck, thyroid, lungs, cardiovascular system, abdomen, lymph nodes, and 
musculoskeletal system/extremities. Interim physical examinations can be performed at the 
discretion of the investigator, if deemed necessary to evaluate AEs or clinical laboratory 
abnormalities. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 59 
6.4.2 Vital Sign Measurements, Height, and Weight 
Vital sign measurements will include systolic and diastolic blood pressures, pulse rate, 
respiratory rate, and temperature. The subject will be seated for at least 5 minutes before all 
measurements are taken. Vital signs will be measured at the time points indicated in the 
schedule of events (Table 2). 
Height will be measured at Screening only. Weight will be measured at the time points 
indicated in the schedule of events (Table 2). 
When procedures are overlapping and occurring at the same time point, the order in which 
procedures are performed should be vital sign measurements followed by blood collection. 
The investigator will determine whether any of the vital sign measurements are clinically 
significant or not clinically significant. Clinical significance is defined as any variation in 
results that has medical relevance and may result in an alteration in medical care (eg, active 
observation, diagnostic measures, or therapeutic measures). If a clinically significant change 
from the screening values is noted, the clinically significant value and the reason for clinical 
significance will be documented on the AE page of the subject’s eCRF. The investigator will 
continue to monitor the subject with additional assessments until the value has reached either 
the reference range or the value at Screening or until the investigator determines that 
follow-up is no longer medically necessary. 
6.4.3 Electrocardiograms 
For all subjects, single ECG (predose) will be obtained, after the subject has been in the 
supine position for at least 5 minutes, on the first day of dosing and on Day 1 of each 
subsequent week at the time points indicated in the schedule of events (Table 2). For subjects 
in the safety run-in subsets and PK/PD subset subjects who are in safety run-in subset only, 
ECGs will be obtained on the first day of dosing at predose, 1, 2, 4, 8, and 12 hours (±10 
min) after the study drug administration. Electrocardiogram assessments will include 
comments on the rhythm; presence of arrhythmia or conduction defects; morphology; or 
ST segment, T wave, and U wave abnormalities; as well as whether the tracings are normal 
or abnormal and if there is any evidence of myocardial infarction. In addition, the following 
parameters will be measured and reported: RR interval, PR interval, QRS width, QT interval, 
and QTcF. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 60 
The investigator will determine whether any of the ECG results are normal or abnormal and 
whether any abnormal results are clinically significant or not clinically significant. Clinical 
significance is defined as any variation in results that has medical relevance and may result in 
an alteration in medical care (eg, active observation, diagnostic measures, or therapeutic 
measures). If a clinically significant change from screening is noted, the clinically significant 
value and the reason for clinical significance will be documented on the AE page of the 
subject’s eCRF. The investigator will continue to monitor the subject with additional 
assessments until the values have reached either the reference range or the values at 
Screening or until the investigator determines that follow-up is no longer medically 
necessary. 
6.4.4 Clinical Laboratory Tests 
Clinical laboratory tests will be performed by PPD’s central laboratory. Blood and urine 
samples will be collected under fasted conditions and at the time points indicated in the 
schedule of events (Table 2). 
For women of childbearing potential only: Serum pregnancy tests will be performed at 
Screening. To confirm pregnancy, urine pregnancy test will be performed locally. For 
post-menopausal female subjects only, FSH testing will be performed at Screening. 
The following hematology, coagulation, serum chemistry, and urinalysis assessments will be 
performed: 
Hematology: Hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, mean corpuscular volume, platelet count, red blood cell 
count, total and differential (absolute and percent) leukocyte count, and erythrocyte 
sedimentation rate 
Coagulation: International normalized ratio, partial thromboplastin time, and prothrombin time, 
ABO and Rh Blood Type 
Serum 
Chemistry: 
Alanine aminotransferase, albumin, alkaline phosphatase, AST, bilirubin (total and 
direct if clinically indicated), blood urea nitrogen, calcium, creatinine, 
gamma-glutamyltransferase, glucose, lactate dehydrogenase, serum electrolytes 
(sodium, potassium, chlorine, magnesium, phosphate) and total protein 
Urinalysis: 
Appearance, bilirubin, color, glucose, ketones, leukocyte esterase, microscopy 
(performed if dipstick is positive; includes bacteria, casts, crystals, epithelial cells, 
red blood cells, and white blood cells), nitrites, occult blood, pH, protein, specific 
gravity, turbidity, and urobilinogen 
 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 61 
Abnormal clinical laboratory values will be flagged as either high or low (or normal or 
abnormal) based on the reference ranges for each laboratory parameter. The investigator will 
determine whether any abnormally high or low results are clinically significant or not 
clinically significant. Clinical significance is defined as any variation in results that has 
medical relevance and may result in an alteration in medical care (eg, active observation, 
diagnostic measures, or therapeutic measures). If a clinically significant change from the 
screening value is noted, the clinically significant value and the reason for clinical 
significance will be documented on the AE page of the subject’s eCRF. The investigator will 
continue to monitor the subject with additional assessments until the values have reached 
either the reference range or the values at Screening or until the investigator determines that 
follow-up is no longer medically necessary. 
The FDA guidance for industry on Drug-Induced Liver Injury: Premarketing Clinical 
Evaluation (July 2009) will be used as a guideline for the assessment of liver enzymes/liver 
function tests (DHHS 2009). 
Clinically significant laboratory values for individual subjects will be listed. A summary for 
the numbers and percentages of subjects with clinically significant laboratory values at any 
time point will be presented. 
6.4.5 
Adverse Events 
6.4.5.1 
Definitions of Adverse Events 
The investigator is responsible for reporting all TEAEs that are observed or reported during 
the study, regardless of their relationship to study drug or their clinical significance. 
An AE is defined as any untoward medical occurrence in a subject enrolled into this study 
regardless of its causal relationship to study drug. Subjects will be instructed to contact the 
investigator at any time after randomization if any symptoms develop. 
A TEAE is defined as any event not present before exposure to study drug or any event 
already present that worsens in either intensity or frequency after exposure to study drug. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 62 
6.4.5.2 
Serious Adverse Events 
An SAE is defined as any event that: 
• Results in death 
• Is immediately life threatening 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, 
they may jeopardize the subject or may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of 
drug dependency or drug abuse. 
Note: The AE terms neutropenia and hypertension should be used only when reporting 
events that meet the following criteria:  
• The term neutropenia is reserved for reporting an absolute neutrophil 
count <1000/mm3 or <1.0 × 109/L and may or may not be associated with fever or 
concurrent infection. 
• The term hypertension is reserved for reporting an increase in systolic blood pressure 
≥160 mmHg, or diastolic blood pressure ≥100 mmHg, or any clinically significant 
increase in blood pressure that requires modification of the subject’s antihypertensive 
regimen. 
6.4.5.3 
Eliciting and Documenting Adverse Events 
Adverse events will be assessed from the time the subject signs the informed consent form 
until end of study visit (Week 16). 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 63 
If the investigator becomes aware of an SAE that occurs after the end of study visit and is 
assessed by the investigator as at least possibly related to the study drug, they need to report 
the SAE. 
At every study visit, subjects will be asked a standard nonleading question to explore a 
response regarding any medically related changes in their well-being. They will also be asked 
if they have been hospitalized, had any accidents, used any new medications, or changed 
concomitant medication regimens (both prescription and over-the-counter medications). 
In addition to subject observations, AEs identified from any study data (eg, laboratory values, 
physical examination findings, ECG changes) or identified from review of other documents 
that are relevant to subject safety will be documented on the AE page in the eCRF. 
6.4.5.4 
Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. 
Information to be collected includes drug treatment, dose, event term, time of onset, 
investigator-specified assessment of severity and relationship to study drug, time of 
resolution of the event, seriousness, any required treatment or evaluations, and outcome. 
Adverse events resulting from concurrent illnesses, reactions to concurrent illnesses, 
reactions to concurrent medications, or progression of disease states must also be reported. 
All AEs will be followed to adequate resolution. The Medical Dictionary for Regulatory 
Activities (MedDRA v20.0) will be used to code all AEs. All AEs, SAEs, drug-related AEs, 
and drug-related SAEs will be summarized using the worst grade per NCI CTCAE v5.0 by 
system organ class and preferred term. 
Any medical condition that is present at the time that the subject is screened but does not 
deteriorate should not be reported as an AE. However, if it deteriorates at any time during the 
study, it should be recorded as an AE. 
6.4.5.5 
Reporting Serious Adverse Events 
Any AE that meets SAE criteria (Section 6.4.5.2) must be reported to PPD immediately (ie, 
within 24 hours) after the time that site personnel first learn about the event. The nonserious 
adverse event of special interest (AESI) defined in Section 6.4.5.6 should be recorded on the 
SAE report form in addition to the eCRF and faxed using the same process as for reporting 
SAEs. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 64 
 
Pharmacovigilance 
 
 
6.4.5.6 
Suspected Unexpected Serious Adverse Reactions and 
Nonserious Adverse Events of Special Interest 
The following nonserious AESI should be recorded on the SAE report form in addition to the 
eCRF and faxed using the same process as for reporting SAEs. 
• Neutropenia with fever defined as absolute neutrophil count <1000/mm3 or <1.0 × 109/L 
on the most recent complete blood count with fever equal to or greater than 38°C that 
does not fulfill any of the serious criteria, ie, hospitalization. 
• Hepatotoxicity defined as ALT >3 × ULN plus total bilirubin >2 × ULN that does not 
fulfill any of the serious criteria, ie, hospitalization. This information should be recorded 
on the drug induced liver injury eCRF each time the elevated laboratory parameters are 
met during the study 
Oscotec Inc. will promptly evaluate all suspected unexpected serious adverse reactions 
(SUSARs) and nonserious AESI against cumulative product experience to identify and 
expeditiously communicate possible new safety findings to investigators, Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC), and applicable health authorities 
based on applicable legislation. 
To determine reporting requirements for single AE cases, Oscotec Inc. will assess the 
expectedness of these events using the study drug investigator’s brochure. 
Oscotec Inc. will compare the severity of each SUSAR and the cumulative event frequency 
reported for the study with the severity and frequency reported in the applicable reference 
document. 
Reporting requirements will also be based on the investigator's assessment of causality and 
seriousness, with allowance for upgrading by Oscotec Inc. as needed. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 65 
6.4.5.7 
Assessment of Severity 
The severity, or intensity, of an AE refers to the extent to which an AE affects the subject’s 
daily activities. The intensity of the AE will be rated using the NCI CTCAE v5.0. 
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be performed. Adverse events characterized 
as intermittent do not require documentation of the onset and duration of each episode. 
6.4.5.8 
Assessment of Causality 
The investigator’s assessment of an AE’s relationship to study drug is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
study. If there is any doubt as to whether a clinical observation is an AE, the event should be 
reported. The relationship or association of the study drug in causing or contributing to the 
AE will be characterized using the following classification and criteria: 
Unrelated: 
This relationship suggests that there is no association between the study drug 
and the reported event. 
Possible: 
This relationship suggests that treatment with the study drug caused or 
contributed to the AE, ie, the event follows a reasonable temporal sequence 
from the time of drug administration or follows a known response pattern to 
the study drug but could also have been produced by other factors. 
Probable: 
This relationship suggests that a reasonable temporal sequence of the event 
with drug administration exists and, based upon the known pharmacological 
action of the drug, known or previously reported adverse reactions to the drug 
or class of drugs, or judgment based on the investigator’s clinical experience, 
the association of the event with the study drug seems likely. The event 
disappears or decreases on cessation or reduction of the dose of study drug. 
Definite: 
This relationship suggests that a definite causal relationship exists between 
drug administration and the AE, and other conditions (concurrent illness, 
progression/expression of disease state, or reaction to concurrent medication) 
do not appear to explain the event. The event reappears or worsens if the 
study drug is re-administered. 
6.4.5.9 
Follow-Up of Subjects Reporting Adverse Events 
All AEs must be reported in detail on the appropriate page in the eCRF and followed to 
satisfactory resolution, until the investigator deems the event to be chronic or not clinically 
significant, or until the subject is considered to be stable. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 66 
6.5 
Pharmacokinetic and Pharmacodynamic Assessments 
6.5.1 Pharmacokinetic Blood Samples 
Serial blood samples (5 mL) for PK assessment of SKI-O-592 and its metabolites (M2 and 
M4) will be collected from all subjects in the PK/PD subset at the following time points:  
• Day 1: 0 hour (morning pre-dose), and at 0.25 (+5 min), 0.5 (±5min), 1, 2, 4, 8 and 
12 hours (±10 min) morning post-dose (12-hr sample should be collected prior to 
the evening dose). 
• Week 12 (Day 84 or 85): 0 hour (morning pre-dose), and 0.25 (+5 min), 0.5 
(±5min), 1, 2, 4, 8, and 12 hours (±10 min). 
In addition, PK samples will also be collected at the following time points on Day 8 
(±2 days) from subjects in the safety run-in period only: 
• Day 8 (±2 days): 0 hour (morning pre-dose), and at 0.25 (+5 min), 0.5 (±5min), 1, 
2, 4, 8 and 12 hours (±10 min) morning post-dose (12-hr sample should be 
collected prior to the evening dose). 
For other subjects not included in the safety run-in period or PK/PD subset, morning 
pre-dose PK samples will be collected during Week 12 only. 
When the PK blood sample collection coincides with safety assessments, PK blood samples 
should be collected as close to the scheduled time point as possible, and safety assessments 
should be performed before PK blood samples are taken. 
For each sample collected, separated plasma will be transferred in approximately equal 
portions into 2 tubes that are labeled for sets A and B for SKI-O-592 and metabolites. Labels 
will include the study number, the subject identification number, an indication that they are 
PK samples, the nominal day and collection time, the analyte(s), and the set (A or B). Plasma 
samples will be stored at approximately –70°C in an upright position. 
Set A samples will be transported, frozen with sufficient dry ice for several days, to the 
bioanalytical facility. 
Set B samples will be retained at the study center until the study is completed and the clinical 
study report is issued, unless shipment to another facility is requested by the Oscotec Inc. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 67 
Instructions regarding the disposition of the B samples will be provided by the Oscotec Inc. 
Specific details and the full protocol for analysis of PK samples can be found in the study 
laboratory manual. 
6.5.2 Pharmacokinetic Variables 
Plasma PK parameters will be calculated for SKI-O-592 and its metabolites M2 and M4 in 
the PK/PD subset using a noncompartmental approach and will include the following, where 
applicable:  
Cmax 
 
maximum observed concentration 
Tmax 
 
time to reach the maximum observed concentration 
AUC0-tau 
area under the concentration versus time curve within a dosing interval 
t1/2 
 
apparent terminal elimination half-life  
Kel 
 
terminal elimination rate constant 
CL/F  
apparent oral clearance (SKI-O-592 only)  
Vz/F 
 
apparent oral volume of distribution (SKI-O-592 only) 
Rmet 
 
metabolite ratio 
RAUC  
accumulation ratio based on AUC0-tau 
Additional PK parameters may be estimated, as deemed appropriate.  
6.5.3 Pharmacodynamic Blood Samples 
Serial blood samples for assessment of the percentage of activated CD63+ basophils in 
peripheral blood will be collected in all subjects in the PK/PD subset at the following times: 
• Day 1: 0 hour (morning pre-dose), and 0.25 (+5 min), 0.5 (±5 min), 1, 2, 4, 8 and 
12 hours (±10 min) morning post-dose (12-hr sample should be collected prior to 
the evening dose).  
• Day 84 or 85 (Week 12): 0 hour (morning pre-dose), and at 0.25 (+5 min), 0.5 
(±5 min), 1, 2, 4, 8, and 12 hours (±10 min). 
Blood samples must be dispatched to the processing laboratory as quickly as possible to 
ensure transport, cataloguing, and processing time is complete within the required timeframe 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 68 
for the selected assay. All blood collection systems must be pyrogen free. Blood samples 
(0.5 mL) will be collected into tubes containing dipotassium ethylene diamine tetra acetic 
acid (K2 EDTA) anticoagulant. Tubes containing ethylene diamine tetra acetic acid or citric 
acid as anticoagulant are prohibited. Samples are to be stored at 2°C to 8°C prior to shipping 
and packed with ice pack for shipping. 
Specific details and the full protocol for analysis of PD samples can be found in the study 
laboratory manual. 
6.5.4 Pharmacodynamic Variables 
The primary PD endpoint will be the change in the percentage of activated CD63+ basophils 
in peripheral blood. The PD parameters will include the following:  
Emax   
 
maximum effect 
TEmax   
 
time to achieve maximum effect 
AUEC0-tau  
 
area under the effect versus time curve within a dosing interval 
Additional PD endpoints/parameters may be evaluated, as deemed appropriate. 
6.6 
Safety Monitoring Committee 
An independent DMC appointed by the Sponsor will review the interim safety and PK data 
of the first 5 subjects enrolled in the safety run-in period. Further details will be provided in 
the DMC charter. 
6.7 
Pregnancy 
Pregnancy is not regarded as an AE unless it is suspected that study drug interfered with the 
effectiveness of a contraceptive medication. Any pregnancy that occurs during study 
participation must be reported using a clinical study pregnancy form. To ensure subject 
safety, each pregnancy must be reported to the sponsor within 2 weeks of learning of its 
occurrence. The pregnancy must be followed up at least 30 days after birth or the first 
well-baby visit to determine the outcome (including spontaneous miscarriage, elective 
termination, normal birth, or congenital abnormality) and the status of mother and child, even 
if the subject was discontinued from the study. Pregnancy complications and elective 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 69 
terminations for medical reasons must be reported as AEs or SAEs. Spontaneous 
miscarriages must be reported as SAEs. 
Any SAE occurring in association with a pregnancy that is brought to the investigator’s 
attention after the subject has completed the study and that is considered by the investigator 
as possibly related to the study drug must be promptly reported to the sponsor. 
Contraception status will be monitored at each visit and documented appropriately. 
6.8 
Laboratory Analyses 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, ECGs, vital sign measurements), including those that worsen from 
baseline, felt to be clinically significant in the medical and scientific judgment of the 
investigator are to be recorded as AEs or SAEs. 
However, any clinically significant safety assessments that are associated with the underlying 
disease, unless judged by the investigator to be more severe than expected for the subject’s 
condition, are not to be reported as AEs or SAEs. 
6.9 
Sample Collections 
The total volume of blood collected for each assessment is discussed in each specific 
laboratory manual. 
6.10 Pharmacogenomic Screening 
A 6-mL whole blood sample for genotyping will be drawn at Baseline (Day 1, before dosing) 
from subjects who have consented to participate in the genetic analysis component of the 
study to potentially explore genetic polymorphisms of the enzymes (eg, UGT1A1) 
responsible for the metabolism of SKI-O-703 and the association of these genetic 
polymorphisms with the PK of SKI-O-703. Further details of blood collection and processing 
will be provided in the laboratory manual. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 70 
7 
Statistical and Analytical Plan 
7.1 
Primary Endpoint - Platelet Response 
• Patient platelet response is defined as platelet count ≥ 30,000/µL and doubling the 
baseline (average of 2 previous counts), at any visit during the treatment period and 
without the use of rescue medication 
7.2 
Secondary Endpoints 
7.2.1 
Subjects Achieving Two or More Pre-specified Platelet Counts 
• Subjects able to achieve 2 or more consecutive platelet counts of ≥ 30,000/µL separated 
by at least 5 days and without use of rescue medication 
• Subjects able to achieve 2 or more consecutive platelet counts of ≥ 30,000/µL with an 
increase of platelet count of ≥ 20,000/µL from baseline separated by at least 5 days and 
without use of rescue medication 
• Subjects able to achieve 2 or more consecutive platelet counts of ≥ 50,000/µL separated 
by at least 5 days and without use of rescue medication 
• Subjects able to achieve 2 or more consecutive platelet counts of ≥ 100,000/µL during the 
treatment period, separated by at least 5 days and without use of rescue medication 
• Subjects able to achieve platelet counts of ≥ 50,000/µL at 3 of the last 4 visits. 
7.2.2 
Change from Baseline in Platelet Counts 
• Change from baseline in the average of the last 2 platelet counts during the treatment 
period 
For each subject, the change from baseline in the mean of the last 2 platelet counts during the 
treatment period will be calculated. For those subjects with only 1 platelet count during 
treatment period, the change from baseline in the single platelet count will be used. 
7.2.3 
Time to First Platelet Response 
• Time to first platelet response (>30,000/µL and 2 x baseline) 
For each subject, the time of the first platelet response is the first visit during treatment 
period in which platelet count ≥ 30,000/µL without use of rescue medication. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 71 
7.2.4 
Others 
• Number of subjects receiving rescue medication at least once during treatment period 
• Subjects with at least one Grade 2 or higher non-skin bleeding event during treatment 
period. 
For each endpoint, a subject will be considered to have had an event if the event was 
observed at least once during the treatment period for rescue medication, and during 
treatment or follow-up period for bleeding event. 
7.3 
Exploratory Endpoints 
7.3.1 
Peak Platelet Count 
• Peak platelet counts during the treatment period without use of rescue medication 
For each subject, peak platelet count is subject’s highest platelet count during the treatment 
period, without use of rescue medication. 
7.3.2 
Bleeding Score 
The ITP bleeding assessment score as described by Page et al. 2007 will be used to 
characterize bleeding tendency. 
Table 3 
The ITP Bleeding Score Assessment 
Site 
Bleeding Grade 
0 
1 
2 
Skin [physical 
Examination (PE)] 
None 
1–5 bruises and/or scattered petechiae 
>5 bruises with size >2 cm and/or 
diffuse petechiae 
Oral (PE) 
None 
1 blood blister or >5 petechiae or gum 
bleeding that clears easily with rinsing 
Multiple blood blisters and/or gum 
bleeding 
Skin (Hx) 
None 
1–5 bruises and/or scattered petechiae 
>5 bruises with size >2 cm and/or 
diffuse petechiae 
Oral (Hx) 
None 
1 blood blister or >5 petechiae and/or 
gum bleeding <5 min 
Multiple blood blisters and/or gum 
bleeding >5 min 
Epistaxis 
None 
Blood when blowing nose and/or 
epistaxis <5 min (per episode) 
Bleeding >5 min (per episode) 
Gastrointestinal 
None 
Occult blood 
Gross blood 
Urinary 
None 
Microscopic (+ve dipstick) 
Macroscopic 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 72 
Site 
Bleeding Grade 
0 
1 
2 
Gynecological 
None 
(normal 
period) 
Spotting not at time of normal period 
Bleeding >spotting not at time of 
period or very heavy period 
Pulmonary 
None 
N/A 
Yes 
Intracranial 
haemorrhage 
None 
N/A 
Yes 
Subconjunctival 
haemorrhage 
None 
Yes 
N/A 
Abbreviations: ITP, immune thrombocytopenia; PE, physical examination; N/A, not applicable 
Note: In case of a breakthrough bleeding, the subjects will discontinue the trial. 
7.3.3 
Quality of Life as Measured by the SF-36 Score 
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. 
The SF-36 is a measure of health status and the survey will be conducted according to the 
SF-36 quality of life questionnaire Version 2.0. 
The assessments will be performed at time points indicated in the schedule of events 
(Table 2). 
7.4 
Sample Size Calculations 
A minimum of 60 subjects will be enrolled in the study. Subjects will receive either 200 mg 
BID or 400 mg BID of SKI-O-703 or placebo in a 2:2:1 ratio. 
Based on Podolanczuk et al (2009) at least 50% of subjects in the active treatment group will 
be responders (R). A sample size of 24 subjects per active treatment group and 12 subjects in 
the placebo group will provide approximately 82.7% power to detect a difference between 
response rates of 50% and 1% in the active treatment and placebo groups, respectively, at the 
2-sided 5% significance level. The test statistic used in the sample size calculation was the 
2-sided Fisher's Exact test using the normal approximation method. 
Subjects that do not receive the study drug or do not provide at least 1 post baseline 
measurement will be excluded from the analysis above and replaced. 
There will be no adjustment for multiple comparisons. The sample size calculation was 
performed using PASS 15 Power Analysis and Sample Size Software (2017). NCSS, LLC. 
Kaysville, Utah, USA, ncss.com/software/pass. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 73 
7.5 
Analysis Sets 
The following analysis sets will be used in the statistical analyses. 
Safety set: The safety set will consist of all subjects who receive at least 1 dose of study drug 
(SKI-O-703 or placebo). Subjects will be analyzed according to the treatment they received. 
This analysis set will be used in the analysis of demographic and safety data. 
Intent-to-Treat (ITT) set: The ITT set will consist of all randomized subjects who receive at 
least 1 dose of study drug (SKI-O-703 or placebo) and have at least 1 post-baseline platelet 
assessments. Subjects will be analyzed according to the treatment arm to which they were 
randomized. This analysis set will be used for efficacy summaries, including the analysis of 
the primary endpoint. 
Per-protocol (PP) set: The PP set will consist of all subjects in ITT set with no major protocol 
violations. Major protocol violations will be identified during the study. Subjects will be 
analyzed according to the treatment arm to which they were randomized. This analysis set 
will be used for efficacy summaries, including the analysis of the primary endpoint. 
Pharmacokinetic (PK) set: The PK set will consist of all subjects who receive SKI-O-703 and 
have at least 1 measurable plasma concentration. Subjects who have partial data and/or major 
protocol deviations that may impact PK, and subjects who experience emesis, will be 
evaluated on a case-by-case basis and may be excluded from the PK analysis set. This 
analysis set will be used for summaries of PK data. 
Pharmacodynamic (PD) set: The PD set will consist of all subjects who receive at least 
1 dose of study drug (SKI-O-703 or placebo) and have at least 1 evaluable postdose PD 
value. Subjects who have partial data and/or major protocol deviations that may impact PD 
will be evaluated on a case-by-case basis and may be excluded from the PD analysis set. This 
analysis set will be used for summaries of PD data. 
Pharmacokinetic (PK)/pharmacodynamic (PD) set: All subjects included in the PK and PD 
analysis sets. This analysis set will be used for the PK/PD analyses. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 74 
7.6 
Description of Subgroups to be Analyzed 
The primary endpoint will be summarized using the following subgroups of interest: 
• Number of previous lines of therapy (0-2 vs. ≥3) 
• Response to previous treatment (non-responders vs. relapsed) 
• Splenectomized subjects vs. non-splenectomized subjects and  
• Subjects with baseline platelet count < 15,000/µL versus subjects with platelet count 
between 15,000/µL to 30,000/µL. 
• Subjects with prior TPO-receptor agonist use versus subjects without prior TPO-receptor 
agonist use. 
7.7 
Statistical Analysis Methodology 
Statistical analysis will be performed using SAS software Version 9.4 or later. The results for 
each efficacy endpoint will be summarized by visit and treatment for all subjects within the 
ITT analysis set using descriptive statistical methods. Continuous variables (quantitative 
endpoints) will be summarized using the mean, the standard deviation (SD), median, range 
(minimum value and maximum value), and interquartile. Categorical variables (qualitative 
endpoints) will be summarized using frequency counts (number) and percentages. Data will 
be listed in data listings. 
Details of the statistical analyses, methods, and data conventions will be described in the 
statistical analysis plan. 
All statistical tests will be 2-sided using a 5% significance levels, leading to 95% (2-sided) 
confidence intervals (CIs). This will be used for each pairwise comparison with placebo, ie, 
there will be no adjustments for multiplicity since this is a Phase 2 study. 
7.7.1 Subject Disposition 
Subject disposition will be summarized by treatment group and will include subjects that 
enrolled, were randomly assigned, discontinued, and completed the study. For discontinued 
subjects, the reasons for discontinuation will be summarized. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 75 
7.7.2 Analyses of Demographic and Baseline Characteristics 
Demographic and baseline characteristics such as age, gender, race, body weight, height, 
body mass index, and medical history will be summarized by treatment group using 
descriptive statistics. 
7.7.3 
Analysis of Platelet Response 
The primary efficacy endpoint will be summarized as overall platelet response rate (ORR) by 
treatment group and analyzed using Fisher’s exact test to compare the difference in ORR 
between each active treatment group and placebo. A logistic regression model will also be 
performed on platelet response and include treatment, baseline platelet count and prior 
TPO-receptor agonist use, provided there are enough subjects in each subgroup. The odds 
ratio for the treatment effect compared to placebo (together with 95% CI and p-value) will be 
provided. 
Summary statistics will be provided on the number (%) of subjects achieving platelet 
response by each treatment group and the combined active treatment group. Fisher’s exact 
test on the differences in the ORR will therefore be provided for: 
• Each active treatment group (200 mg BID, 400 mg BID) vs. placebo 
• Combine active treatment groups vs. placebo 
• 200 mg BID vs. 400 mg BID. 
Furthermore, summary statistics will be provided on the number (%) of subjects achieving 
platelet response by each treatment group and the subgroups defined in Section 7.6. 
A subject will be classified as a platelet responder if subject shows at least 1 platelet count 
≥ 30,000/µL and doubling the baseline (average of 2 previous counts), at any visit during 
treatment period, without use of rescue medication. The ITT analysis set will be used in the 
analysis of the primary endpoint. 
7.7.4 
Analysis of Secondary Endpoints 
For each binary endpoint (ie, definition of subject achieving 2 or more consecutive platelet 
counts), a logistic regression model will be performed and include treatment, baseline platelet 
count and prior TPO-receptor agonist use, provided there are enough subjects in each 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 76 
subgroup. The odds ratio for the treatment effect compared to placebo (together with 95% CI 
and p-value) will be provided. 
Time to platelet response will be estimated using the Kaplan-Meier method. Each active 
treatment group curve will be compared against placebo curve using log-rank test. In 
addition, a proportional hazard model will be implemented as well with treatment, baseline 
platelet count, and prior TPO-receptor agonist use. 
Change from baseline in the average of the last 2 platelet counts will be analyzed using an 
analysis of covariance with baseline platelets count as covariate, treatment, and prior 
TPO-receptor agonist use. Each active treatment group will be compared with placebo. 
Summary statistics of the following subjects will be provided by each treatment group: 
• Subjects receiving rescue medication during the treatment period 
• Subjects with Grade 2 or higher non-skin bleeding event during the treatment or 
follow-up period 
A subject will be considered to have an event if the event was observed at least once during 
the treatment period or follow-up period as mentioned above. 
7.7.5 
Analyses of Exploratory Endpoints 
Peak platelet will be summarized by treatment groups. The median peak platelet, and the 
lower and upper quartile will be provided by treatment group. The difference in median peak 
platelet will be calculated for: 
• Each active treatment group (200 mg BID, 400 mg BID) vs. placebo 
• Combined active treatment groups vs. placebo  
• 200 mg BID vs. 400 mg BID 
Bleeding score will be summarized by treatment group and the combined active treatment 
groups. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 77 
7.7.6 
Pharmacokinetic/Pharmacodynamic Analyses 
7.7.6.1 
Pharmacokinetic Analyses 
Plasma concentrations of SKI-O-592 and its metabolites (M2 and M4) will be listed and 
summarized separately for each treatment and day at each nominal time point using 
descriptive statistics (number of observations [n], mean, SD, coefficient of variation [CV], 
minimum, median, and maximum). Individual and mean plasma concentration versus time 
profiles will be plotted for each treatment and day. 
PK parameters for SKI-O-592 and its metabolites will be calculated using noncompartmental 
methods. Descriptive statistics (n, geometric mean, geometric CV, mean, SD, CV, minimum, 
median, and maximum) for the PK parameters for SKI-O-592 and its metabolites will be 
presented for each treatment and day. Treatment comparisons will be performed as deemed 
appropriate. 
7.7.6.2 
Pharmacodynamic Analyses 
Absolute and percentage change from baseline in the percentage of activated CD63+ 
basophils in peripheral blood will be listed and summarized separately for each treatment and 
day at each nominal time point using descriptive statistics (number of observations [n], mean, 
SD, CV, minimum, median, and maximum). Individual, mean absolute and percentage 
change from baseline in the percentage of activated CD63+ basophils will be plotted versus 
time for each treatment and day. 
PD parameters for the percentage of activated CD63+ basophils will be calculated using 
non-compartmental methods. Descriptive statistics (n, mean, SD, CV, minimum, median, and 
maximum) for the PD parameters will be presented for each treatment and day. Treatment 
comparisons will be performed as deemed appropriate. 
7.7.6.3 
Exploratory PK/PD Analyses 
PK/PD relationship between plasma concentrations of SKI-O-592, M2, and M4 and change 
from baseline in the percentage of activated CD63+ basophils in peripheral blood on Day 1 
and Week 12 will be assessed. Individual and mean plasma concentrations of SKI-O-592, 
M2, and M4 will be plotted versus change from baseline in the percentage of activated 
CD63+ basophils in peripheral blood on Day 1 and Week 12. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 78 
Exploratory PK/PD modeling may also be performed; full details will be provided in a 
separate Statistical Analysis Plan. 
7.7.7 
Safety Analyses 
Continuous parameters (such as laboratory measurements, ECG results, and vital signs) will 
be summarized separately for each treatment at each nominal time point using descriptive 
statistics (mean, SD, minimum, median, and maximum). 
Discrete parameters (such as deaths, SAEs, AEs, concomitant medications, and physical 
examination results) will be summarized separately for each treatment at each nominal time 
point using frequency counts and percentages. All AEs, SAEs, drug-related AEs, and drug-
related SAEs will be summarized using the worst grade per NCI CTCAE v5.0 by system 
organ class and preferred term. All safety data will be listed. 
Safety results will be summarized using the safety set by treatment groups and the combined 
active treatment group, unless otherwise specified. 
7.7.8 
Interim Analyses 
An unblinded interim safety and PK data review will be performed by the DMC once the 
subjects in the safety run-in period complete their Day 8 (±2 days) assessments. Subjects in 
the safety run-in period will continue to be dosed whilst the interim analysis is being 
conducted. However, further enrollment in each treatment group will only resume after safety 
and PK data of the first week for the first 5 subjects are reviewed and considered satisfactory 
by the DMC. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 79 
8 
Data Quality Assurance 
This study will be conducted according to the ICH E6(R2) risk and quality processes 
described in the applicable procedural documents. The quality management approach to be 
implemented in this study will be documented and will comply with the current ICH 
guidance on quality and risk management (ICH 2005). 
8.1 
Data Management 
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate case histories for the subjects treated as part of the research under this 
protocol. The investigator agrees to maintain accurate eCRFs and source documentation as 
part of the case histories. These source documents may include laboratory reports and ECG 
strips. 
Investigative site personnel will enter subject data into Oracle™Clinical Remote Data 
Capture. The analysis data sets will be a combination of these data and data from other 
sources (eg, laboratory data). 
Clinical data management will be performed in accordance with applicable sponsor standards 
and data cleaning procedures to ensure the integrity of the data, eg, removing errors and 
inconsistencies in the data. Adverse events and concomitant medication terms will be coded 
using MedDRA Version 20.0 or later, an internal validated medication dictionary. 
After database lock, each study site will receive a CD-ROM containing all of their site 
specific eCRF data as entered into Oracle Clinical Remote Data Capture for the study, 
including full discrepancy and audit history. Additionally, a CD-ROM copy of all of the study 
site’s data from the study will be created and sent to the sponsor for storage. PPD will 
maintain a duplicate CD-ROM copy for their records. In all cases, subject initials will not be 
collected or transmitted to the sponsor. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 80 
9 
Ethics 
9.1 
Independent Ethics Committee or Institutional Review Board 
Federal regulations and the ICH guidelines require that approval be obtained from an 
IRB/IEC before participation of human subjects in research studies. Before study onset, the 
protocol, informed consent, advertisements to be used for the recruitment of study subjects, 
and any other written information regarding this study to be provided to the subject or the 
subject’s legal guardian must be approved by the IRB/IEC. Documentation of all IRB/IEC 
approvals and of the IRB/IEC compliance with ICH harmonised tripartite guideline E6(R2): 
Good Clinical Practice (GCP) will be maintained by the site and will be available for review 
by the sponsor or its designee. 
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must 
identify the IRB/IEC name and address, the clinical protocol by title or protocol number or 
both, and the date approval or a favorable opinion was granted. 
The investigator is responsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1 year or otherwise specified by the IRB/IEC. The 
investigator must promptly supply the sponsor or its designee, the IRB/IEC, and, where 
applicable, the institution, with written reports on any changes significantly affecting the 
conduct of the study or increasing the risk to subjects. 
9.2 
Ethical Conduct of the Study 
The study will be performed in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, ICH GCP, the protocol, and all applicable regulations. 
9.3 
Subject Information and Consent 
A written informed consent in compliance with the respective applicable regulatory authority 
regulations shall be obtained from each subject before entering the study or performing any 
unusual or nonroutine procedure that involves risk to the subject. An informed consent 
template may be provided by the sponsor to investigative sites. If any institution-specific 
modifications to study-related procedures are proposed or made by the site, the consent 
should be reviewed by the sponsor or its designee or both before IRB/IEC submission. Once 
reviewed, the consent will be submitted by the investigator to his or her IRB/IEC for review 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 81 
and approval before the start of the study. If the ICF is revised during the course of the study, 
all active participating subjects must sign the revised form. 
Before recruitment and enrollment, each prospective subject or his or her legal guardian will 
be given a full explanation of the study and be allowed to read the approved ICF. Once the 
investigator is assured that the subject/legal guardian understands the implications of 
participating in the study, the subject/legal guardian will be asked to give consent to 
participate in the study by signing the ICF. 
The investigator shall retain the signed original ICF(s) and give a copy of the signed original 
form to the subject or legal guardian. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 82 
10 Investigator’s Obligations 
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be changed based on industry and government standard operating procedures, 
working practice documents, or guidelines. Changes will be reported to the IRB/IEC but will 
not result in protocol amendments. 
10.1 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain subject confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written 
permission of the subject (or the subject’s legal guardian), except as necessary for monitoring 
and auditing by the sponsor, its designee, the US FDA, or the IRB/IEC. 
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the 
study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
10.2 Financial Disclosure and Obligations 
Investigators are required to provide financial disclosure information to allow the sponsor to 
submit the complete and accurate certification or disclosure statements required under 
21 Code of Federal Regulations (CFR) 54. In addition, the investigator must provide to the 
sponsor a commitment to promptly update this information if any relevant changes occur 
during the course of the investigation and for 1 year following the completion of the study. 
Neither the sponsor nor PPD is financially responsible for further testing or treatment of any 
medical condition that may be detected during the screening process. In addition, in the 
absence of specific arrangements, neither the sponsor nor PPD is financially responsible for 
further treatment of the subject’s disease. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 83 
10.3 Investigator Documentation 
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R2) 8.2 
and Title 21 of the CFR by providing the following essential documents, including but not 
limited to: 
• IRB/IEC approval 
• Original investigator-signed investigator agreement page of the protocol 
• Form FDA 1572, fully executed, and all updates on a new fully executed Form 
FDA 1572 
• Curriculum vitae for the investigator and each subinvestigator listed on Form FDA 1572 
• Financial disclosure information to allow the sponsor to submit complete and accurate 
certification or disclosure statements required under 21 CFR 54. In addition, the 
investigators must provide to the sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 
1 year after the completion of the study. 
• IRB/IEC-approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided to 
the subject or legal guardian, and 
• Laboratory certifications and normal ranges for any local laboratories used by the site, in 
accordance with 42 CFR 493. 
10.4 Study Conduct 
The investigator agrees that the study will be conducted according to the principles of ICH 
E6(R2). The investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations. Study information from this protocol will be 
posted on publicly available clinical trial registers before enrollment of subjects begins. 
10.5 Adherence to Protocol 
The investigator agrees to conduct the study as outlined in this protocol in accordance with 
ICH E6(R2) and all applicable guidelines and regulations. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 84 
10.6 Adverse Events and Study Report Requirements 
By participating in this study, the investigator agrees to submit reports of SAEs according to 
the timeline and method outlined in the protocol. In addition, the investigator agrees to 
submit annual reports to the study site IRB/IEC as appropriate. 
10.7 Investigator’s Final Report 
Upon completion of the study, the investigator, where applicable, should inform the 
institution; the investigator/institution should provide the IRB/IEC with a summary of the 
study’s outcome and the sponsor and regulatory authority(ies) with any reports required. 
10.8 Records Retention 
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents 
should be retained for a longer period; however, if required by the applicable regulatory 
requirements or by an agreement with the sponsor. It is the responsibility of the sponsor to 
inform the investigator/institution as to when these documents no longer need to be retained. 
10.9 Publications 
After completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be submitted, and other related issues. The sponsor has final approval authority over all 
such issues. 
Data are the property of the sponsor and cannot be published without prior authorization 
from the sponsor, but data and publication thereof will not be unduly withheld. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 85 
11 Study Management 
11.1 Monitoring 
11.1.1 
External Data Monitoring Committee 
An independent DMC appointed by the Sponsor will review the interim safety and PK data 
of the first 5 subjects enrolled in the safety run-in period (See Section 7.7.8). Further details 
will be provided in the DMC charter. 
11.1.2 
Monitoring of the Study 
The clinical monitor, as a representative of the sponsor, has the obligation to follow the study 
closely. In doing so, the monitor will visit the investigator and study site at periodic intervals, 
in addition to maintaining necessary telephone and letter contact. The monitor will maintain 
current personal knowledge of the study through observation, review of study records and 
source documentation, and discussion of the conduct of the study with the investigator and 
personnel. 
All aspects of the study will be carefully monitored, by the sponsor or its designee, for 
compliance with applicable government regulation with respect to current GCP and current 
standard operating procedures. 
11.1.3 
Inspection of Records 
Investigators and institutions involved in the study will permit study-related monitoring, 
audits, IRB/IEC review, and regulatory inspections by providing direct access to all study 
records. In the event of an audit, the investigator agrees to allow the sponsor, representatives 
of the sponsor, or a regulatory agency (eg, FDA) access to all study records. 
The investigator should promptly notify the sponsor and PPD of any audits scheduled by any 
regulatory authorities and promptly forward copies of any audit reports received to the 
sponsor. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 86 
11.2 Management of Protocol Amendments and Deviations 
11.2.1 
Modification of the Protocol 
Any changes in this research activity, except those necessary to remove an apparent, 
immediate hazard to the subject, must be reviewed and approved by the sponsor or its 
designee. Amendments to the protocol must be submitted in writing to the investigator’s 
IRB/IEC for approval before subjects can be enrolled into an amended protocol. 
11.2.2 
Protocol Deviations 
The investigator or designee must document and explain in the subject’s source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
subjects without prior IRB/IEC approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB/IEC for review and approval, to the sponsor for agreement, 
and to the regulatory authorities, if required. 
A deviation from the protocol is an unintended or unanticipated departure from the 
procedures or processes approved by the sponsor and the IRB/IEC and agreed to by the 
investigator. A significant deviation occurs when there is nonadherence to the protocol by the 
subject or investigator that results in a significant, additional risk to the subject. Significant 
deviations can include nonadherence to inclusion or exclusion criteria, or nonadherence to 
FDA regulations or ICH GCP guidelines, and will lead to the subject being withdrawn from 
the study (Section 4.2). 
Protocol deviations will be documented by the clinical monitor throughout the course of 
monitoring visits. Principal investigators will be notified in writing by the monitor of 
deviations. The IRB/IEC should be notified of all protocol deviations in a timely manner. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 87 
11.3 Study Termination 
Although Oscotec Inc. has every intention of completing the study, Oscotec Inc. reserves the 
right to discontinue the study at any time for clinical or administrative reasons which may 
include (but not limited to) the followings: 
• Unacceptable risk to a subject participating in the study 
• The decision on the Sponsor to suspend or discontinue evaluation of the study drug 
• Insufficient adherence to protocol  
• Failure to comply with regulation, etc. 
The end of the study is defined as the date on which the last subject completes the last visit 
(includes follow-up visit). 
11.4 Final Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
clinical study reports are prepared and provided to the regulatory agencies as required by the 
applicable regulatory requirement(s). The sponsor will also ensure that the clinical study 
reports in marketing applications meet the standards of the ICH harmonised tripartite 
guideline E3: Structure and content of clinical study reports. 
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report. The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the 
opportunity to review the complete study results. 
Upon completion of the clinical study report, Oscotec Inc. will provide the investigator with 
the full summary of the study results. The investigator is encouraged to share the summary 
results with the study subjects, as appropriate. The study results will be posted on publicly 
available clinical trial registers. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 88 
12 Reference List 
Department of Health and Human Services (DHHS), Food and Drug Administration, Center 
for Drug Evaluation and Research, Center for Biologics Evaluation and Research (US). 
Guidance for industry: Drug-induced liver injury: Premarketing clinical evaluation. 
July 2009 [28 screens]. Available from: 
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf (accessed on 
13 Mar 2018) 
Genosco Inc. (Cambridge, Massachusetts, United States). In vivo efficacy of SKI-O-703 in 
anti-CD41 antibody induced murine ITP (Immune Thrombocytopenic Purpura) model. 
2017 Jul 18. Final study report. Study No.: GNS-SYK-1306. 39 p. 
ICH Steering Committee. Quality risk management Q9: ICH harmonised tripartite guideline. 
International Council for Harmonisation. 09 November 2005. 
Kessler CM, Talavera F, Sacher RA, et al. Immune Thrombocytopenic Purpura (ITP). 
Updated on 04 Nov 2017. Available from: https://emedicine.medscape.com/article/202158-
overview#a4 (accessed on 13 Mar 2018). 
Mitchell BW and Bennett CM. Chronic Immune Thrombocytopenia. In: Shaz BH. Hillyer 
CD, Roshal M, Abrams CS Eds. Transfusion Medicine and Hemostasis. Elsevier Inc. 
2013:635-9. 
Mócsai A, Zhou M, Meng F, et al. Syk is required for integrin signaling in neutrophils. 
Immunity. 2002;16(4):547-58. 
Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding 
score: assessment of bleeding in patients with ITP. Br J Haematol. 2007;138(2):245-8. 
Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for 
treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 
2009;113(14):3154-60. 
Rogers NC, Slack EC, Edwards AD, et al. Syk-dependent cytokine induction by Dectin-1 
reveals a novel pattern recognition pathway for C type lectins. Immunity. 2005;22(4):507-17. 


Oscotec Inc. 
SKI-O-703 
Protocol: OSCO-P2101 Version 4.0 (Amendment 3) 
22 April 20 
 
Page 89 
Turner M, Schweighoffer E, Colucci F, et al. Tyrosine kinase SYK: essential functions for 
immunoreceptor signalling. Immunol Today. 2000;21(3):148-54. 
Zarbock A, Abram CL, Hundt M, et al. PSGL-1 engagement by E-selectin signals through 
Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling. 
J Exp Med. 2008;205(10):2339-47. 

SAP_001.pdf: 
Confidential 
Oscotec Inc. 
OSCO-P2101 
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 
Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK 
Inhibitor, in Patients with Persistent and Chronic Immune Thrombocytopenia 
(ITP) 
14FEB2023 
Final Statistical Analysis Plan 
Version 2.0
Prepared by: 
On behalf of Oscotec Inc. 
Korea Bio-Park, Building A, 9th Floor 
700 Daewangpangyo-ro, Bundang-gu
Seongnam-si, Gyeonggi-do 13488 
The Republic of Korea
Approved
Double-Blind, P
ed
Double-Blind
cacy and Safety o
ed
cacy and Safety
and Chronic Im
ve
and Chronic Im
(ITP) 
v
(ITP) 
14FEB2023 
ro
14FEB2023 
nal 
p
nal Statistical An
pr
Statistical An
Vers
pp
Vers
P
p
P


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
 
 II
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS ...................................................................................................... V
1.
INTRODUCTION ............................................................................................................ 7
2.
OBJECTIVES ................................................................................................................... 7
2.1.
PRIMARY OBJECTIVE ....................................................................................................... 7
2.2.
SECONDARY OBJECTIVES ................................................................................................ 7
2.3.
EXPLORATORY OBJECTIVES ............................................................................................ 7
3.
INVESTIGATIONAL PLAN .......................................................................................... 8
3.1.
OVERALL STUDY DESIGN AND PLAN .............................................................................. 8
3.2.
STUDY ENDPOINTS ........................................................................................................ 11
3.2.1.
Primary Endpoint...................................................................................................... 11
3.2.2.
Secondary Endpoints ................................................................................................ 11
3.2.2.1.
Patients Achieving Two or More Pre-specified Platelet Counts ........................ 11
3.2.2.2.
Change from Baseline in Platelet Counts ........................................................... 11
3.2.2.3.
Time to First Platelet Response .......................................................................... 12
3.2.2.4.
Others ................................................................................................................. 12
3.2.3.
Exploratory Endpoints .............................................................................................. 12
3.2.3.1.
Peak Platelet Count ............................................................................................ 12
3.2.3.2.
Bleeding Score ................................................................................................... 12
3.2.3.3.
Quality of Life as Measured by the SF-36 Score ............................................... 13
3.3.
DOSE INTERRUPTION AND REDUCTION .......................................................................... 13
4.
GENERAL STATISTICAL CONSIDERATIONS ..................................................... 14
4.1.
REPORTING CONVENTION ............................................................................................. 14
4.2.
BASELINE DEFINITION AND STUDY DAY ....................................................................... 14
4.3.
ANALYSIS VISIT WINDOW ............................................................................................. 15
4.4.
SAMPLE SIZE ................................................................................................................. 15
4.5.
RANDOMIZATION, STRATIFICATION, AND BLINDING ..................................................... 15
4.6.
ANALYSIS SET ............................................................................................................... 16
4.6.1.
Safety set ................................................................................................................... 16
4.6.2.
Intent-to-Treat (ITT) set ............................................................................................ 16
4.6.3.
Per-protocol (PP) set ................................................................................................ 16
4.6.4.
Pharmacokinetic (PK) set ......................................................................................... 16
4.6.5.
Pharmacodynamic (PD) set ...................................................................................... 16
4.6.6.
Pharmacokinetic (PK)/pharmacodynamic (PD) set ................................................. 17
4.7.
IMPUTATION OF MISSING DATE ..................................................................................... 17
5.
PATIENT DISPOSITION ............................................................................................. 18
5.1.
DISPOSITION .................................................................................................................. 18
5.2.
PROTOCOL DEVIATIONS ................................................................................................ 18
6.
DEMOGRAPHICS AND BASELINE CHARACTERISTICS .................................. 18
6.1.
DEMOGRAPHICS ............................................................................................................ 18
6.2.
BASELINE DISEASE CHARACTERISTICS ......................................................................... 19
Approved
.
d
.
.............
d
.............
-specified Pla
d
-specified Pla
Counts ...................
ed
Counts ...............
..............................
ed
.............................
.............................
ve
.............................
.............................
ve
.............................
..............................
ov
..............................
..............................
ov
..............................
easured by the SF-3
ro
easured by the SF-3
R
p
REDUCTION
pro
EDUCTION........
pr
........
CAL CONSIDER
pr
CAL CONSIDER
NTION
p
NTION .................
pp
.................
TION AND
App
TION AND S
pp
STUDY
pp
TUDY D
p
D
T
A
T W
A
WINDOW
Ap
INDOW..........
Ap
..........
E
A
E..........................
Ap
..........................
ON
A
ON,
A
, S
A
STRATIFIC
A
TRATIFIC
.........
A
.........


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
  III
6.3.
ALCOHOL, NICOTINE AND DRUG USAGE ....................................................................... 19
6.4.
GENETIC ANALYSIS ....................................................................................................... 19
6.5.
MEDICAL HISTORY ........................................................................................................ 20
6.6.
PRIOR AND CONCOMITANT PROCEDURE ........................................................................ 20
6.5.1.
Prior Procedure ........................................................................................................ 20
6.5.2.
Concomitant Procedure ............................................................................................ 20
7.
TREATMENTS AND MEDICATIONS ....................................................................... 20
7.1.
PRIOR AND CONCOMITANT MEDICATIONS .................................................................... 20
7.2.
RESCUE MEDICATIONS .................................................................................................. 21
7.3.
PRIOR THERAPY ............................................................................................................ 21
7.4.
STUDY TREATMENTS ..................................................................................................... 22
7.4.1.
Extent of Exposure .................................................................................................... 22
7.4.2.
Treatment Compliance and Modifications................................................................ 22
8.
EFFICACY ANALYSIS................................................................................................. 23
8.1.
PRIMARY EFFICACY ENDPOINT ..................................................................................... 23
8.1.1.
Primary Analysis ....................................................................................................... 23
8.1.2.
Sensitivity Analysis.................................................................................................... 24
Sensitivity analysis based on rescue medication with 28-day effective window: .............. 24
Sensitivity analysis based on treatment-policy strategy: .................................................... 24
8.2.
SECONDARY EFFICACY ENDPOINT ................................................................................ 25
8.2.1.
Patients Achieving Two or More Pre-specified Platelet Count ................................ 25
8.2.2.
Change from Baseline in Platelet Counts ................................................................. 26
Primary Analysis ................................................................................................................. 26
Sensitivity Analysis based on treatment-policy strategy .................................................... 26
Sensitivity analysis based on hypothetical strategy ............................................................ 26
8.2.3.
Time to First Platelet Response ................................................................................ 27
8.2.4.
Others ........................................................................................................................ 27
8.3.
EXPLORATORY ENDPOINTS ........................................................................................... 27
8.3.1.
Peak Platelet Count .................................................................................................. 27
8.4.
SUBGROUP ANALYSIS ................................................................................................... 28
9.
SAFETY ANALYSIS ..................................................................................................... 28
9.1.
ADVERSE EVENTS ......................................................................................................... 28
9.2.
ADVERSE EVENTS OF SPECIAL INTEREST ...................................................................... 30
9.3.
CLINICAL LABORATORY EVALUATIONS ........................................................................ 30
9.3.1.
Hematology ............................................................................................................... 31
9.3.2.
Serum Chemistry ....................................................................................................... 31
9.3.3.
Urinalysis .................................................................................................................. 32
9.4.
VITAL SIGN MEASUREMENTS ........................................................................................ 32
9.5.
PHYSICAL EXAMINATION .............................................................................................. 33
9.6.
ELECTROCARDIOGRAM ................................................................................................. 33
9.7.
BLEEDING SCORE .......................................................................................................... 33
9.8.
QUALITY OF LIFE AS MEASURED BY THE SF-36 SCORE ................................................ 34
10.
PHARMACOKINETICS ............................................................................................... 34
Approved
.....
d
.....
..................
d
..................
.............................
ed
.........................
..............................
e
..........................
.............................
ve
.............................
medication with 28-
ve
medication with 28-
ent-policy strategy
ov
ent-policy strategy
OINT
OINT .......................
ov
 .......................
or More Pre-specifi
ro
or More Pre-specifi
in Platelet Counts .
pro
in Platelet Counts .
..............................
pr
..............................
ed on treatment-pol
pp
ed on treatment-pol
sed on hypothetica
App
sed on hypothetica
Platelet Response .
App
Platelet Response .
Ap
.............................
Ap
.............................
RY
A
RY E
A
ENDPOINTS
Ap
NDPOINTS ...
A
...
t Count .........
A
t Count .........
SIS
A
SIS ....
....


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
  IV
10.1.
PHARMACOKINETIC DATA HANDLING .......................................................................... 34
10.2.
PLASMA PHARMACOKINETIC CONCENTRATIONS ........................................................... 34
10.3.
PLASMA PHARMACOKINETIC PARAMETERS .................................................................. 35
10.4.
PHARMACOKINETIC STATISTICAL ANALYSES................................................................ 36
10.4.1.
Assessment of Accumulation .................................................................................. 36
11.
PHARMACODYNAMICS ............................................................................................ 36
11.1.
PHARMACODYNAMIC DATA HANDLING ........................................................................ 36
11.2.
PHARMACODYNAMIC DATA .......................................................................................... 36
11.3.
PHARMACODYNAMIC PARAMETERS .............................................................................. 37
11.
INTERIM ANALYSIS ................................................................................................... 37
12.
CHANGES IN THE PLANNED ANALYSIS .............................................................. 38
13.
REFERENCES ................................................................................................................ 39
14.
APPENDICES ................................................................................................................. 40
15.1.
SCHEDULE OF EVENTS ................................................................................................... 40
ed
.......
d
.......
....................
d
....................
Approved
...........................
ed
..........................


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
 
 V 
List of Abbreviations 
Abbreviation 
Definition 
AE
adverse event 
AESI 
adverse event of special interest 
ANCOVA 
analysis of covariance 
ATC 
Anatomical Therapeutic Chemical 
AUC
area under the concentration versus time curve 
AUC0-tau
area under the plasma concentration-time curve within a dosing interval 
AUEC 
area under the effect versus time curve 
AUEC0-tau 
area under the effect versus time curve within a dosing interval 
BID 
twice daily 
BLQ 
below the limit of quantification 
BMI 
body mass index 
CI
confidence interval 
CL/F 
apparent oral clearance 
Cmax
maximum observed concentration 
eCRF
electronic case report form 
CTCAE 
Common Terminology Criteria for Adverse Events 
Ctrough
trough concentration observed at steady state 
CV
coefficient of variation 
ECG 
electrocardiogram 
EOT 
end-of-treatment 
ITP 
immune thrombocytopenia 
ITT
Intent to treat 
IVRS
interactive voice response system 
Kel
terminal phase elimination rate constant 
Kel lower 
lower bound used for the estimation of Kel
Kel upper 
upper bound used for the estimation of Kel
K-M 
Kaplan-Meier 
LS
least-square 
MedDRA 
Medical Dictionary for Regulatory Activities 
ORR 
overall platelet response rate 
PD
pharmacodynamic(s) 
PK
pharmacokinetic(s) 
PP
per protocol 
PT
preferred term 
QTcF 
corrected QT interval by Fridericia formula 
RAUC
accumulation ratio 
Approved
ncentration
ve
ncentration
ort form 
ov
ort form 
nology Criteria for 
ov
nology Criteria for 
tration observed at
ro
tration observed at
of variation
pro
of variation
rdiogram 
pr
rdiogram 
-treatment
pp
-treatment
mune thrombocytop
App
mune thrombocytop
Ap
ntent to treat 
Ap
ntent to treat 
interactive voice 
Ap
interactive voice 
minal phase
A
minal phase
ound


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
  VI
Abbreviation 
Definition 
Rmet
metabolite ratio 
Rsq (r2) 
coefficient of determination 
SAE 
serious adverse event 
SAP 
statistical analysis plan  
SD
standard deviation 
SE
standard error 
SOC 
system organ class 
t1/2
apparent terminal elimination half-life 
t1/2,eff
effective half-life 
TEAE 
treatment-emergent adverse event 
TEmax
Time to achieve maximum effect 
Tmax
time to reach maximum observed concentration 
Vz/F
apparent volume of distribution 
WHODD 
World Health Organization Drug Dictionary 
Approved
t 
d
t 
ved concentra
d
ved concentra
ution
ed
ution
tion Drug Dictiona
ve
tion Drug Dictiona


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
 7
1. Introduction 
This Statistical Analysis Plan (SAP) describes the analyses and data presentations for 
Oscotec Inc.’s protocol OSCO-P2101 Version 4.0 (Amendment 3, dated 22 Apr 2020) “A 
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study 
to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients with 
Persistent and Chronic Immune Thrombocytopenia (ITP)” which was originally issued on 
09 Jan 2019. It contains definitions of analysis populations, derived variables and 
statistical methods for the analysis of efficacy, safety, pharmacokinetics (PK) and 
pharmacodynamics (PD). 
There is one final analysis and one interim analysis planned for this study. This SAP is 
prepared for final analysis, and interim analysis is planned in a separate interim analysis 
SAP. Throughout these SAPs, the treatment groups will be referred to as the 200 mg twice 
daily (BID) group, the 400 mg BID group, and the placebo group. The purpose of the SAP 
is to ensure the credibility of the study findings by pre-specifying the statistical approaches 
to any data analysis prior to database lock. This SAP will be finalized and signed prior to 
the final database lock.  
All statistical analyses detailed in this SAP will be conducted using SAS® 9.4 or later (SAS 
Institute Inc., Cary, North Carolina). 
2. Objectives 
2.1. Primary Objective 
To evaluate the safety and efficacy on the primary endpoint (platelet response) of select 
(200 mg BID and 400 mg BID) doses of SKI-O-703 compared to placebo in patients with 
persistent and chronic ITP, with a platelet count <30,000/µL on 2 occasions at least 7 days 
apart with the confirmatory count being taken during Screening. 
2.2. Secondary Objectives 
The secondary objectives of this study are as below: 
•
To evaluate the efficacy on the secondary endpoints of select (200 mg BID and 
400 mg BID) doses of SKI-O-703 compared to placebo in patients with persistent 
and chronic ITP 
•
To investigate the PK profile of SKI-O-592 (the free base of SKI-O-703) and its 
metabolites (M2 and M4) in patients with persistent and chronic ITP 
•
To evaluate the effects of SKI-O-703 on PD biomarkers in patients with persistent 
and chronic ITP. 
2.3. Exploratory Objectives 
The exploratory objectives of this study are as below: 
Approved
nned
d
nned for 
d
for 
nned in a sepa
d
nned in a sepa
 will be referred to
ed
 will be referred
he placebo group. T
ed
he placebo group. T
s by pre-specifying
ve
s by pre-specifying
his SAP will be fin
ve
his SAP will be fin
SAP will be condu
ro
SAP will be condu
.
e
A
e
nd efficacy on the p
Ap
nd efficacy on the p
mg BID) doses of 
Ap
mg BID) doses of 
P,
A
P, with
A
with a plate
A
a plate
count be
A
count be


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
 8
•
To evaluate the PK/PD relationship between plasma concentrations of SKI-O-592, 
M2, and M4 and the percent change in activated CD63+ basophils in peripheral 
blood in patients with persistent and chronic ITP 
•
To evaluate the changes of the exploratory endpoints of select (200 mg BID and 
400 mg BID) doses of SKI-O-703 compared to placebo. 
3. Investigational Plan 
3.1. Overall Study Design and Plan 
This is a randomized, double-blind, multicenter, placebo-controlled, parallel dose study to 
evaluate the efficacy, safety, tolerability, PK, and PD of select (200 mg BID and 400 mg 
BID) doses of SKI-O-703 in persistent and chronic ITP patients who have failed to 
respond or relapsed after prior therapy, with a platelet count <30,000/μL on 2 occasions at 
least 7 days apart with the confirmatory count being taken during Screening (the most 
recent result from the central laboratory will be considered as the confirmatory platelet 
count, when an unscheduled visit(s) is performed during the screening period). 
A minimum of 60 patients are planned to enroll in 3 treatment groups (24 patients in each 
of the active treatment groups and 12 patients in the placebo group). Patients will be 
randomly assigned to the 3 groups using a 2:2:1 ratio to receive one of the 2 select doses of 
SKI-O-703 or placebo. First 5 patients randomly assigned in the study will have the safety 
run-in period for the first 1 week with interim safety and PK assessments on Day 8 
(±2 days). Patients in the safety run-in period will continue to be dosed whilst the interim 
analysis is being conducted. However, further enrollment in each treatment group will only 
resume after safety and PK data of the first week for the first 5 patients are reviewed and 
considered satisfactory by the Data Monitoring Committee (DMC). A subset of at least 20 
patients, who are not included in the safety run-in period, will be randomized to undergo 
PK/PD assessments at a selected number of sites. Randomization will be stratified to 
balance patients with respect to prior TPO-receptor agonist use (yes/no) and degree of 
baseline thrombocytopenia (ie, baseline platelet count < or ≥15,000/µL). A schematic 
diagram of the overall study design is presented in Figure 3-1 and Figure 3-2.
Approved
f select 
d
f select 
P patients wh
d
P patients wh
let count <30,000/
ed
let count <30,00
ing taken during Sc
ed
ing taken during S
considered as the 
ve
considered as the 
med during the scr
ve
med during the scr
o enroll in 3 treatm
ov
o enroll in 3 treatm
patients
ro
patients in the place
ro
in the place
using a 2:2:1 ratio t
pro
using a 2:2:1 ratio t
ients
p
ients randomly ass
pr
randomly ass
k with interim safe
pp
k with interim safe
ty run-
p
ty run-in
pp
in
Ap
period wi
pp
period wi
d. However, further
App
d. However, further
PK data of the first 
Ap
PK data of the first 
by the Data Monit
Ap
by the Data Monit
A
luded in the sa
A
luded in the sa
ected num
A
ected num
pri


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
 9
Figure 3-1  
Study Design Schematic (for the First 5 Patients in the Safety Run-in 
Period only) 
Abbreviation: BID, twice daily 
Note: First 5 patients randomly assigned in the study will have safety run-in period for the first 1 week with 
interim safety and PK assessments on Day 8 (±2 days). Patients in the safety run-in period will continue to be 
dosed whilst the interim analysis is being conducted. However, further enrollment in each treatment group 
will only resume after safety and PK data of the first week for the first 5 patients are reviewed and considered 
satisfactory by the Data Monitoring Committee. 
Ap
ly assigned in the stud
Ap
ly assigned in the stud
sments on Day 8
Ap
sments on Day 8 (±2
p
(±2
p
ysis is being cond
A
ysis is being cond
PK data of 
A
PK data of 
Comm
A
C
App
Approved


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
10
Figure 3-2  
Study Design Schematic (For Patients Other Than Enrolled in the 
Safety Run-in Period) 
Abbreviation: BID, twice daily 
Screening Period 
The study will include up to 4 weeks of screening period. All potential patients will sign 
and date the informed consent form (ICF) prior to any study assessments or procedures. 
These patients will be assessed as per the eligibility criteria at Screening. After completing 
all screening assessments, patients who meet all the inclusion and none of the exclusion 
criteria will proceed to the treatment period. 
12-week Treatment Period 
•
1-week Safety Run-in Period (for the first 5 patients only): First 5 patients 
randomly assigned in the study will have the safety run-in period for the first 1 
week with interim safety and PK assessments on Day 8 (±2 days). Patients in the 
safety run-in period will continue to be dosed whilst the interim analysis is being 
conducted. However, further enrollment in each treatment group will only resume 
after safety and PK data of the first week for the first 5 patients are reviewed and 
considered satisfactory by the DMC. 
For all patients, on Day 1, patient’s eligibility will be confirmed and baseline safety 
evaluations will be performed (ECG, physical examination, vital sign measurements, and 
App
up to 4 weeks of scr
Ap
up to 4 weeks of scr
consent form (ICF
Ap
consent form (ICF
essed as per 
A
essed as per 
tients
A
tients w
A
w
proved


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
11
safety laboratory assessment). Eligible patients will be randomly assigned to receive either 
one of the doses of SKI-O-703 or placebo. On Day 1, the investigative site staff will 
administer the morning dose. The evening dose of study medication will be administered 
12 hours after the morning dose. Patients will be administered the study medication with 
enough water to swallow the capsule. 
After dosing, all patients will be subjected to safety assessments and a subset of at least 
20 patients, who are not included in the safety run-in period, will be subjected to PK and 
PD assessments according to the Schedule of Events (Appendix 15.1). Patients enrolled in 
the safety run-in period will be admitted for 24 hours on Days 1, 8, and 84 of the study. 
Patients selected for the PK/PD portion of the study will be admitted for 24 hours on 
Days 1 and 84 of the study. 
The maximum duration of study participation for a patient will be 20 weeks, which 
consists of up to 4 weeks of screening period, 12 weeks of treatment period, and 4 weeks 
of follow-up period. 
3.2. Study Endpoints 
3.2.1. Primary Endpoint 
The primary endpoint, patient platelet response, is defined as platelet count ≥ 30,000/µL 
and doubling the baseline (average of 2 previous counts), at any visit during the treatment 
period and without the use of rescue medication. Refer baseline definition to Section 4.2. 
3.2.2. Secondary Endpoints 
3.2.2.1.
Patients Achieving Two or More Pre-specified Platelet Counts 
•
Patients able to achieve 2 or more consecutive platelet counts of ≥ 30,000/µL 
separated by at least 5 days and without use of rescue medication 
•
Patients able to achieve 2 or more consecutive platelet counts of ≥ 30,000/µL with 
an increase of platelet count of ≥ 20,000/µL from baseline separated by at least 5 
days and without use of rescue medication 
•
Patients able to achieve 2 or more consecutive platelet counts of ≥ 50,000/µL 
separated by at least 5 days and without use of rescue medication 
•
Patients able to achieve 2 or more consecutive platelet counts of ≥ 100,000/µL 
during the treatment period, separated by at least 5 days and without use of rescue 
medication 
•
Patients able to achieve platelet counts of ≥ 50,000/µL at 3 of the last 4 visits. 
3.2.2.2.
Change from Baseline in Platelet Counts 
•
Change from baseline in the average of the last 2 platelet counts during the 
treatment period. 
Approved
atient 
d
atient will be 2
d
will be 2
eeks of treatment p
ed
eeks of treatmen
et response,
pro
et response, is defi
pro
is defi
e of 2 previous cou
pr
of 2 previous cou
escue medication.
pp
escue medication.
Ap
R
Endpoints
App
Endpoints
atients Achieving T
Ap
atients Achieving T
achieve 2 or more
Ap
achieve 2 or more
A
ast 5 days and
A
ast 5 days and
ve 2 or 
A
ve 2 or


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
12
For each patient, the change from baseline in the mean of the last 2 platelet counts during 
the treatment period will be calculated. For those patients with only 1 platelet count during 
treatment period, the change from baseline in the single platelet count will be used. 
3.2.2.3.
Time to First Platelet Response 
•
Time to first platelet response (>30,000/µL and 2 × baseline) 
For each patient, the time of the first platelet response is the first visit during treatment 
period in which platelet count ≥ 30,000/µL without use of rescue medication. 
3.2.2.4.
Others 
•
Number of patients receiving rescue medication at least once during treatment 
period 
•
Patients with at least one Grade 2 or higher non-skin bleeding event during 
treatment period. 
For each endpoint, a patient will be considered to have had an event if the event was 
observed at least once during the treatment period for rescue medication, and during 
treatment or follow-up period for bleeding event. 
3.2.3. Exploratory Endpoints 
3.2.3.1.
Peak Platelet Count 
•
Peak platelet counts during the treatment period without use of rescue medication 
For each patient, peak platelet count is patient’s highest platelet count during the treatment 
period, without use of rescue medication. 
3.2.3.2.
Bleeding Score 
The ITP bleeding assessment score as described by Page et al. 2007 will be used to 
characterize bleeding tendency. 
Table 3-1 The ITP Bleeding Score Assessment 
Site 
Bleeding Grade 
0 
1 
2 
Skin [physical 
Examination 
(PE)] 
None 
1–5 bruises and/or scattered petechiae 
>5 bruises with size >2 cm and/or 
diffuse petechiae 
Oral (PE) 
None 
1 blood blister or >5 petechiae or 
gum bleeding that clears easily with 
rinsing 
Multiple blood blisters and/or 
gum bleeding 
pproved
t lea
d
t lea
on-skin bleeding
d
on-skin bleedin
d to have had an ev
ve
d to have had an ev
period for rescue m
ov
period for rescue m
g event.
ov
g event.
oints 
p
oints 
elet Count 
pr
elet Count 
App
uring the treatment 
pp
uring the treatment 
atelet count is patien
Ap
atelet count is patien
escue medication.
Ap
escue medication.
ding Score
A
ding Score
core


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
13
Site 
Bleeding Grade 
0 
1 
2 
Skin (Hx) 
None 
1–5 bruises and/or scattered petechiae 
>5 bruises with size >2 cm and/or 
diffuse petechiae 
Oral (Hx) 
None 
1 blood blister or >5 petechiae and/or 
gum bleeding <5 min 
Multiple blood blisters and/or 
gum bleeding >5 min 
Epistaxis 
None 
Blood when blowing nose and/or 
epistaxis <5 min (per episode) 
Bleeding >5 min (per episode) 
Gastrointestinal 
None 
Occult blood 
Gross blood 
Urinary 
None 
Microscopic (+ve dipstick) 
Macroscopic 
Gynecological 
None 
(normal 
period) 
Spotting not at time of normal period 
Bleeding >spotting not at time of 
period or very heavy period 
Pulmonary 
None 
N/A 
Yes
Intracranial 
haemorrhage 
None 
N/A 
Yes
Subconjunctival 
haemorrhage 
None 
Yes
N/A 
•
abbreviation: ITP, immune thrombocytopenia; PE, physical examination; N/A, not applicable 
•
Note: In case of a breakthrough bleeding, the patients will discontinue the trial. 
3.2.3.3.
Quality of Life as Measured by the SF-36 Score 
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. 
The SF-36 is a measure of health status and the survey will be conducted according to the 
SF-36 quality of life questionnaire Version 2.0. 
The assessments will be performed at time points indicated in Schedule of Events 
(Appendix 15.1).
3.3. Dose Interruption and Reduction 
It is recognized that some AEs may require dose adjustment or study drug discontinuation. 
Intra-patient dose reduction or escalation is permitted and based upon treatment-related 
adverse events observed. Guidelines for dose interruption or reduction are specified in 
Protocol Section 3.1.1. 
After experiencing an AE, patients whose laboratory results return to baseline values and 
remain stable for 4 consecutive weeks have the option to increase the dose of SKI-O-703 1 
dose level up to the randomized dose level.
oved
Yes
d
Yes
d
ed
Yes
ed
Yes
ed
ed
ed
ed
N/
e
N/
ve
Approv
ove
penia; PE, physical ex
ov
penia; PE, physical ex
ing, the patients will d
ro
ing, the patients will d
Life as Measured by
pr
Life as Measured by
rvey is a 36-item, p
pp
rvey is a 36-item, p
alth status and the s
pp
alth status and the s
onnaire Version 2.0
App
onnaire Version 2.0
A
e performed at tim
Ap
e performed at tim
d Re
d R


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
14
4. General Statistical Considerations 
4.1. Reporting Convention 
Continuous variables (quantitative endpoints) will be summarized using the mean, the 
standard deviation (SD), median, range (minimum value and maximum value), and 
interquartile. Categorical variables (qualitative endpoints) will be summarized using 
frequency counts (number) and percentages, unless otherwise specified. 
For the summary statistics of all numerical variables unless otherwise specified, minimum 
and maximum will be displayed to the same level of precision as reported. Mean, median
and interquartile will be displayed to one level of precision greater than the data collected. 
Standard deviation / standard error will be displayed to two levels of precision greater than 
the data collected. All percentages will be rounded to one decimal place. If the percentage 
is 100, no decimal is required. 
P-values will be rounded to three decimal places. If a p-value is less than 0.001 it will be 
reported as “<0.001.” If a p-value is greater than 0.999 it will be reported as “>0.999.” 
All statistical tests will be 2-sided using a 5% significance levels, leading to 95% (2-sided) 
confidence intervals (CIs). This will be used for each pairwise comparison with placebo, 
i.e., there will be no adjustments for multiplicity since this is a Phase 2 study, and interim 
analysis will only be performed on safety and PK analysis. 
Patients will be identified in the listings by the subject identifier. Data will be displayed in 
all listings sorted by treatment group. 
4.2. Baseline Definition and Study Day 
For platelet count related endpoints, baseline will be defined as the lowest platelet count 
within 1 month prior to or on the date that the first dose of study drug (SKI-O-703 or 
placebo) is taken. Data from Central lab will be used first. Otherwise, baseline will be 
defined as the last non-missing evaluation prior to or on the date that the first dose of study 
drug (SKI-O-703 or placebo) is taken.  
The study day will be calculated as:  
•
Study day = assessment date - first dose of study drug (SKI-O-703 or placebo) date 
+ 1, if assessment date is on or after the first dose date. 
•
Study day = assessment date – first dose of study drug (SKI-O-703 or placebo) 
date, if assessment date is prior to the first dose date. 
Approved
wo 
d
wo 
ne decim
d
ne decim
 If a p-value is less
ed
 If a p-value is les
an
an 0.999
ve
0.999 it will be r
ve
it will be r
5%
o
5% significance lev
ov
significance lev
used for each pairw
ov
used for each pairw
multiplicity 
ro
multiplicity since th
ro
since th
safety and PK anal
pro
safety and PK anal
e listings by the sub
pp
e listings by the sub
nt group.
App
nt group.
nition
A
nition and Study D
Ap
and Study D
A
endpoints, b
A
endpoints, b
the da
A
the da


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
15
4.3. Analysis Visit Window 
No analysis visit window is assigned. All data are summarized based on the visit name 
collected on the CRF page.  
4.4. Sample Size 
A minimum of 60 patients will be enrolled in the study. Patients will receive either 200 mg 
BID or 400 mg BID of SKI-O-703 or placebo in a 2:2:1 ratio. 
Based on Podolanczuk et al (2009) at least 50% of patients in the active treatment group 
will be responders (R). A sample size of 24 patients per active treatment group and 
12 patients in the placebo group will provide approximately 82.74% power to detect a 
difference between response rates of 50% and 1% in the active treatment and placebo 
groups, respectively, at the 2-sided 5% significance level. The test statistic used in the 
sample size calculation was the 2-sided Fisher's Exact test using the normal approximation 
method. 
Patients that do not receive the study drug or do not provide at least 1 post baseline 
measurement will be excluded from the analysis above and replaced. 
There will be no adjustment for multiple comparisons. The sample size calculation was 
performed using PASS 15 Power Analysis and Sample Size Software (2017). NCSS, LLC. 
Kaysville, Utah, USA, ncss.com/software/pass. 
4.5. Randomization, Stratification, and Blinding 
Patients will be randomly assigned in a 2:2:1 ratio to receive SKI-O-703 200 mg BID, 
SKI-O-703 400 mg BID, or matching placebo. A subset of at least 20 patients will be 
randomized to undergo PK/PD assessments at a selected number of sites. An interactive 
voice response system (IVRS) will be used to administer the randomization schedule. The 
randomization schedule will be generated using SAS software Version 9.4 or later (SAS 
Institute Inc., Cary, North Carolina) for IVRS, which will link sequential patients 
randomization numbers to treatment codes. The randomization will be stratified by prior 
TPO-receptor agonist use (yes/no) and degree of baseline thrombocytopenia (ie, baseline 
platelet count < or ≥15,000/L). It will also use an appropriate block size, which will not 
be revealed. 
Patients who are randomly assigned and not dosed will be replaced. Patients who 
discontinue the study for any reason after dosing will not be replaced. 
This is a double-blind study. Neither the patients nor the investigator/site personnel will be 
aware of the treatment assignment for the patients in each cohort. Additionally, the study 
drugs will be identical in number and appearance for each cohort. Blinding will be 
Approved
ely 
d
ely 
e active tr
d
e active tr
evel. The test st
d
evel. The test 
act test
ed
act test using the n
ed
using the
r do not provide at 
ve
r do not provide at 
nalysis above and r
ov
nalysis above and r
ple comparisons. T
ro
ple comparisons. T
Analysis and Sampl
pro
Analysis and Sampl
/software/pass.
pr
/software/pass.
ratification, and B
App
ratification, and B
y assigned in a 2:2
Ap
y assigned in a 2:2
D, 
A
D, or matching pla
Ap
or matching pla
K/PD assessm
A
K/PD assessm
) will b
A
) will b


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
16
maintained throughout the study by use of active or placebo dosage forms of similar 
appearance. 
The DMC will receive first 1-week safety and PK unblinded data by treatment group or 
unblinded (if necessary) confidential reports of the first 5 patients enrolled in the safety 
run-in period from an independent statistician for review, which has to be handled strictly 
confidentially. None of these reports can be delivered to unauthorized persons. 
4.6. Analysis Set
4.6.1. Safety set 
The Safety set will consist of all patients who receive at least 1 dose of study drug 
(SKI-O-703 or placebo). Patients will be analyzed according to the treatment they 
received. This analysis set will be used in the analysis of demographic and safety data. 
4.6.2. Intent-to-Treat (ITT) set 
The ITT set will consist of all randomized patients who receive at least 1 dose of study 
drug (SKI-O-703 or placebo) and have at least 1 post-baseline platelet assessments. 
Patients will be analyzed according to the treatment arm to which they were randomized. 
This analysis set will be used for efficacy summaries, including the analysis of the primary 
endpoint.
4.6.3. Per-protocol (PP) set 
The PP set will consist of all patients in ITT set with no major protocol violations that may 
impact the analysis. Major protocol violations will be identified during the study according 
to the protocol deviation list and treatment compliance defined in Section 7.4.2. Patients 
will be analyzed according to the treatment arm to which they were randomized. This 
analysis set will be used for efficacy summaries, including the analysis of the primary 
endpoint.
4.6.4. Pharmacokinetic (PK) set 
The PK set will consist of all patients who receive SKI-O-703 and have at least 
1 measurable plasma concentration. Patients who have partial data and/or major protocol 
deviations that may impact PK, and patients who experience emesis, will be evaluated on a 
case-by-case basis and may be excluded from the PK analysis set. This analysis set will be 
used for summaries of PK data. 
4.6.5. Pharmacodynamic (PD) set 
The PD set will consist of all patients who receive at least 1 dose of study drug 
(SKI-O-703 or placebo) and have at least 1 evaluable postdose PD value. Patients who 
have partial data and/or major protocol deviations that may impact PD will be evaluated on 
a case-by-case basis and may be excluded from the PD analysis set. This analysis set will 
be used for summaries of PD data.
Approved
rding to
d
rding to
of demograp
d
of demograp
ents
v
ents who receive at
ve
who receive at
st 1 post-baseline p
ve
st 1 post-baseline p
treatment arm to w
ov
treatment arm to w
y summaries, inclu
ov
y summaries, inclu
set
p
set
atients in ITT
pp
atients in ITT set w
p
set w
rotocol violations w
App
rotocol violations w
st and treatment co
App
st and treatment co
Ap
ng to the treatment
Ap
ng to the treatment
d for efficacy sum
Ap
d for efficacy sum
c (


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
17
4.6.6. Pharmacokinetic (PK)/pharmacodynamic (PD) set 
All patients included in the PK and PD analysis sets. This analysis set will be used for the 
PK/PD analyses. 
4.7. Imputation of Missing Date 
Incomplete Start and Stop Date of Concomitant Medications and Adverse Events: 
For the purpose of inclusion in prior and/or concomitant medication tables and treatment-
emergent adverse events (TEAE), incomplete medication/AE start and stop dates will be 
imputed as follows: 
Missing start dates (where UK, UKN and UNKN indicate unknown or missing day, month 
and year respectively):  
• UK-MMM-YYYY: If the month and year are different from the month and year of 
the first dose of study drug, assume 01-MMM-YYYY. If the month and year are the 
same as the first dose of study drug month and year and the end date (after any 
imputation) is on or after the first dose of study drug, then assume the date of the first 
dose of study drug. If the month and year are the same as the first dose of study drug 
month and year and the end date (after any imputation) is prior to the first dose of 
study drug, then assume the end date for the start date; 
• DD-UKN-YYYY/UK-UKN-YYYY: If the year is different from the year of the first 
dose of study drug, assume 01-JAN-YYYY of the collected year. If the year is the 
same as the first dose of study drug year and the end date (after any imputation) is on 
or after the first dose of study drug, then assume the date of the first dose of study 
drug. If the year is the same as the first dose of study drug and the end date (after any 
imputation) is prior to the first dose of study drug, then assume the end date for the 
start date. 
Missing stop dates (where UK, UKN and UNKN indicate unknown or missing day, month 
and year respectively):  
• UK-MMM-YYYY: Assume the last day of the month; 
• DD-UKN-YYYY/UK-UKN-YYYY: Assume 31-DEC-YYYY.
If start date is completely missing and end date is not prior to the first dose, then the 
medication will be classified as both prior and concomitant. If the start date is completely 
missing and the end date is prior to the first dose of study drug, then the medication will be 
classified as prior. If the end date is missing, then the medication will be classified as 
ongoing. Medications for which the start and end dates are missing will be classified as 
prior and concomitant. 
If start date is completely missing and end date is not prior to the first dose, then the AE
will be classified as TEAE. AEs for which the start and end dates are missing will be 
classified as TEAEs. 
Approved
rent
d
rent
YYY. If t
d
YYY. If t
year and the en
d
year and the e
dy drug, then assum
ed
dy drug, then ass
are the same as the 
ed
are the same as the 
ny imputation) is p
ve
ny imputation) is p
for the start date;
ve
for the start date;
Y: If the year is diff
ov
Y: If the year is diff
AN-YYYY of the co
rov
AN-YYYY of the co
drug year and the en
ro
drug year and the en
y drug, then assume
pro
y drug, then assume
e as the first dose o
pr
e as the first dose o
e first dose of study
pp
e first dose of study
re UK, UKN and U
Ap
re UK, UKN and U
A
Assume the
A
Assume the
UKN-Y
A
UKN-Y


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
18
5. Patient Disposition 
5.1. Disposition 
The number of patients screened, the number and percentage of patients who failed 
screening, and the violated eligibility criteria will be summarized. The above percentages 
will be based on the number of patients screened. 
A summary of the analysis sets includes the number and percentage of patients for the 
following categories: Safety set, ITT set, and PP set. The above percentages will be based 
on the number of patients randomized. 
Patient disposition will be summarized for the ITT set. A disposition of patients includes 
the number and percentage of patients who completed study treatment, discontinued study 
treatment, completed the study, and discontinued from the study. The reasons for study 
discontinuation, the reasons for study treatment discontinuation will also be summarized in 
this table, as collected on eCRF pages.
The number and percentage of patients by region, study site and treatment group will be 
tabulated based on all randomized patients. 
Patient disposition data will be presented in listings. 
5.2. Protocol Deviations 
The protocol deviations/violations will be identified and assessed by clinical research 
physician or designee following institution standard operational procedures. The protocol 
deviations/violations will be summarized for all randomized patients by treatment group 
and overall based on all randomized patients.
A listing of patients with protocol deviations/violations will be provided with detail 
protocol deviation category and description presented. 
6. Demographics and Baseline Characteristics 
The demographics and baseline characteristics will be summarized by treatment group 
based on ITT set, unless otherwise specified. The patient data will also be presented in 
listings. 
6.1. Demographics 
The following demographics and baseline characteristics will be summarized based on ITT
set, and repeated on Safety set: 
•
Age (years)  
pproved
di
d
di
tudy tre
d
tudy tre
m the study. Th
d
m the study. T
continuation
ed
continuation will a
d
wil
gion, study site and
ve
gion, study site and
s. 
s. 
ted in listings. 
ro
ted in listings. 
App
ations will be ident
App
ations will be ident
owing institution st
App
owing institution st
ll be summarized fo
Ap
ll be summarized fo
l randomized pati
Ap
l randomized pati
tocol de
A
tocol de
d


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
19
•
Sex (Male, Female) 
•
Race (White, Black or African American, Asian, American Indian or Alaska 
Native, Native Hawaiian or Other Pacific Islander, Other) 
•
Ethnicity (Hispanic or Latino, Not Hispanic or Latino) 
•
Height (cm) 
•
Weight (kg) 
•
Body mass index (BMI) (kg/m^2)  
Body mass index is calculated as (body weight in kilograms) / (height in meters)2. A 
patient’s age in years is calculated using the date of the informed consent and date of birth.  
Patient demographic and baseline characteristics will be presented in a listing. 
6.2. Baseline Disease Characteristics 
The following disease characteristics will be summarized: 
•
Number of previous lines of therapy 
•
Number of previous lines of therapy categories (0-2 vs. ≥3) 
•
Response to previous treatment (non-responders vs. relapsed) 
•
Previous splenectomy (yes vs. no) 
•
Baseline platelet count 
•
Baseline platelet count categories (<15,000/µL vs. 15,000/µL-30,000/µL) 
•
TPO-receptor agonist use (yes vs. no) 
Patient baseline and disease characteristics will be presented in a listing. 
6.3. Alcohol, Nicotine and Drug Usage 
The following characteristics will be summarized based on ITT set, and repeated on Safety 
set: 
•
Alcohol status (never a drinker, current drinker, ex-drinker) 
•
Nicotine status (never smoked, smoker, ex-smoker) 
•
Drug status (never, current, former) 
6.4. Genetic Analysis 
The following genetic analysis components will be summarized based on ITT set, and 
repeated on Safety set: 
•
CYP1A2 Genotype 
•
CYP1A2 Phenotype 
•
UGT1A1 Genotype 
•
UGT1A1 Phenotype 
pproved
marized: 
ed
marized: 
categories (0-2 vs.
ve
categories (0-2 vs.
on-responders vs. r
ov
on-responders vs. r
o) 
o) 
gories (<15,000/
pro
gories (<15,000/µL
o
µL
App
 (yes vs. no)
pr
 (yes vs. no)
characteristics will
App
characteristics will
tine 
A
tine and Drug 
Ap
and Drug 
A
Us
p
Us
ics will be s
A
ics will be s


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
20
6.5. Medical History 
Medical history will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA v21.0 or later). The number and percentage of patients with any medical history 
will be summarized overall and by treatment for each system organ class (SOC) and 
preferred term (PT). SOCs and PTs will be presented in a descending order of overall 
patient frequency, then the patient frequency within treatment groups from high dose to 
low dose and placebo group, if applicable.  
Patient medical history data including specific details will be presented in a listing. 
6.6. Prior and Concomitant Procedure 
6.5.1. Prior Procedure 
Procedures collected on the Prior and Concomitant Procedures eCRF pages will be coded 
to SOC and PT terms using MedDRA (v21.0 or later). The procedures with the date prior 
to the start of study drug (SKI-O-703 or placebo) will be counted as prior procedures. The 
number and percentage of patients who had any prior procedures will be presented, and 
summaries will be provided overall and by treatment for each SOC and PT.
A listing will be generated for all procedures (including prior and concomitant) collected. 
6.5.2. Concomitant Procedure 
The procedures with the date on or after the start of study drug (SKI-O-703 or placebo) 
will be counted as concomitant procedures. The number of patients having concomitant 
procedures will be summarized overall and by treatment for each SOC and PT. 
7. Treatments and Medications 
7.1. Prior and Concomitant Medications 
Use of all concomitant medications that the patient is receiving at the time of Screening or 
receives during the study must be recorded in the patient’s eCRF. All medications will be 
coded according to the World Health Organization Drug Dictionary (WHODD) Enhanced 
B3 March 2018 or later. 
A prior medication is defined as any medication that has a stop date prior to the first dose 
of study drug (SKI-O-703 or placebo). Concomitant medications are defined as 
medications that are started between the first dose of study drug (SKI-O-703 or placebo) 
date and the last dose of study drug (SKI-O-703 or placebo) date, both inclusive, or started 
before the first dose of study drug (SKI-O-703 or placebo) date but ended or remain 
ongoing while on treatment. Incomplete medication start and stop dates will be imputed as 
per Section 4.7.  
Approved
rocedures eCR
d
rocedures eCR
er). The procedure
ed
er). The procedu
) will be counted as
ed
) will be counted a
y prior procedures 
ve
y prior procedures 
reatment
v
reatment for each
ve
for each S
dur
dures
o
es (including pr
ov
(including pr
dure
p
dure
or after the start of 
pr
or after the start of 
t procedures. The n
pp
t procedures. The n
zed overall and by t
App
zed overall and by t
Medications
Ap
Medications
A
itant Me
A
itant Me


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
21
The frequency table will be provided by treatment group and overall on ITT set. The 
number and percentages of patients who had any prior medications will be summarized 
overall and by treatment groups, therapeutic drug classes (ATC level 2) and generic drug 
names. Therapeutic drug classes and generic drug names will be presented in a descending 
order of overall patient frequency, then the patient frequency within treatment groups from 
high dose to low dose and placebo group, if applicable. Similar frequency tables will be 
provided for permitted concomitant medications and prohibited concomitant medications 
on ITT set. The prohibited concomitant medications are defined in protocol Section 5.8.3. 
The list of prohibited concomitant medications should be reviewed and finalized by 
sponsor designee before final database lock. 
A listing of prior and concomitant medications by patient will be provided, with an 
indicator to identify the prior and concomitant medications. 
7.2. Rescue Medications 
In case of bleeding events requiring rescue medication, the following rescue medications 
are permitted: IVIG 1 g/kg/day for 2 days (ie, 2 g/kg), romiplostim 2 to 5 μg/kg, 
dexamethasone 40 mg/day for 4 days, other high dose parenteral steroids (ie, solumedrol 1 
g IV), platelet transfusions (these may be reserved for serious or life threatening bleeding 
events), or standard of care as per participating countries. Patients should be withdrawn in 
case of CNS bleeding or life-threatening GI bleeding (see protocol Section 4.2.1). 
Rescue medications will be coded to therapeutic drug classes (ATC level 2) and generic 
drug names using WHODD Enhanced B3 March 2018 or later. The number and 
percentages of patients who had any rescue medications will be summarized overall and by 
treatment, therapeutic drug classes (ATC level 2) and generic drug names based on ITT 
set. Therapeutic drug classes and generic drug names will be presented in a descending 
order of overall patient frequency, then the patient frequency within treatment groups from 
high dose to low dose and placebo group, if applicable.  
A listing with all rescue medications will be generated. 
7.3. Prior Therapy 
Therapies collected on the Prior Therapy eCRF pages will be coded to therapeutic drug 
classes (ATC level 2) and generic drug names using WHODD Enhanced B3 March 2018 
or later. The number and percentages of patients who had any prior therapy will be 
summarized overall and by treatment, therapeutic drug classes (ATC level 2) and generic 
drug names based on ITT set. Therapeutic drug classes and generic drug names will be 
presented in a descending order of overall patient frequency, then the patient frequency 
within treatment groups from high dose to low dose and placebo group, if applicable.  
Approved
nt
d
nt will b
d
will b
ations.
d
ations.
dication, the follow
ve
dication, the follow
e, 2 g/kg), romiplos
ve
e, 2 g/kg), romiplos
er high dose parent
ov
er high dose parent
e reserved for serio
ov
e reserved for serio
ticipating countries
ro
ticipating countries
ening GI bleeding (
pro
ening GI bleeding (
ded to therapeutic 
pp
ded to therapeutic 
Enhanced B3 Mar
App
Enhanced B3 Mar
ho had any rescue m
Ap
ho had any rescue m
rug classes (ATC l
Ap
rug classes (ATC l
lasses and generi
A
lasses and generi
quency, the
A
quency, the
cebo g
A
b


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
22
A listing with all prior therapies will be generated. 
7.4. Study Treatments 
On Day 1, eligible patients will be randomly assigned to receive either SKI-O-703 200 mg 
BID, SKI-O-703 400 mg BID or placebo. SKI-O-703 200 mg BID, 400 mg BID, and 
placebo will be administered orally. On Day 1, the investigative site staff will administer 
the morning dose. The evening dose of study medication will be administered 12 hours 
after the morning dose. Patients will be administered the study medication with enough 
water to swallow the capsule. From Day 2 to Week 12, patients will self-administer study 
drug. 
7.4.1. Extent of Exposure 
Duration of exposure is defined as the total number of days a patient is exposed to study 
drug (SKI-O-703 or placebo) and will be presented as the total number of days from the 
first dose date (Day 1) to the last dose date (date of last dose minus the date of first dose + 
1) as recorded on the End of Treatment page on the CRF.  
The duration of exposure to study drug by treatment will be summarized for all patients in 
the Safety set and will be presented in a table by summary statistics. The duration of 
exposure will then be classified into one of the following categories: < 2 weeks, 2 to <4 
weeks, 4 to <6 weeks, 6 to <8 weeks, 8 to <10 weeks, 10 to 12 weeks and will be presented 
as the number and percentage of patients in each duration category. Percentages will be 
computed from the number of patients in the Safety set.  
7.4.2. Treatment Compliance and Modifications 
Each patient’s dosing schedule should be closely monitored by the site at each study visit. 
This will ensure that all patients enrolled into the study maintain their original dosing 
schedule beginning with the first dose of study drug. 
Study drug compliance will be calculated for each patient by taking into account whether a 
patient takes all doses of study drug as instructed. The number of tablets taken will be 
calculated from subject dosing data in eCRF.  
The overall study drug compliance (%) will be calculated by dividing the total number of 
tablets taken by the total number of tablets prescribed and then multiplying by 100. 
Compliance (%) = [(total no. of tablets taken) / (No. of days exposure× No. of tablets 
prescribed per day)] × 100
The overall study drug compliance will be summarized by treatment based on Safety set.  
proved
f days a patien
d
f days a patien
d as the total numb
ed
d as the total num
of last dose minus 
ed
of last dose minus
n the CRF. 
ve
n the CRF. 
treatment will be s
ov
treatment will be s
table by summary 
ov
table by summary 
one of the following
ro
one of the following
ks, 8 to <10 weeks, 
pro
ks, 8 to <10 weeks, 
App
patients in each du
pr
patients in each du
patients in the Safe
pp
patients in the Safe
nt Compliance an
Ap
nt Compliance an
chedule should be
Ap
chedule should be
atients 
A
atients enroll
A
enroll
first do
A
first do


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
23
A patient is considered compliant if overall study drug compliance is between 80% - 
120%.  
Summary statistics on percentage of treatment compliance as well as the number and 
percentage of patients in each compliance category (<80%, 80%-120%, and >120% 
compliant) will be presented overall. Percentages will be calculated out of the number of 
patients who were dosed at that dosing period in the Safety set.  
Patients drug accountability data will be provided in a listing. 
8. Efficacy Analysis 
The results for each efficacy endpoint will be summarized by treatment for all patients 
within the ITT set using descriptive statistical methods, and repeated within the PP set. 
Continuous variables (quantitative endpoints) will be summarized using the mean, the 
standard deviation (SD), median, range (minimum value and maximum value), and 
interquartile. Categorical variables (qualitative endpoints) will be summarized using 
frequency counts (number) and percentages. Data will be listed in data listings. 
All statistical tests will be 2-sided using a 5% significance levels, leading to 95% (2-sided) 
confidence intervals (CIs). This will be used for each pairwise comparison with placebo, 
ie, there will be no adjustments for multiplicity since this is a Phase 2 study, and interim 
analysis will only be performed on safety and PK analysis. 
If there are multiple post-baseline platelet count results in the same visit, the result from 
central lab will be used first. If there are more than one central lab result in the same visit, 
the result with larger platelet count will be used. However, if only local lab results exist, 
the local lab result with larger platelet count will be used.  
8.1. Primary Efficacy Endpoint 
The primary efficacy endpoint, patient platelet response, is defined as platelet count ≥ 
30,000/µL and doubling the baseline (average of 2 previous counts), at any visit during the 
treatment period and without a use of rescue medication. Refer baseline definition to 
Section 4.2. The average based on last 2 platelet counts at the time of evaluation.
8.1.1. Primary Analysis 
The platelet responses after using rescue medication during treatment period will be set to 
missing and will be imputed as the average of the last 2 previous non-missing platelet 
counts. For example, if platelet count in Week 2 Day 8, Week 3 and Week 5 are 45,000, 
missing, and 48,000 respectively, the average will be calculated by results from Week 2 
Day 8 and Week 5. 
Approved
ed by tr
d
ed by tr
ds, and repeate
d
ds, and repeate
be summarized usi
ed
be summarized u
m value and maxim
ed
m value and maxim
endpoints) will be
ve
endpoints) will be
Data will be listed
ve
Data will be listed
a 5%
o
a 5% significance 
ov
significance 
e used for each pai
ro
e used for each pai
multiplicity 
pro
multiplicity since t
pro
since t
n safety and PK an
pr
n safety and PK an
eline
Ap
eline platelet count
App
platelet count
st. If there are more
App
st. If there are more
telet count will be 
Ap
telet count will be 
A
h larger platelet co
Ap
h larger platelet co
po


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
24
The primary efficacy endpoint will be summarized as overall platelet response rate (ORR) 
with exact unconditional 95% confidence intervals (CI) by treatment group. The ORR 
difference and exact unconditional 95% CI will be provided between each of active 
treatment groups and placebo group, and between two active treatment groups. The p-value 
from Fisher’s exact test will be presented.  
For patients whose ORR cannot be adequately determined, their ORR will be imputed 
using a non-responder imputation (NRI) approach. 
Summary statistics will be provided on the number (%) of patients achieving platelet 
response by each treatment and the combined active treatment groups.  The differences in 
the ORR, 95% CI and p-value from a Fisher’s exact test will therefore be provided for: 
•
Each active treatment group (200 mg BID, 400 mg BID) vs. placebo 
•
Combine active treatment groups vs. placebo 
•
200 mg BID vs. 400 mg BID. 
A logistic regression model will also be performed on platelet response as dependent 
variable and treatment group, baseline platelet count and prior TPO-receptor agonist use as 
covariates.  The odds ratio for the treatment effect compared to placebo (together with 
95% CI and p-value) will be provided. 
Bar plots on difference in proportions of ORR and exact unconditional 95% CI will be 
provided by treatment group and combined active treatment group. 
8.1.2. Sensitivity Analysis 
Sensitivity analysis based on rescue medication with 28-day effective window: 
The primary analysis will be repeated applying a 28-day window on rescue medication. 
Specifically, if a patient meets platelet response definition before a rescue therapy or after 
28 days since a use of rescue medication, the patient will be considered as a responder. 
The same analysis on ORR including summary statistics and logistic regression described 
in the primary analysis above will be carried out.  
Sensitivity analysis based on treatment-policy strategy:  
The primary analysis will be repeated on assessments in all scheduled visits from post-
baseline until Week 12, regardless of patients using rescue medication or discontinuation. 
The missing platelet count values will be imputed by Multiple Imputation (MI) method for 
all treatment groups, under the missing at random (MAR) framework. 
The SAS procedure MI will be used to impute missing platelet count at the scheduled 
analysis visits (up to Week 12) to create 25 complete data sets. The missing data patterns 
Approved
me
d
me
t will th
d
t will th
0 mg BID) vs
d
0 mg BID) vs
bo 
bo 
formed on platelet r
ve
formed on platelet r
telet count and prio
ov
telet count and prio
ment effect compare
ov
ment effect compare
d. 
d. 
tions of ORR and e
pr
tions of ORR and e
nd combined active
pp
nd combined active
ty Analysis 
Ap
ty Analysis 
ed on rescue medi
Ap
ed on rescue medi
be repeated 
A
be repeated 
A
plate
A
plate
d


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
25
will be checked by treatment and at the scheduled visits for the platelet count. If there are 
non-monotone missing patterns, two separate imputation procedures will be used to 
complete the imputation process.  
In the first step, the Markov Chain Monte Carlo (MCMC) method will be used to impute 
missing values by treatment to create 25 imputed data sets with monotone missing 
patterns. The seed will be set to 7032101, the imputed values will be rounded to 3 decimals 
with 10^9/L unit and a single chain will be used to produce imputations.  
In the second step, the monotone regression method will be used to impute the remaining 
missing values for the 25 data sets with monotone missing patterns. The MONOTONE 
REG statement will be used with seed 2101703. The missing values at each visit will be 
imputed based on treatment, values at baseline and previous visits, and prior TPO-receptor 
agonist use.  
If model fail to converge because the number of visits is more than number of subjects, the 
model will be reformed. The nearest visits (Week 1 Day 1 to Week 2 Day 8, Week 3 to 
Week 7, and Week 9 to Week 12) will be imputed by two steps imputation procedures 
described above separately with unique seed. For visits Week 1 Day 1 to Week 2 Day 8, 
the seed used in first step is 7032101 and in second step is 2101703. For visits Week 3 to 
Week 7, the seed used in first step is 1021984 and in second step is 1984102. For visits 
Week 9 to Week 12, the seed used in first step is 1072018 and in second step is 2018107. 
After the completion of two steps imputations, the response will be defined based on 
platelet counts in the 25 complete datasets and the same logistic regression model 
described in Section 8.1.1 will be used to analyze the 25 complete datasets. The SAS 
procedure MIANALYZE will be used to combine the results for the statistical inferences.  
8.2. Secondary Efficacy Endpoint 
8.2.1. Patients Achieving Two or More Pre-specified Platelet Count 
When considering the achieving two or more pre-specified platelet count, the visit with 
missing result will be excluded. 
A logistic regression model will be performed on each endpoint defined in Section 3.2.2.1
and include treatment, baseline platelet count and prior TPO-receptor agonist use, provided 
there are enough patients in each subgroup determined by each factor. The odds ratio for 
each active treatment effect compared to placebo (together with 95% CI and p-value) will 
be provided. Each endpoint will be summarized in number (%) of patients by treatment 
group. 
For patients whose pre-specified platelet count achievement cannot be adequately 
determined, their achievement will be imputed using the same NRI approach as described 
in Section 8.1.
pproved
its 
e
its is more 
ed
is more th
d
than
d
an nu
1 Day 1 to Week 2
ed
1 Day 1 to Week
ted by two
ve
ted by two steps 
e
steps im
im
For visits Week 1 
ve
For visits Week 1 
n second step is 21
ov
n second step is 21
21984 and in second
ov
21984 and in second
first step is 107201
ro
first step is 107201
imputations,
pr
imputations,
App
the re
pr
the re
tete datasets and 
p
datasets and the 
p
the 
ll be used to analyz
pp
ll be used to analyz
will be used to comb
App
will be used to comb
icacy Endpoint
A
icacy Endpoint
ving 
A
i


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
26
Bar plots on proportions of patients achieving two or more pre-specified platelet counts on 
each defined endpoint and exact unconditional 95% CI will be provided by treatment 
group and combined active treatment group. 
8.2.2. Change from Baseline in Platelet Counts 
Primary Analysis 
The primary Analysis will be performed on all observed data until Week 12, regardless of 
rescue medication and discontinuation. 
Change from baseline in the average of the last 2 platelet counts will be analyzed using an
analysis of covariance (ANCOVA) model with covariates including baseline platelets 
count, treatment, rescue medication use, and prior TPO-receptor agonist use. 
The within-group least-square (LS) means, the associate standard errors (SE), and the 
treatment differences in LS means, the associated SE, 95% CIs and p-values will be 
derived from the model to compare each active treatment group against placebo. 
Descriptive statistics of baseline value, observed value and change from baseline will be 
presented by treatment group. 
Sensitivity Analysis based on treatment-policy strategy 
The primary analysis will be repeated based on assessments in all scheduled visits from 
post-baseline until Week 12, regardless of patients using rescue medication or 
discontinuation. The same MI method will be applied as outlined in Section 8.1.2. 
For each of m=25 imputed datasets, same ANCOVA model as defined in primary analysis 
will be carried out. Results from each of imputed datasets will be combined to generate the 
adjusted mean of change from baseline in platelet counts for each treatment group, as well 
as between-group difference (comparing each active treatment group against placebo) and 
the 95% CI for the difference. 
Sensitivity analysis based on hypothetical strategy 
The primary analysis will be repeated based on a hypothetical scenario if the rescue 
medication had not occurred. Specifically, applying the same rescue medication window, 
all assessments happened within 28 days of the use of rescue medication will be 
considered as missing, regardless if they are collected or not. Then all missing data will be 
imputed until Week 12 by Multiple Imputation (MI) method for all treatment groups, 
under: 
•
Missing at random (MAR) framework: 
Under this framework, the same MI method will be applied as outlined in Section 
8.1.2.
•
Missing not at random (MNAR) framework: 
Approved
cou
d
cou
tes includ
d
tes includ
O-receptor ago
d
O-receptor ag
ssociate
ed
ssociate standard er
ed
standard e
ted SE, 95% CIs an
ve
ted SE, 95% CIs an
ive treatment group
ve
ive treatment group
served value and
ov
served value and ch
ch
ment-policy strategy
pro
ment-policy strategy
eated based on
pr
eated based on asse
pr
asse
egardless of patient
pp
egardless of patient
MI method will be a
App
MI method will be a
ted datasets, same A
Ap
ted datasets, same A
A
ults from each of
Ap
ults from each of
from baselin
A
from baselin
compa
A
compa


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
27
Two imputation steps will be performed under this assumption.  First step for 
arbitrary missing is MCMC monotone imputation which is the same as described in 
Section 8.1.2.  The second step is control-based pattern imputation using monotone 
regression method with seed 2010703, in which the missing data in all active 
treatment groups and placebo group will be imputed based on placebo group using 
the neighboring-case missing values method with k=2.
If model fail to converge because the number of visit is more than number of 
subjects, the same approach in Section 8.1.2 will be applied. When imputed value 
out of range (ie value <0), the value will be replaced by min value in dataset. 
The same ANCOVA model defined in primary analysis will be carried out to analyze the 
25 complete datasets. The SAS procedure MIANALYZE will be used to combine the 
results for the statistical inferences 
8.2.3. Time to First Platelet Response 
Time to platelet response based on the non-response imputation defined in Section 8.1.1
will be summarized by treatment group using Kaplan-Meier (K-M) methods with median 
time to platelet response (including two-sided 95% CI). K-M estimates of platelet response 
rates at 2-week intervals (e.g., 2-week, 4-week, etc) will be provided with corresponding 
two-sided 95% CIs by treatment group. The K-M curve for time to platelet response (later 
visit meet criteria) will be presented graphically and compared against placebo curve using 
log-rank test.  
In addition, a proportional hazard model will be implemented as well with treatment, 
baseline platelet count, and prior TPO-receptor agonist use. The hazard ratios, 95% CIs 
and p-values will be provided to compare each active treatment group against placebo. 
A listing of time to platelet response will also be provided. 
8.2.4. Others 
Summary statistics will be provided to each endpoint listed in Section 3.2.2.4 by each 
treatment group. 
8.3. Exploratory Endpoints  
8.3.1. Peak Platelet Count 
Descriptive statistics of peak platelet count will be provided by treatment group. The 
difference in median peak platelet will be calculated for: 
•
Each active treatment group (200 mg BID, 400 mg BID) vs. placebo 
•
Combined active treatment groups vs. placebo  
•
200 mg BID vs. 400 mg BID 
Approved
il
d
il
E will b
d
E will b
ponse imputation d
ve
ponse imputation d
g Kaplan
ve
g Kaplan-Meier (K
ve
-Meier (K
ded 95% CI). K-M
ov
ded 95% CI). K-M
4-week
o
4-week,
o
, etc) will be
ov
 etc) will be
p. The K-M curve f
ro
p. The K-M curve f
d graphically and 
pro
d graphically and co
o
co
azard model will be
App
azard model will be
d prior 
Ap
d prior TPO-recepto
App
TPO-recepto
Ap
vided to compare e
Ap
vided to compare e
et response w
A
et response w


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
28
Box plots will be provided to display the distribution of peak platelet count by treatment 
group and combined active treatment group. 
8.4. Subgroup Analysis 
The primary endpoint will be summarized using the number (%) of patients achieving 
platelet response by each treatment group and the following subgroups of interest: 
•
Number of previous lines of therapy (0-2 vs. ≥3) 
•
Response to previous treatment (non-responders vs. relapsed) 
•
Splenectomized patients vs. non-splenectomized patients and 
•
Patients with baseline platelet count < 15,000/µL versus patients with platelet count 
between 15,000/µL to 30,000/µL. 
•
Patients with prior TPO-receptor agonist use versus patients without prior 
TPO-receptor agonist use. 
•
Patients with background medication (defined in protocol Section 5.8) vs. patients 
without background medication. 
9. Safety Analysis 
Continuous parameters will be summarized separately for each treatment at each scheduled 
visit using descriptive statistics (mean, SD, minimum, median, and maximum). Discrete 
parameters will be summarized separately for each treatment at each nominal time point 
using frequency counts and percentages. 
Safety results will be summarized using the Safety set by treatment groups and the 
combined active treatment group, unless otherwise specified. 
9.1. Adverse Events 
The Medical Dictionary for Regulatory Activities (MedDRA v21.0 or later) will be used to 
code all adverse events (AE). All AEs, serious AEs (SAE), drug-related AEs, and drug-
related SAEs will be summarized using the worst grade per National Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events (CTCAE) by system organ class 
and preferred term. The intensity of the AE will be rated using the NCI CTCAE v5.0. 
An AE is defined as any untoward medical occurrence in a patient enrolled into this study 
regardless of its causal relationship to study drug. For the purpose of inclusion in TEAE 
tables, incomplete AE onset and end dates will be imputed according to Section 4.7.
A treatment-emergent AE (TEAE) is defined as any event not present before exposure to 
study drug or any event already present that worsens in either intensity or frequency after 
exposure to study drug.  
Approved
rsus patie
d
rsus patie
ned in protocol Sec
ed
ned in protocol S
ed separately for ea
ov
ed separately for ea
SD, minimum, me
ro
SD, minimum, me
rately for each treat
ro
rately for each treat
tages. 
p
tages. 
ized using the S
pp
ized using the Saf
p
afe
p
efef
p
fef
group, unless otherw
App
group, unless otherw
ts
A
ts
r Regulator
A
r Regulator
All A
A
All A


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
29
A treatment-related TEAE is defined as an TEAE which is considered to be related to the 
study drug and reported as “Possible”, “Probable” or “Definite” on the eCRF. Any TEAE 
with a missing relationship will be classified as a treatment-related TEAE. 
A SAE is defined as an AE that  
•
Results in death 
•
Is immediately life threatening 
•
Requires inpatient hospitalization or prolongation of existing hospitalization 
•
Results in persistent or significant disability/incapacity 
•
Is a congenital anomaly/birth defect 
An overall summary of the following AE categories will be provided by treatment group 
and combined active treatment group: 
•
Patients with any TEAE 
•
Patients with any treatment-related TEAE 
•
Patients with any serious adverse event (SAE)  
•
Patients with any treatment-related SAE 
•
Patients with any grade 3 or 4 TEAE 
•
Patients with any grade 3 or 4 treatment-related TEAE 
•
Patients with any TEAE leading to Dose Reduced or Drug Interrupted 
•
Patients with any TEAE leading to Drug Withdrawn 
•
Patients with any TEAE leading to death 
Tables summarizing the incidence of TEAEs by treatment group and combined active 
treatment group in SOC and PT will be provided for each of the following AE categories: 
•
All TEAEs 
•
Treatment-related TEAEs 
•
Grade 3 or 4 TEAEs 
•
Grade 3 or 4 treatment-related TEAEs 
•
TEAEs leading to Dose Reduced or Drug Interrupted 
•
TEAEs leading to Drug Withdrawn 
•
All SAEs 
•
Treatment-related SAEs 
•
TEAEs leading to death 
The number and percentage of patients who experience any TEAE categories will be 
summarized by treatment group and combined active treatment group for each system 
organ class (SOC) and preferred term (PT), with SOCs and PTs within each SOC 
presented in a descending order of patient incidence within combined active treatment 
groups, then from high dose to low dose and placebo group if applicable. 
pproved
be p
d
be p
SAE) 
ve
SAE) 
AE
AE
E
o
E
atment-related TEA
ov
atment-related TEA
g to Dose Reduced
ro
g to Dose Reduced
ding to Drug Withd
pro
ding to Drug Withd
eading to death 
pr
eading to death 
App
dence of TEAEs by
pp
dence of TEAEs by
d PT will be provid
App
d PT will be provid
ed TEAEs
Ap
ed TEAEs
AEs
A
AEs
nt-relate
A
nt-relate
R


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
30
Summary table of All TEAEs by maximum toxicity grade will also be provided. If patient 
reports multiple occurrences of a specific AE, the patient will be counted only once on the 
maximum grade. 
Separated listings will be prepared for All AEs, SAEs, Grade 3 or 4 TEAEs, TEAEs 
leading to treatment modification or discontinuation and TEAEs leading to death. The 
verbatim term, PT and SOC, as well as event dates and other attributes that were collected 
on eCRF will be included in the listing. 
9.2. Adverse Events of Special Interest 
Adverse events of special interest (AESI) as listed below will be summarized by treatment 
group and combined active treatment group:  
•
Neutropenia
•
Hepatotoxicity
The number and percentage of patients who experience any TEAE of special interest will 
be presented for each preferred term in a descending order of frequency within combined 
treatment group, then from high dose to low dose and placebo group if applicable. If 
patient reports multiple occurrences of an AESI, the patient will be counted only once. 
A listing of AESI will be provided with verbatim term, PT and SOC presented, as well as 
other relevant event attributes collected on eCRF. 
9.3. Clinical Laboratory Evaluations 
Clinical laboratory tests will be performed by both central and local laboratory. All 
summaries will be based on the standard international (SI) units provided by both central 
and local lab.  
The laboratory values will be graded using CTCAE version 5.0. For hematologic and 
chemistry laboratory values that fall outside of the grade criteria of CTCAE version 5.0, 
the grade of 0 will be assigned. 
Abnormal clinical laboratory values will be flagged as either high or low based on the 
reference ranges for each laboratory parameter.  
Summary statistics of observed values, change and percent changes from baseline in 
numeric laboratory parameters will be provided by treatment group and combined active 
treatment group, and scheduled visit indicated in the schedule of events in Appendix 15.1.
Numeric values reported as less than (<) or greater than (>) a laboratory-defined limit will 
be included with the “<” or “>” signs ignored.  
Approved
wi
d
wi
xperience any TEA
ve
xperience any TEA
scending order of fr
ve
scending order of fr
ow dose and placeb
ov
ow dose and placeb
an AESI, the patien
ov
an AESI, the patien
with verbatim term
pro
with verbatim term
lected on eCRF.
pr
lected on eCRF.
Ap
y Evaluations 
App
y Evaluations 
will be performed 
Ap
will be performed 
ed on the standard 
Ap
ed on the standard 
ad


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
31
For relevant laboratory parameter, frequency summaries of categorical shifts from baseline 
grade to each post-baseline visit grade, and to the worst post-baseline grade during 
treatment will be provided in the graded hematology and serum chemistry parameters by 
treatment group and combined active treatment group.
Line plots of means and SEs will be created to display actual values and change from 
baseline by scheduled visit. 
When there are multiple values within a post-baseline visit for a particular laboratory 
parameter (except platelet; refer rule of platelet to Section 8), the worst value will be taken 
(worst being the smallest value for criteria below a certain threshold or the largest value for 
criteria above a certain threshold). If a patient has a value below the threshold and above 
the threshold, the value furthest from the threshold will be chosen. If the distances are the 
same, the value with the recent date/time will be chosen. 
All laboratory data will be listed, including unscheduled/repeat visits.  
All laboratory data outside the normal range will be listed. For each laboratory test, 
individual patients with any values outside the standard reference range will have all their 
test results listed. 
9.3.1. Hematology 
Hematology will be collected at visits indicated in the schedule of events (Appendix 15.1).
The following hematology assessments will be performed: 
Hematocrit, hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglobin 
concentration, mean corpuscular volume, platelet count, red blood cell count, total and 
differential (absolute and percent) leukocyte count, and erythrocyte sedimentation rate. 
9.3.2. Serum Chemistry 
Serum chemistry will be collected at visits indicated in the schedule of events (Appendix 
15.1).
The following serum chemistry assessments will be performed: 
Alanine aminotransferase, albumin, alkaline phosphatase, AST, bilirubin (total and direct 
if clinically indicated), blood urea nitrogen, calcium, creatinine, 
gamma-glutamyltransferase, glucose, lactate dehydrogenase, serum electrolytes (sodium, 
potassium, chlorine, magnesium, phosphate) and total protein.
Approved
b
d
b
be chos
d
be chos
en. 
d
en. 
heduled/repeat visit
ed
heduled/repeat visi
will be listed. For 
ve
will be listed. For 
 the standard refere
ov
 the standard refere
t visits indicated in
pp
t visits indicated in
Ap
assessments will b
App
assessments will b
 mean corpuscular 
Ap
 mean corpuscular 
rpuscular volume,
Ap
rpuscular volume,
d percent) leuk
A
d percent) leuk


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
32
9.3.3. Urinalysis 
Urinalysis will be collected at visits indicated in the schedule of events (Appendix 15.1).
The following urinalysis assessments will be performed: 
Appearance, bilirubin, color, glucose, ketones, leukocyte esterase, microscopy (performed 
if dipstick is positive; includes bacteria, casts, crystals, epithelial cells, red blood cells, and 
white blood cells), nitrites, occult blood, pH, protein, specific gravity, turbidity, and 
urobilinogen. 
9.4. Vital Sign Measurements 
Vital sign measurements will include systolic and diastolic blood pressures, pulse rate, 
respiratory rate, and temperature. Vital signs will be measured at visits indicated in the 
schedule of events (Appendix 15.1).
Height will be measured at Screening only. Weight will be measured at visits indicated in 
the schedule of events (Appendix 15.1).
Summary tables presenting observed values and changes from baseline will be provided 
for vital sign data by treatment group and combined active treatment group. Changes from 
baseline to each scheduled post-baseline visit will be presented.  
The relevant vital sign values at each visit will be classified into the categories of low, 
normal, and high based on the reference ranges defined as: 60 to 100 beats/minute for 
pulse rate, 12 to 20 breaths/minute for respiratory rate, 36.5 to 37.5 ºC for oral temperature, 
90 to 140 mmHg for systolic blood pressure, and 60 to 90 mmHg for diastolic blood 
pressure. 
Shift tables from baseline to post-baseline visits in terms of low, normal and high will be 
provided for pulse rate, respiratory rate and blood pressure by treatment group and 
combined active treatment group.  
When there are multiple values within a visit for a particular vital sign variable, the worst 
value will be taken (worst being the smallest value for criteria below a certain threshold or 
the largest value for criteria above a certain threshold). If a patient has a value below the 
threshold and above the threshold, the value furthest from the threshold will be chosen. If 
the distances are the same, the value with the recent date/time will be chosen. 
Unscheduled visits will be included in the calculation of baseline. 
All vital sign data by patient and parameter will be presented in a listing. 
oved
ic b
d
ic b
easured at
d
easured at
ght will be measure
ed
ght will be measure
Approv
es and changes fro
ov
es and changes fro
nd combined active
rov
nd combined active
ine visit 
ro
ine visit will be pre
ro
will be pre
each visit will be cl
pr
each visit will be cl
reference ranges de
pp
reference ranges de
minute for respirato
App
minute for respirato
lic blood pressure, 
App
lic blood pressure, 
A
to post-base
A
to post-base
atory r
A
atory r


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
33
9.5. Physical Examination 
A complete physical examination will be performed at the screening visit and an 
abbreviated physical examination at visits indicated in the schedule of events (Appendix 
15.1).  
An abbreviated physical examination will include checks of general appearance, head and 
neck, abdomen, lymph nodes, skin, cardiovascular system, respiratory system, and 
musculoskeletal system. A complete physical examination will include assessments of 
skin, head, ears, eyes, nose, throat, neck, thyroid, lungs, cardiovascular system, abdomen, 
lymph nodes, and musculoskeletal system/extremities. 
Physical examination data by patient and parameter will be presented in a listing. 
9.6. Electrocardiogram 
Electrocardiogram (ECG) assessments will include comments on the rhythm; presence of 
arrhythmia or conduction defects; morphology; or ST segment, T wave, and U wave 
abnormalities; as well as whether the tracings are normal or abnormal and if there is any 
evidence of myocardial infarction. In addition, the following parameters will be measured 
and reported: RR interval, PR interval, QRS width, QT interval, and QTcF. 
The investigator will determine whether any of the ECG results are normal or abnormal 
and whether any abnormal results are clinically significant or not clinically significant. 
Clinical significance is defined as any variation in results that has medical relevance and 
may result in an alteration in medical care (eg, active observation, diagnostic measures, or 
therapeutic measures). 
Summary tables will be presented for ECG data and change from baseline by treatment 
group and combined active treatment group. The ECG investigator interpretations will be 
summarized in shift tables comparing the ECG value interpretation categories of each post-
baseline visit with the value at the baseline visit. In addition, the worst post-baseline ECG 
value will be compared with the value at the baseline visit (with worst of all being 
Abnormal Clinically Significant and best being Normal). 
ECG data by patient and ECG parameter will be presented in a listing. 
9.7. Bleeding Score
Bleeding score will be summarized at visits indicated in the schedule of events (Appendix 
15.1) by treatment group and the combined active treatment groups. 
Approved
be p
d
be p
ude comments on th
ed
ude comments on th
y; or ST 
ve
y; or ST segment, T
ve
segment, T
gs are normal or ab
ve
gs are normal or ab
ition, the following
ov
ition, the following
QRS 
r
QRS width, QT
rov
width, QT int
v
int
ether any of the EC
pro
ether any of the EC
s are clinically sign
pr
s are clinically sign
d as any variation in
pp
d as any variation in
n medical care (eg, 
App
n medical care (eg, 
e presented for EC
Ap
e presented for EC
ve treatment g
A
ve treatment g
mparin
A
mparin


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
34
9.8. Quality of Life as Measured by the SF-36 Score 
The SF-36 Score consists of 8 scales: physical function scale, role physical scale, bodily 
pain scale, general health scale, vitality scale, social functioning scale, role emotional 
scale, and mental health scale. Scale scores range from 0 to 100, with higher scores 
indicating better health.  
Three overall scores will be further derived: physical component summary, mental 
component summary, and health utility score (SF-6D). The SF-6D provides a single index 
for use in economic evaluation or for determination of quality adjusted life years, derived 
from seven of the eight scales in SF-36.  
All 8 scale scores, 3 overall scores, and the answer to the Global Health questionnaire item 
(SF-36 question 1) will be summarized by scheduled visit. Change from baseline in scale 
scores, physical health summary measure, mental health summary measures, SF-6D, and 
the Global Health questionnaire item will be analyzed and reported using the same 
ANCOVA model as specified for change from baseline in platelet counts in Section 8.2.2, 
using observed cases. 
10. Pharmacokinetics 
10.1.
Pharmacokinetic Data Handling 
Plasma concentrations that are below the limit of quantification (BLQ) will be treated as 
zero for calculation of descriptive statistics and all PK analyses. Missing concentrations 
will be excluded from all calculations. 
All concentrations and PK parameters will be rounded to 3 significant figures for reporting 
purposes. The only exceptions will be actual sampling times and Tmax (which will be 
rounded to 2 decimal places) and the number of data points (which will be reported as 
integers). Summary statistics will be rounded to the same precision as individual data, with 
the exception of n (which will be reported as an integer). Estimates and confidence 
intervals from all statistical comparisons will be reported to 2 decimal places, and 
associated p-values will be reported to 4 decimal places. 
10.2.
Plasma Pharmacokinetic Concentrations 
Serial blood samples (5 mL) for PK assessment of SKI-O-592 and its metabolites (M2 and 
M4) will be collected from all subjects in the PK/PD subset at the following time points:  
•
Day 1: 0 hour (morning pre-dose), and at 0.25, 0.5, 1, 2, 4, 8 and 12 hours 
morning post-dose (12-hr sample should be collected prior to the evening dose). 
•
Week 12 (Day 84): 0 hour (morning pre-dose), and 0.25, 0.5, 1, 2, 4, 8, and 
12 hours. 
d
Gl
d
Gl
sit. Chan
d
sit. Chan
alth summary m
d
alth summary m
proved
zed and reported u
ed
zed and reported
aseline in platelet c
ed
aseline in platelet c
App
ta Handling
ro
ta Handling
elow the limit of qu
pr
elow the limit of qu
ive statistics and al
pp
ive statistics and al
culations.
App
culations.
PK parameters will
Ap
PK parameters will
eptions will be ac
Ap
eptions will be ac
es) and the n
A
es) and the n
will be
A
will be


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
35
In addition, PK samples will also be collected at the following time points on Day 8 from 
subjects in the safety run-in period only: 
•
Day 8: 0 hour (morning pre-dose), and at 0.25, 0.5, 1, 2, 4, 8 and 12 hours 
morning post-dose (12-hr sample should be collected prior to the evening dose). 
In all non-PK/PD subset subjects, trough PK samples will be collected during Week 12 
only, for these samples plasma concentrations of SKI-O-592, M2, and M4 will be 
presented in data listings. 
Individual plasma concentrations of SKI-O-592, M2, and M4 will be presented from the 
PK/PD subset in data listings and presented graphically versus actual time by treatment 
and analyte on both linear and semi-logarithmic scales. 
Plasma concentrations of SKI-O-592, M2, and M4 will be summarized using descriptive 
statistics (n, mean, SD, CV, minimum, median, and maximum) by time point for each 
treatment and day separately. Mean plasma concentrations will be plotted by treatment for 
each analyte versus nominal time on both linear and semi-logarithmic scales.
10.3.
Plasma Pharmacokinetic Parameters 
The following plasma PK parameters will, where possible, be estimated on Days 1, 84 and 
8 (for the first 5 subjects enrolled in the safety run-in period) for SKI-O-592, M2, and M4 
using actual sampling times via non-compartment analysis using Phoenix WinNonlin 
version 6.4 or higher: 
Ctrough  
Trough concentration observed at steady state (Day 8 and 84 only). 
Cmax 
 
Maximum observed concentration. 
Tmax 
 
Time of the maximum observed concentration. 
AUC0-tau 
Area under the concentration versus time curve within a dosing interval (τ), 
calculated using the linear trapezoidal rule. 
t1/2,eff 
Effective half-life, calculated as [ln(2)/((-ln(1-(1/RAUC))/τ))] (Day 8 and 84 
only). 
Rmet 
Metabolite ratio, calculated as [(AUC0-tau (metabolite)/ (AUC0-tau (parent)]. 
RAUC 
Accumulation ratio based, calculated as [AUC0-tau (Day 8 and 84)/ AUC0-tau
(Day 1)]. 
proved
M
d
M
versus a
d
versus a
s. 
d
s. 
M4 will be summari
ed
M4 will be summar
 and maximum) by
ve
 and maximum) by
concentrations will 
ve
concentrations will 
linear and semi-log
ov
linear and semi-log
etic Parameters 
ro
etic Parameters 
App
eters will, where po
pr
eters will, where po
ed in the safety run
pp
ed in the safety run
via non
Ap
via non-compartme
App
-compartme
A
concentration obse
Ap
concentration obse
served c
A
served c


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
36
Actual PK blood sampling times will be used for the assessment of all PK parameters. 
Plasma PK parameters for SKI-O-592, M2, and M4 will be presented in data listings and 
summarized separately using the following descriptive statistics for each treatment and 
analyte (n, geometric mean, geometric CV, mean, SD, CV, minimum, median, and 
maximum). For Tmax, only n, median, minimum and maximum will be reported. 
Note: due to the limited duration of sampling after each dose (i.e. 12 hours), parameters 
associated with the estimation of a terminal elimination phase (e.g., Kel, t1/2, CL/F, Vz/F, 
AUC0-∞, etc.) will not be presented. 
10.4.
Pharmacokinetic Statistical Analyses 
10.4.1. Assessment of Accumulation 
The accumulation ratio will be estimated by making comparisons of AUC0-tau and Cmax on 
Day 84 with corresponding estimates on Day 1 for each treatment separately; a mixed-
effects model will be fitted to log-transformed AUC0-tau and Cmax including day (Day 1 or 
84) as a fixed effect and subject as a random effect. This model will be used to estimate the 
accumulation ratio (Day 84 / Day 1) with 95% CIs for each treatment. The geometric least 
squares means and ratio with 95% CIs will be tabulated by treatment and parameter. 
11. Pharmacodynamics 
11.1.
Pharmacodynamic Data Handling 
Subjects with baseline CD63+ values below the limit of detection will be defined as low 
responders and excluded from the PD set and all summaries of PD data. Baseline will be 
defined as the percentage of activated CD63+ cells at predose samples on Day 1. 
All PD data will be rounded to 3 significant figures for reporting purposes. The only 
exceptions will be actual sampling times and TEmax (which will be rounded to 2 decimal 
places). Summary statistics will be rounded to the same precision as individual data, with 
the exception of n (which will be reported as an integer). 
11.2.
Pharmacodynamic Data 
Serial blood samples for assessment of the percentage of activated CD63+ basophils in 
peripheral blood will be collected in all subjects in the PK/PD subset at the following 
times: 
•
Day 1: 0 hour (morning pre-dose), and 0.25, 0.5, 1, 2, 4, 8 and 12 hours morning 
post-dose (12-hr sample should be collected prior to the evening dose).  
roved
ing comparisons of
ed
ing comparisons o
 for each treatment
ve
 for each treatment
ed AUC
v
ed AUC0-tau
v
0-tau and C
ve
and C
om effect. This mod
ov
om effect. This mod
h 95% CIs for each
ov
h 95% CIs for each
Appro
s will be tabulated b
ro
s will be tabulated b
namic Data Hand
App
namic Data Hand
CD63+ values below
Ap
CD63+ values below
ed from the PD set
Ap
ed from the PD set
A
of activated 
A
of activated 


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
37
•
Day 84 (Week 12): 0 hour (morning pre-dose), and at 0.25, 0.5, 1, 2, 4, 8, and 
12 hours.
Absolute and percentage change from baseline (CFB) in activated CD63+ basophils will 
be listed by treatment, day and sampling time. Individual change from baseline in CD63+ 
data will be plotted for each treatment versus time on linear scales using actual times. 
Absolute and percentage change from baseline in CD63+ basophils will be summarized by 
time point for each treatment and day using the following descriptive statistics: n, mean, 
SD, CV, median, minimum and maximum. Mean percentage change from baseline in 
CD63+ basophils will be plotted versus time by treatment and day using nominal times on 
linear scales. 
11.3.
Pharmacodynamic Parameters 
The following PD parameters will be estimated on Day 1 and 84 using change from 
baseline in activated CD63+ basophils in peripheral blood using actual sampling times via 
non-compartment analysis using Phoenix WinNonlin version 6.4 or higher: 
Emax 
Maximum effect 
TEmax 
Time to achieve maximum effect 
AUEC0-tau 
Area under the effect versus time curve within a dosing interval 
Actual PK blood sampling times will be used for the assessment of all PD parameters, and 
negative baseline-adjusted values will be included in the analysis. 
PD parameters will be presented in data listings and summarized separately using the 
following descriptive statistics for each treatment and analyte (n, mean, SD, CV, 
minimum, median, and maximum). For TEmax, only n, median, minimum and maximum 
will be reported.
11. Interim Analysis 
An unblinded interim safety and PK data review will be performed by the DMC once the 
patients in the safety run-in period complete their Day 8 (±2 days) assessments. Patients in 
the safety run-in period will continue to be dosed whilst the interim analysis is being 
conducted. However, further enrollment in each treatment group will only resume after 
safety and PK data of the first week for the first 5 patients are reviewed and considered 
satisfactory by the DMC. 
Approved
on Day 1 and 84 us
ved
on Day 1 and 84 us
pheral blood using 
ve
pheral blood using 
WinNonlin version 6
ov
WinNonlin version 6
ximum effect
pr
ximum effect
effect versus time 
pp
effect versus time 
g times will be used
Ap
g times will be used
ted values will be i
Ap
ted values will be i
sented in da
A
sented in da
s for e
A
s for e


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
38
An independent DMC appointed by the Sponsor will review the interim safety and PK data 
of the first 5 patients enrolled in the safety run-in period. Further details will be provided in 
the DMC charter, and a separate Interim Analysis SAP.
12. Changes in the Planned Analysis 
Change from v0.2 (sponsor mail approved version): 
•
General: for coding dictionary (MEDDRA, WHODrug), add "or later" wording to 
apply newest version if needed. 
•
General: applied changes in Protocol Amendment 3. 
•
Section 4.2: added baseline definition for platelet count related endpoints 
•
Section 4.6.3:  
-
specified the PD that may impact the analysis will be excluded from PP set. 
-
fixed typo for incorrected referring link (Section 7.2.2 -> Section 7.4.2) 
•
Section 7.4.2: change the source of dose taken 
•
Section 8: specified the priority of using result when multiple 
•
Section 8.1.1: specified the scenario when there are missing visit result.  
•
Section 8.1.2: 
-
correct the value round  
-
specified the scenario that model fail to converge due to more visits then 
subjects 
•
Section 8.2.1: specified the scenario when there is missing visit result. 
•
Section 8.2.2: specified the scenario that model fail to converge due to more visits 
then subjects or imputed value out of range. 
•
Section 8.2.3: specified the visit/date used for time to response. 
•
Section 9.3: 
-
corrected used results. Both central and local lab results will be used. 
-
removed the clinically significant since it's not applicable for this study. 
-
removed the platelet count in choosing records when multiple. 
-
removed the redundant description 
•
Section 9.4: removed the clinically significant since it's not applicable for this 
study. 
Change from v1.0 (sponsor approved version) 
•
Section 7.4.2: Aligned compliance calculation using Subject Diary as resource 
proved
ysis 
d
ysis 
(Section 7
d
(Section 7
n n 
sult when multiple
ed
sult when multip
en there are missing
ved
en there are missing
model fail to conv
ov
model fail to conv
cenario when there
ro
cenario when there
e scenario that mod
pr
e scenario that mod
App
value out of range
pr
value out of range
d the visit/date use
pp
d the visit/date use
used results. Both c
Ap
used results. Both c
d the clinically sign
Ap
d the clinically sign
A
the platelet cou
A
the platelet cou
redundan
A
redundan
e cl


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
39
13. References 
Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study 
for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 
2009;113(14):3154-60. 
Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding 
score: assessment of bleeding in patients with ITP. Br J Haematol. 2007;138(2):245-8. 
Approved


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
40
14. Appendices 
15.1.
Schedule of Events
The total study duration will be 20 weeks per patients, which consists of up to 4 weeks of 
screening period. The treatment period will be 12 weeks (split into 1-week safety run-in 
period and 11-week treatment period for the first 5 patients). The post-treatment follow-up 
period will be of 4 weeks. Each assessment will be carried out at timepoints indicated in 
the Schedule of Events table and clarified in the footnotes presented below the table. The 
schedule of events is summarized in Table 15-1. 
Table 15-1    Schedule of Events 
  
  
On-treatment Visits 
Follow-up 
Clinic Visits 
Early 
Withdrawal/ 
Unscheduled 
visit 
  
Screening 
(D-28 to 
D-1)
W1
(D1), 
W5 
and 
9 (±3 
days)
W1D4 
(±1 
days)
W2D8
(±2 
days)
W3, 
7, 11 
(±3 
days) 
W12 
(D84) 
(EOT) 
(±3 
days) 
End of Study 
W16 (±1 
week) 
Clinic visits 
X 
Xa
Xa* 
Xa 
Xa 
Xa
X 
Informed consent 
X 
 
 
 
Inclusion/Exclusion 
criteria 
X 
Xh
 
 
AEs 
<-----------------------------------------------------------------------------------------
---------------------> 
X 
Concomitant 
medications 
X 
X 
X* 
X 
X 
X 
X 
Height 
X 
 
 
 
 
Weight 
X 
X 
X* 
 
X 
X 
X 
Physical 
examination/medical 
historyb
X 
X 
X* 
X 
X 
X 
X 
ECGc
X 
X 
X 
 
X 
X 
X 
Vital signs 
X 
X 
X* 
X 
X 
X 
X 
Urinalysis 
X 
X 
X* 
X 
X 
X 
X 
Hep B & C, HIV 
X 
 
 
 
 
Pregnancy test/ FSHd 
X 
 
 
 
 
 
Contraception status 
X 
X 
 
X* 
 
X 
X 
X 
ABO and Rh blood 
type
X 
 
 
 
 
Serum chemistry 
X 
X 
X* 
X 
X 
X 
X 
Hematology, 
differential 
X 
X 
Xa,e 
Xa,e 
X 
X 
X 
X 
PT/INR PTT 
X 
 
 
 
 
X 
Approved
sits 
d
sits 
Cli
d
D8
v
D8
(±2
(±2
days)
v
days)
W3,
ed
W3,
7, 11 
ve
7, 11 
(±
ve
(±3
ve
3
days)
ov
days)
W12 
ed
W12 
(D84)
e
(D84)
(EOT)
e
(EOT)
(±3
(±3
da
da
ed
ed
ed
oved
X
o
Xa
o
a*
X
o
*
Xa
ov
ov
ov
rov
ro
ro
ro
pr
pr
----------------------------
p
----------------------------
---------
pp
---------
p
X
Ap
X
pp
pp
pp
App
X
A
X
Ap
Ap
Ap
Ap
Ap
Ap
Ap
Ap
X
X
A
X
X
Ap
Ap
Ap
Ap
X
A
X
A


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
41
  
  
On-treatment Visits 
Follow-up 
Clinic Visits 
Early 
Withdrawal/ 
Unscheduled 
visit 
  
Screening 
(D-28 to 
D-1)
W1
(D1), 
W5 
and 
9 (±3 
days)
W1D4 
(±1 
days)
W2D8
(±2 
days)
W3, 
7, 11 
(±3 
days) 
W12 
(D84) 
(EOT) 
(±3 
days) 
End of Study 
W16 (±1 
week) 
Study drug dispensing 
 
X 
 
 
X 
 
Xf
Study drug 
administration 
 
X 
X 
X* 
X 
X 
Xf
Blood samples for PK 
and PD assessmentsg
Xh
X* 
 
X 
Bleeding Scorei
X 
X* 
 
X 
X 
X 
Quality of life using 
SF-36 score 
 
X 
 
 
 
X 
X 
X 
Pharmacogenomic 
screeningj
 
X 
 
 
 
 
Approved
X
d
X
d


Oscotec Inc. 
Final Statistical Analysis Plan, Version 2.0
Protocol: OSCO-P2101 
Date Issued: 14FEB2023 
42
Abbreviations: AEs, adverse events; D, Day; ECG, 12-lead electrocardiogram; EOT, end-of-treatment; FSH, follicle 
stimulating hormone; hep, hepatitis; HIV, human immunodeficiency virus; PD, pharmacodynamics; PK, 
pharmacokinetics; PT/INR, prothrombin time/international normalized ratio, PTT, partial thromboplastin time; W, 
Week 
* 
Patients in the safety run-in period will have clinic visit on Week 2/Day 8 (±2 days) for the mentioned assessments 
including hematology (differential) tests. For other patients, this visit will be laboratory only visit to perform 
hematology (differential) tests only. 
a 
Clinic / laboratory visit windows are about ± 3 days for all dosing period and laboratory visits and about ± 1 week 
for clinic follow-up visits. The W12/D84 (EOT) visit should be performed while on therapy. 
b 
Complete physical examination at Screening and abbreviated physical examination at other visits. 
c 
For all patients: ECG on the first day of dosing and on Day 1 of each subsequent week as specified in the table 
above. For patients in the safety run-in only: ECG on the first day of dosing at 1, 2, 4, 8, and 12 hours after the study 
drug administration. 
d 
For women of childbearing potential only: Serum pregnancy tests are performed at Screening. FSH testing is needed 
for post-menopausal female patients only. 
e 
Laboratory only visits will be performed on Day 4 (Week 1) for all patients and on Week 2/Day 8 (±2 days) for 
patients other than those enrolled in the safety run-in period.  
f 
Study drug dispensing and administration can occur at unscheduled visit.  
g 
Samples to be collected as follows: 
For the patients in the safety run-in period only (for PK only; no PD assessments): 
•
Day 1: morning predose, 0.25, 0.5, 1, 2, 4, 8, and 12 hours (evening predose).  
•
Day 8 (±2 days): morning predose, 0.25, 0.5, 1, 2, 4, 8, and 12 hours (evening predose).
•
Week 12: morning predose, 0.25, 0.5, 1, 2, 4, 8, and 12 hours. 
For the patients in the PK/PD subset only (for PK/PD): 
•
Day 1: morning predose, 0.25, 0.5, 1, 2, 4, 8, and 12 hours (evening predose).  
•
Week 12: morning predose, 0.25, 0.5, 1, 2, 4, 8, and 12 hours. 
For other patients not included in the safety run-in period or PK/PD subset (for PK only): 
•
Week 12: morning predose. 
h 
Only on Day 1 (Week 1). 
i 
Bleeding score assessment as described by Page et al 2007 should be performed on Day 1 of each week specified in 
the above table and at follow-up visit. 
j 
A blood sample for genotyping will be drawn at baseline (Day 1, before dosing) from patients who have consented 
to participate in the genetic analysis component of the study. 
Approved
atients an
d
atients an
ed visit. 
d
ed visit. 
only; no PD assessments
ed
only; no PD assessments
, and 12 hours (evening 
ve
, and 12 hours (evening 
0.5, 1, 2, 4, 8, and 12 ho
ve
0.5, 1, 2, 4, 8, and 12 ho
1, 2, 4, 8, and 12 hours.
ov
1, 2, 4, 8, and 12 hours.
PK/PD): 
o
PK/PD): 
5, 1, 2, 4, 8, and 12 hour
ro
5, 1, 2, 4, 8, and 12 hour
25, 0.5, 1, 2, 4, 8, and 12
pro
25, 0.5, 1, 2, 4, 8, and 12
safety run-in period or P
pr
safety run-in period or P
ose.
p
ose.
scribed by 
Ap
scribed by Page
App
Page et al 200
pp
et al 200
App
Ap
up visit.
Ap
up visit.
ping will be drawn at bas
Ap
ping will be drawn at bas
A
ic analysis component o
Ap
ic analysis component o